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SUMMARY
In the yeast Saccharomyces cerevtstee, two biochemical pathways ensure that
activated cytoplasmic or peroxisomal acetyl-groups are made available for
mitochondrial energy production when the cells utilise non-fermentable carbon
sources. The first pathway is the glyoxylate cycle, where two activated acetyl-groups
are incorporated into each cycle, which releases a C4 intermediate. This intermediate
is then transported to the mitochondria where it can enter the tricarboxylic acid cycle.
The second pathway is the carnitine shuttle. Activated acetyl-groups react with
carnitine to form acetylcarnitine, which is then transported to the mitochondria where
the acetyl group is transferred.
In this study it was shown that the deletion of the glyoxylate cycle specific citrate
synthase, encoded by CIT2, results in a strain that is dependent on carnitine for
growth on non-fermentable carbon sources. Using a /::"cit2 strain, mutants affected in
carnitine-dependent metabolic activities were generated. Complementation of the
mutants with a genomic library resulted in the identification of four genes involved in
the carnitine shuttle. These include: (i) the mitochondrial and peroxisomal carnitine
acetyltransferase, encoded by CAT2; (ii) the outer-mitochondrial carnitine
acetyltransferase, encoded by YA T1; (iii) the mitochondrial carnitine translocase,
encoded by CRC1; and (iv) a newly identified carnitine acetyltransferase, encoded by
YAT2. All three carnitine acetyltransferases are essential in a carnitine-dependent
strain.
The dependence on exogenous carnitine of the /::"cit2 strain when grown on non-
fermentable carbon sources suggested that S. cerevisiae does not biosynthesise
carnitine. Measurements using electrospray mass spectrometry confirmed this
hypothesis. As a result an investigation was initiated into carnitine biosynthesis in
order to genetically engineer a S. cerevisiae strain that could endogenously
biosynthesise carnitine.
The filamentous fungus, Neurospora crassa, was one of the first organisms used
in the seventies to identify the precursor and intermediates of carnitine biosynthesis.
However, it was only about twenty years later that the first genes encoding these
enzymes where characterised. Carnitine biosynthesis is a four-step process, which
starts with trimethyllysine as precursor. Trimethyllysine is converted to hydroxy-
trimethyllysine by the enzyme trimethyllysine hydroxylase (TMLH). Hydroxy-
trimethyllysine is cleaved to trimethylamino-butyraldehyde by the
hydroxytrimethyllysine aldolase (HTMLA) releasing glycine. Trimethylamino-
butyraldehyde is dehydrogenated to trimethylamino-butyrate (y-butyrobetaine) by
trimethylamino-butyraldehyde dehydrogenase (TMABA-DH). In the last step, y-
butyrobetaine is converted to t-carnltine by y-butyrobetaine hydroxylase (BBH).
The N. crassa TMLH homologue was identified in the genome database based
on the protein sequence homology of the human TMLH. Due to the high amount of
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introns predicted for this gene, the cDNA was cloned and subjected to sequencing,
which then revealed that the gene indeed had seven introns. Functional expression
of the gene in S. cerevisiae and subsequent enzymatic analysis revealed that the
gene coded for a TMLH. It was therefore named cbs-1 for "carnitine biosynthesis
gene no. 1JJ. Most of the kinetic parameters were similar to that of the human TMLH
enzyme. Following this, a genomic copy of the N. crassa BBH homologue was cloned
and functionally expressed in S. cerevisiae. Biochemical analysis revealed that the
BBH enzyme could biosynthesise L-carnitine from y-butyrobetaine and the gene was
named cbs-2. In addition, the gene could rescue the growth defect of the carnitine-
dependent Scii? strain on non-fermentable carbon sources when y-butyrobetaine was
present. This is the first report of an endogenously carnitine biosynthesising strain of
S. cerevisiae.
The cloning of the remaining two biosynthesis genes presents particular
challenges. To date, the HTMLA has not been characterised on the molecular level
making the homology-based identification of this protein in N. crassa impossible.
Although the TMABA-DH has been characterised molecularly, the protein sequence
is conserved for its function as a dehydrogenase and not conserved for its function in
carnitine biosynthesis, as in the case of TMLH and BBH. The reason for this is
probably due to the fact that the enzyme is involved in other metabolic processes.
The use of N. crassa carnitine biosynthesis mutants would probably be one way in
which to overcome these obstacles.
The !1cit2 mutant proved useful in studying carnitine related metabolism. We
therefore searched for suppressors of !1cit2, which resulted in the cloning of RAS2. In
S. cerevisiae, two genes encode Ras proteins, RAS1 and RAS2. GTP-bound Ras
proteins activate adenylate cyclase, Cyr1 p, which results in elevated cAMP levels.
The cAMP molecules bind to the regulatory subunit of the cAMP-dependent kinase
(PKA), Bcy1 p, thereby releasing the catalytic subunits Tpk1 p, Tpk2p and Tpk3p. The
catalytic subunits phosphorylate a variety of regulators and enzymes involved in
metabolism. Overexpression of RAS2 could suppress the growth defect of the Sclt?
mutant on glycerol. In general, overexpression of RAS2 enhanced the proliferation of
wild-type cells grown on glycerol. However, the enhancement of proliferation was
much better for the !1cit2 strain grown on glycerol. In this respect, the retrograde
response may play a role. Overexpression of RAS2 resulted in elevated levels of
intracellular citrate and citrate synthase activity. It therefore appears that the
suppression of !1cit2 by RAS2 overexpression is a result of the general upregulation
of the respiratory capacity and possible leakage of citrate and/or citrate synthase
from the mitochondria. The phenotype of RAS2 overexpression contrasts with the
hyperactive RAS2val19allele, which causes a growth defect on glycerol. However,
both RAS2 overexpression and RAS2val19activate the cAMP/PKA pathway, but the
RAS2val19dependent activation is more severe. Finally, this study implicated the
Ras/cAMP/PKA pathway in the proliferation effect on glycerol by showing that in a
Mpk1 strain, the growth effect is blocked. However, the enhanced proliferation was
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still observed in the Mpk2 and Mpk3 strains when RAS2 was overexpressed.
Therefore, it seems that Tpk1 p plays an important role in growth on non-fermentable
carbon sources, a notion that is supported by the literature.
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OPSOMMING
In die gis Saccharomyces cerevtstee, is daar twee metaboliese weë waarmee
geaktiveerde asetielgroepe na die mitochondrium vervoer kan word wanneer die sel
op nie-fermenteerbare koolstofbronne groei. Die een weg is die glioksilaatsiklus,
waar die geaktiveerde asetielgroepe geïnkorporeer word in die siklus en dan
vrygestel word as Ca-intermediêre. Hierdie intermediêre word dan na die
mitochondrium vervoer waar dit in die trikarboksielsuursiklus geïnkorporeer word. Die
ander weg is die karnitiensiklus, waar geaktiveerde asetielgroepe met karnitien
reageer om asetielkarnitien te vorm wat dan na die mitochondrium vervoer word waar
dit die asetielgroep weer vrygestel.
Hierdie studie het getoon dat die delesie van die glioksilaatsiklus spesifieke
sitraatsintetase, gekodeer deur CIT2, die gisras afhanklik maak van karnitien vir groei
op nie-fermenteerbare koolstofbronne. Deur gebruik te maak van 'n ócit2 gisras, kon
mutante, wat geaffekteer is in karnitien-verwante metaboliese aktiwiteite, gegenereer
word. Komplementering van die mutante met 'n genomiese biblioteek het gelei tot die
identifisering van vier gene betrokke by die karnitiensiklus. Hierdie gene sluit in: (i)
die mitochondriale en die peroksisomale karnitienasetieltransferase, gekodeer deur
CAT2; (ii) die buite-mitochondriale karnitienasetieltransferase, gekodeer deur YAT1;
(iii) die mitochondriale karnitientranslokase, gekodeer deur CRC1; en (iv) 'n nuut-
geïdentifiseerde karnitienasetieltransferase, gekodeer deur YAT2. Daar benewens, is
ook gewys dat al drie karnitienasetieltransferases noodsaaklik is in 'n karriltien-
afhanklike gisras.
Die afhanklikheid van eksogene karnitien van die ócit2 gisras, wanneer dit
gegroei word op nie-fermenteerbare koolstofbronne, was aanduidend dat
S. cerevisiae nie karnitien kan biosintetiseer nie. Metings deur middel van
elektronsproeimassaspektrometrie het hierdie veronderstelling bevestig. Gevolglik is
'n ondersoek deur ons geïnisieer in die veld van karnitienbiosintese om 'n
S. cerevisiae gisras geneties te manipuleer om karnitien sodoende endogenies te
biosintetiseer.
Die filamentagtige fungus, Neurospora crassa, was een van die eerste
organismes wat in die sewentiger jare gebruik is om die voorloper en intermediêre
van karnitienbiosintese te identifiseer. Dit was egter eers sowat twintig jaar later dat
die eerste gene wat vir hierdie ensieme kodeer, gekarakteriseer is.
Karnitienbiosintese is 'n vierstap-proses wat met trirnetlellisten as voorloper begin.
Trimetiellisien word omgeskakel na hidroksi-trimetiellisien deur die ensiem
trimetiellisienhidroksilase (TMLH). Hidroksietrimetlelllsien word dan gesplits om
trimetielaminobuteraldehied te vorm deur die werking van die
hidroksitrimetiellisienaldolase (HTMLA) met die gevolglike vrystelling van glisien.
Trimetielaminobuteraldehied word dan na trimetielaminobuteraat (y-butirobeteïen)
deur trimetielaminobuteraldehied dehidrogenase (TMABA-DH) gedehidrogeneer. In
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die laaste stap word y-butirobeteïen deur middel van die y-butirobeteïen hidroksilase
(BBH) na L-karnitien omgeskakel.
Op grond van die proteïenvolgordehomologie in die genoomdatabasis tussen die
menslike TMLH en N. crassa se TMLH is laasgenoemde geïdentifiseer. As gevolg
van die groot getal introns wat vir hierdie geen voorspel is, is die cDNA-weergawe
daarvan gekloneer en aan volgordebepaling onderwerp. Dit het getoon dat die geen
inderdaad sewe introns bevat. Funksionele uitdrukking van die geen in S. cerevisiae
en ensiematiese analise het getoon dat die geen vir 'n TMLH kodeer en is gevolglik
cbs-1 genoem; dit staan vir "karnitien biosintese geen no. 1tt. Meeste van die
kinetiese parameters was ook soortgelyk aan die van die menslike TMLH-ensiem.
Hierna is 'n genomiese kopie van N. crassa se BBH-homoloog gekloneer en
funksioneel in S. cerevisiae uitgedruk. Biochemiese analise het getoon dat die
uitgedrukte BBH-ensiem L-karnitien vanaf y-butirobeteïen kan biosintetiseer en die
geen is cbs-2 genoem. Daar benewens kon die geen die groeidefek van die
karnitien-afhanklike tlcit2-gisras ophef wanneer dit op nie-fermenteerbare
koolstofbronne in die teenwoordigheid van y-butirobeteïen aangekweek is. Hierdie is
die eerste verslag oor 'n endogeniese karnitien-biosintetiserende ras van
S. cerevisiae.
Die klonering van die oorblywende twee karnitienbiosintetiserende gene het
sekere uitdagings. Tot op datum, is die HTMLA nog nie tot op genetiese vlak
gekarakteriseer nie, wat dan die homologie-gebaseerde identifikasie van hierdie
proteïen in N. crassa onmoontlik maak. Alhoewel die TMABA-DH geneties
gekarakteriseer is, is die proteïenvolgorde ten opsigte van sy funksie as 'n
dehidrogenase gekonserveer, maar nie vir sy funksie in karnitienbiosintese soos in
die geval van TMLH en BBH nie. Die rede hiervoor is moontlik omdat die ensiem ook
in ander metaboliese prosesse betrokke is. Die gebruik van N. crassa
karnitienmutante sal moontlik een manier wees om hierdie probleme te oorkom.
Die tlcit2-mutant het handig te pas gekom vir die bestudering van karnitien-
verwante metabolisme. Dus is daar vir onderdrukkers van die tlcit2-mutant gesoek
wat gelei het tot die klonering van die RAS2-geen. In S. cere visiae , kodeer twee
gene vir Ras-proteïene, RAS1 en RAS2. GTP-gebonde Ras-proteïene aktiveer
adenilaatsiklase, Cyr1 p, wat verhoogde intrasellulêre cAMP-vlakke tot gevolg het.
Die cAMP bind aan die regulatoriese subeenheid van die cAMP-proteïenkinase
(PKA), Bcy1 p, en daardeur word die katalitiese subeenhede, Tpk1 p, Tpk2p en
Tpk3p, vrygestel. Die katalitiese subeenheid fosforileer 'n verskeidenheid van
reguleerders en ensieme betrokke by metabolisme. Ooruitdrukking van RAS2 het die
groeidefek van die tlcit2-mutant op gliserolonderdruk. Oor die algemeen, verbeter
die ooruitdrukking van RAS2 die proliferasie van die wildetipe op gliserol bevattende
media. Alhoewel, die verbetering van proliferasie was baie meer opmerklik in die
tlcit2-gisras. In hierdie verband, speel die gedegenereerde response dalk 'n rol.
Ooruitdrukking van RAS2 het verhoogde intrasellulêre vlakke van sitraat- en
sitraatsintetase-aktiwiteit tot gevolg gehad. Dit wou dus voorkom asof die
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onderdrukking van die ócit2-groeidefek deur RAS2 se ooruitdrukking die gevolg was
van algemene opreguiering van respiratoriese kapasiteit en die lekkasie van sitraat
en/of sitraatsintetase uit die mitochondria. Die fenotipe van RAS2 ooruitdrukking
kontrasteer die hiperaktiewe RAS2va/19 alleel, wat 'n groeidefek op gliserol media
veroorsaak. Alhoewel beide RAS2-00ruitdrukking en RAS2va/19 die cAMP/PKA-weg
aktiveer, is gevind dat die RAS2va/19-afhanklike aktivering strenger is. Ten slotte, die
cAMP/PKA-weg is in die proliferasie effek op gliserol media geïmpliseer deur te wys
dat in 'n Mpk1-gisras, die groeieffek geblokkeer is. Alhoewel, die verbeterde
proliferasie is steeds waargeneem in die Mpk2-en Mpk3-gisrasse toe die RAS2-geen
ooruitgedruk is. Dus, dit wil voorkom asof Tpk1 p 'n belangrike rol in die groei van
gisselle op nie-fermenteerbare koolstofbronne speel; 'n veronderstelling wat deur die
literatuur ondersteun word.
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~~ Chapter 1: General Introduction and Project Aims
1. Introduction
The yeast Saccharomyces cerevisiae has for more than a hundred years contributed
enormously to our understanding of biochemical pathways. Since Louis Pasteur first
proposed in 1860 that living cells, or rather yeast, convert grape sugars to alcohol,
this organism has been used as a model system. Later, Hans and Eduard Buchner
showed in 1897 that cell free extracts of yeast can convert sugar into ethanol and
thereby started to elucidate the metabolic pathway of glycolysis. This work initiated
the field of metabolic pathway analysis in living systems (Cohen, 1984). Today, with
the advent of yeast genetics, the genetic components of most biochemical pathways
have been determined, contributing to the molecular understanding of metabolism.
A biochemical pathway that has long been known, but has not been investigated
in yeast in any detail, is referred to as the carnitine shuttle. However, a significant
amount of data have been generated with regards to the function and genetic
components of the carnitine shuttle in mammalian cells.
2. Metabolic role of carnitine
In mammalian cells, the carnitine shuttle serves an essential function by transferring
activated short- and long-chained fatty acids into the mitochondria and the shuttle is
therefore required for survival. Carnitine reacts with acyl-CoA, to form acylcarnitine
and free CoA in the cytoplasma through the action of carnitine acyltransferases.
Acylcarnitine can then be translocated across the inner-mitochondrial membrane
through the carnitine-acylcarnitine translocase. Inside the mitochondria, the acyl
group is released to form acyl-CoA and carnitine; and the carnitine is shuttled back to
the cytoplasma. In this way, there can be a continuous flow of short- and long-
chained fatty acids into the mitochondria (Bieber, 1988).
Unlike mammalian cells, yeast does not generate and use long-chain acyl-CoA
groups; and only the 2-carbon acetyl-CoA moiety is present. Subsequently, carnitine
acetyltransferases (CATs) are the only carnitine acyltransferases present in yeast
(Bremer, 1983). Kispal et al. (1993) cloned the first CAT from yeast using specific
CAT antibodies that allowed them to identify the cDNA clones. They showed that this
CAT, encoded by CAT2, is responsible for most of the measured enzyme activity in
yeast. At the same time another CAT, encoded by YAT1, was cloned and shown to
be associated with the outer-mitochondrial membrane (Schmalix and Bandlow,
1993). These studies were restricted to enzymatic analysis and no significant insights
were achieved regarding the metabolic role of the carnitine shuttle. Later, important
data were generated with regards to the function of Cat2p in the cell by elucidating
the dual location in the peroxisome and the mitochondria when cells were grown on
fatty acids (Elgersma et al., 1995). At the same time, in a major breakthrough in the
field, it was shown that there are two pathways through which the activated acetyl
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~~ Chapter 1: General Introduction and Project Aims 2
groups of acetyl-CoA could enter the mitochondria when cells were grown on fatty
acids such as oleate (van Roermund et al., 1995). In these conditions, the fatty acids
are broken down in the peroxisome, which is the sole site for fatty acid degradation,
to form acetyl-CoA (Kunau et al., 1988). Metabolically, the activated acetyl groups in
the peroxisome can be transferred in two ways to the mitochondria for energy
production: (i) transfer of the acetyl group to carnitine, through the activity of Cat2p,
to form acetylcarnitine, which can then be transferred to the mitochondria or; (ii) entry
into the peroxisomal glyoxylate cycle, resulting in the net release of C4 intermediates,
which can be transferred to the mitochondria to enter the tricarboxylic acid (TCA)
cycle.
3. Carnitine biosynthesis
Humans, rats, plants and some fungi are able to biosynthesise carnitine from E-N-
trimethyllysine (TMl) in a four-step process (Lindstedt and Lindstedt, 1970; Kaufman
and Broquist, 1977; Bremer, 1983). TMl is provided by the lysosomal hydrolysis of
proteins that contain this amino acid as a result of the post-translational modification
of lysine residues. In the first step of the carnitine biosynthesis, TMl is hydroxylated
to P-hydroxY-E-N-trimethyllysine by E-N-trimethyllysine hydroxylase (Bremer, 1983;
Rebouche and Engel, 1980). Subsequently, P-hydroxY-E-N-trimethyllysine, is cleaved
into y-trimethyl-aminobutyraldehyde and glycine by P-hydroxY-E-N-trimethyllysine
aldolase (Bremer, 1983; Rebouche and Engel, 1980). The aldehyde is then oxidised
by y-trimethyl-aminobutyraldehyde dehydrogenase to form y-butyrobetaine (Hulse
and Henderson, 1980; Rebouche and Engel,1980; Bremer, 1983). Finally, y-
butyrobetaine is hydroxylated at the 3-position by y-butyrobetaine hydroxylase to
form L-carnitine (Englard, 1979; Bremer, 1983; Rebouche and Engel, 1980).
The genetic code for one of these enzymes was first elucidated in 1998 (Vaz et
al., 1998). Subsequently, enzymes required for the catalysis of three of the four
reactions required for carnitine biosynthesis have been characterised at the
molecular level, either in rat, mouse or man, most of the work being done by the
same group (Vaz et al., 1998; Galland et al., 1999, Vaz et al., 2000; Vaz et al., 2001).
4. Project background
The initial aim of our research was to clone a carnitine transporter from S. cerevisiae.
It was decided to use a mutant screen approach and the question arose whether the
carnitine shuttle is the only pathway through which activated acetyl groups can be
transferred to the mitochondria. The answer to this question was experimentally
demonstrated by showing that by deleting the glyoxylate cycle citrate synthase,
encoded by CIT2, the cells grew normally on fatty acids but they did not grow in
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these conditions when the carnitine acetyltransferase, encoded by CAT2, was also
deleted. Deletion of CAT2 alone did not affect growth on fatty acids. Therefore, in the
Scii? mutant strain, the cell is dependent on the carnitine shuttle, and subsequently
L-carnitine, to grow in these conditions (van Roermund et al., 1995).
The glyoxylate cycle is a modified TCA cycle, which incorporates acetyl-CoA, but
instead of releasing CO2, releases succinate, requiring the inflow of two acetyl-CoAs
and the unique intermediate, glyoxylate (Kornberg, 1966). As in the case of the TCA
cycle, the incorporation of acetyl-CoA is catalysed by a citrate synthase, Cit2p,
through the binding of acetyl-CoA to oxaloacetate, releasing CoA and forming citrate.
The glyoxylate cycle citrate synthase, Cit2p, is cytosolic (and peroxisomal when cells
are grown on fatty acids) whereas the TCA cycle citrate synthase, Cit1 p, is
mitochondrial (Kispal et al., 1988). Another mitochondrial citrate synthase exists,
Cit3p, but its specific function is not clear (Jia et al., 1997). Deleting either Cit1 p or
Cit2p does not result in a phenotype on rich media with a non-fermentable carbon
source, but deleting both results in a severe growth defect in these conditions (Kispal
et al., 1988).
The phenotype of the t:..cit2mutant grown on non-fermentable carbon sources
would indicate to us if S. cerevisiae could endogenously biosynthesise carnitine. By
growing the Scit? strain on synthetic non-fermentable carbon sources (no carnitine),
growth would indicate endogenous biosynthesis and no growth no biosynthesis.
Results obtained showed that the latter is the case and that exogenous carnitine
could rescue this growth defect. Therefore, a carnitine-dependent strain of
S. cerevisiae was generated. This strain allowed; (i) the development of a genetic
screen to identify genes coding for proteins involved in the carnitine shuttle; (ii) the
assesment of the ability of a heterologous gene product to endogenously produce
carnitine in S. cerevisiae; (iii) the development of a plate assay for the identification of
carnitine producing microorganisms; and (iv) the cloning of carnitine-independent
suppressors of the t:..cit2 mutant. Indeed, this strain was used in all four papers
presented in the results section of this work (Chapters 3-6).
5. Specific aims
The specific aims of this study were:
(i) to identify genes encoding proteins involved in the carnitine shuttle;
(ii) to assert the specific function of the proteins in the carnitine shuttle;
(iii) to heterologously clone and express possible carnitine biosynthesising genes;
(iv) to characterise the cloned genes and products on genetic and enzymatic level;
(v) to develop a carnitine biosynthesising S. cerevisiae strain; and
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(vi) to develop a better understanding of the regulation and metabolism of
S. cerevisiae on non-fermentable carbon sources in regards to the carnitine
shuttle and glyoxylate cycle.
The results and discussions regarding the fulfilment of these aims are discussed
in Chapters 3-6. To give a comprehensive background to the work, a literature
review, Chapter 2, was compiled on the role of carnitine acyltransferase and carnitine
biosynthesis enzymes in eukaryotic metabolism.
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1. The carnitine acyltransferase system
1.1 Carnitine: The molecule and its history
Carnitine (L-3-hydroxy-4-N,N,N-trimethylaminobutyrate) is a quaternary ammonium
compound with high polarity. It was discovered more than a century ago in muscle
cells and its chemical structure was determined 30 years later (Tomita and Sendju,
1927; Bremer, 1983). The metabolic importance of carnitine came to light during the
middle of the last century when it was shown that carnitine is essential for the
mealworm Tenebrio molitor, hence the other name, vitamin BT (Carter et aI., 1952).
Later, the role of carnitine in the shuttling of acyl groups to the mitochondria was
discovered by two sets of work, which indicated that carnitine could be reversibly
acetylated by acetyl-CoA, and that carnitine induced f3-oxidation (Friedman and
Fraenkel, 1955; Fritz 1963). Today, a literature search using carnitine as keyword
delivers more than 7000 scientific publications in peer-reviewed journals, indicating
its importance in living systems. The chemical structure of carnitine is shown in
Figure 1.
Figure 1. Chemical structure of carnitine (L-3-hydroxy-4-N,N,N-trimethylaminobutyrate)
1.2 Esterification of carboxylic acids to CoA and carnitine
The primary function of carnitine in living organisms is to act as a shuttling molecule
in order to transfer activated acyl groups across intracellular membranes. The
activation of carboxylic acids through esterification to CoA is a common biochemical
mechanism which cells use to make these compounds available for metabolic
processes. In eukaryotes, however, there are physiological and metabolic obstacles
the cell has to overcome. First, the organellar membranes are impermeable to acyl-
CoA and secondly, activation of the acetyl groups removes free CoA from the limited
pool available in the different cellular compartments (Bremer, 1983). To overcome
these obstacles, the cell trans-esterifies acyl groups to carnitine to form
acylcarnitines, which can then be transferred in-between intracellular compartments.
This is a reversible reaction and the acylcarnitines can react again with free CoA to
form carnitine and acyl-CoA. This process forms a shuttle mechanism and is
therefore called the carnitine shuttle. Through the carnitine shuttle, the CoA pools
can also be balanced in the different cellular compartments (Bremer, 1983).
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RCO-S-CoA + carnitine-OH ¢:> RCO-O-carnitine + CoA-SH
On the molecular level, the carnitine shuttle requires specific carnitine/
acylcarnitine translocases in the organellar membranes that can channel these
compounds in and out of the cellular compartments. In addition, enzymes are
required in these compartments that can reversibly acylate carnitine. These enzymes
are called carnitine acyltransferases and they will be discussed in more detail with
regards to their structure and function.
1.3 Carnitine acyltransferases
The yeast Saccharomyces cerevisiae only possesses one class of carnitine
acyltransferase, namely carnitine acetyltransferase (Bremer et al., 1983; Kispal et al.,
1993; Schmalix and Bandlow, 1993; Swiegers et al., 2001). On the other hand,
mammalian cells possess several classes of carnitine acyltransferases. The different
classes are distinguished by the chain-length of the carboxylic acids that are
esterified to carnitine by the enzyme. This can either be short-chain carboxylic acids
e.g. acetyl or different lengths of long-chain carboxylic acids e.g. octanoyl and
palmitoyl. The carnitine acyltransferases found in mammalian cells are carnitine
palmitoyltransferase 1 and 2, carnitine octanoyltransferase and carnitine
acetyltransferase (Bremer, 1983). These enzymes can be sub-classified in two
groups based on their inhibition and non-inhibition by malonyl-CoA. The malonyl-CoA
sensitive acyltransferases have their catalytic sites facing the cytosol, the exclusive
location of malonyl-CoA (Frazer et al., 1997; Zammit et al., 1997; Zammit et al.,
1998). Interestingly, there is an inverse relationship between fatty acid oxidation (a
pathway where carnitine acyltransferases play an important role) and malonyl-CoA
concentration (McGarry and Foster, 1979). In mammals, malonyl-CoA serves as an
important regulatory target for insulin, which stimulates an increase in the
concentration of malonyl-CoA whereas glucagon results in the decrease of malonyl-
CoA concentration, making this an important area of diabetes research (Beynen et
al., 1979). A schematic representation of the localisation and function of carnitine
acyltransferases in mammalian cells is given in Figure 2.
1.3.1 Carnitine acetyltransferases
Carnitine acetyltransferases (CATs) are found in most eukaryotic organisms. CATs
catalyse the reversible reaction between acetyl-CoA and carnitine to form
acetylcarnitine and free CoA.
acetyl-CoA + carnitine ¢:> acetylcarnitine + CoA
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Figure 2. Localisation and function of camitine acyltransferases in mammalian cells. The
camitine palmitoyltransferase 1 (CPT1) is located in the outer-mitochondrial membrane and
catalyses the reaction of long-chain acyl-CoA to long-chain acylcarnitine which is then
tranlocated by the mitochondrial inner-membrane CACT into the mitochondrial matrix. The
camitine palmatoyltransferase 2 (CPT2) enzyme is attached to the inner-mitochondrial
membrane and converts the long-chain acylcamitine to long-chain acyl-CoA, releasing
camitine. Long-chain acyl-CoA is oxidised to acetyl-CoA which can be converted by the
mitochondrial matrix CAT to acetylcarnitine and translocated out of the mitochondria and/or it
can be used in the TCA cycle for energy production.
In some organisms, such as the yeast S. cere visiae , CATs are the only carnitine
acyltransferases present (Kispal et al., 1993; Schmalix and Bandlow, 1993; Swiegers
et al., 2001). CATs are relatively easily extracted and purified from living material and
have been isolated from pigeon breast (the commercially available CAT) and yeast
such as Candida tropicalis (Chase et al., 1967; Ueda et at., 1982). In rat liver cells,
the enzyme is found in the lumina of the mitochondria, peroxisomes and also in
mircrosomes, with most activity being associated with the mitochondria (Markwell et
al., 1973; Kahonen, 1976). The presence of a cytosolic CAT has not been confirmed
in mammalian cells. It has been concluded in a study on heart cells that, if cytosolic
CATs are present, their activity is probably very low (Abbas et al., 1998). In other
organisms such as the filamentous fungi Aspergillus nidulans and the yeast
S. cerevisiae, it has however been shown that cytosolic CATs are present and active
(Stemple et al., 1998; Swiegers et al., 2001; Kroppenstedt et al., unpublished).
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In humans, a single gene appears to encode peroxisomal and mitochondrial CAT
(Corti et al., 1994). The differential splicing of the mRNA results in two transcripts,
with the longer transcript containing the N-terminal mitochondrial targeting signal.
After mitochondrial matrix protease modification the mitochondrial CAT is smaller
(67,5 kDa) compared to the peroxisomal CAT (69 kDa). Both enzymes contain the
peroxisomal C-terminal AKL peroxisomal target, suggesting that the mitochondrial
signal overrides the peroxisomal signal (Corti et al., 1994). In the yeast S. cerevisiae,
a similar transcriptional regulation of the CAT2 gene, encoding carnitine
acetyltransferase, exists (Elgersma et al., 1995). As in humans, the CAT2 mRNA is
differentially spliced in order to translate peroxisomal and mitochondrial targeted
CATs. However, evidence for mitochondrial modification of the mitochondrial CAT
has not been presented.
In mammalian cells, medium- and long-chain fatty acid ~-oxidation (degradation
of fatty acids) occurs in the mitochondria. However, very-long-chain fatty acids first
undergo partial ~-oxidation in the peroxisome and the resulting catabolic product,
acetyl-CoA, is transferred from the peroxisome to the mitochondria. This process is
facilitated by peroxisomal and mitochondrial CATs. In contrast, the peroxisome is the
sole site for ~-oxidation in S. cerevisiae (Kunau et al., 1988). The activated acetyl
residue is transferred out of the peroxisome through the activity of Cat2p and the
carnitine shuttle (van Roermund et al., 1995). The CoA pool in the peroxisomes of
eukaryotic cells is limited and CATs are therefore essential for ~-oxidation to proceed
because they free CoA by removing activated acetyl groups from the peroxisome.
In mammalian cells, acetyl-CoA in the mitochondria originates from only two
sources: fatty acid ~-oxidation and glucose metabolism (glycolysis). In the second
case, pyruvate is transferred from the cytosol through the pyruvate dehydrogenase
complex (PDH) leading to the formation of acetyl-CoA in the mitochondria. In addition
to these two origins, yeast and filamentous fungi can also recruit acetyl-CoA to the
mitochondria from the cytosol. In this case, acetyl-CoA is generated through the
metabolism of ethanol and acetate. This may explain the presence of a cytosolic CAT
in these organisms.
Recent work on CATs in S. cerevisiae has indicated some interesting phenotypes
of CAT deletion mutants when cells are grown on non-fermentable carbon sources
(e.g. fatty acids, ethanol, acetate) (van Roermund et al., 1995; Swiegers et al., 2001).
In yeast, unlike in mammals, the carnitine shuttle is not the only pathway through
which peroxisomal and cytosolic activated acetyl groups can be transferred to the
mitochondria. The glyoxylate cycle, which is not present in mammals, can incorporate
two acetyl-CoAs and release succinate, which can be transferred to the mitochondria.
Therefore, strains of S. cerevisiae that have a disrupted glyoxylate cycle because of
the deletion of the citrate synthase, encoded by CIT2, are dependent on L-carnitine,
and therefore the carnitine shuttle, for growth on non-fermentable carbon sources.
Disruption of any of the three identified CATs in the !1cit2 mutant results in a severe
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growth defect on non-fermentable carbon sources, even in the presence of carnitine
(Swiegers et al., 2001). Indeed, S. cerevisiae has three CAT encoding genes: (i)
CAT2, encoding the mitochondrial CAT (Kispal et al., 1993; Elgersma et al., 1995);
(ii) YAT1, encoding an outer-mitochondrial CAT and (iii) YAT2, encoding the cytosolic
CAT; (Swiegers et al., 2001; Kroppenstedt et al., unpublished). A presentation of the
carnitine acetyltransferases in S. cerevisiae is shown in Chapter 3, Figure 4.
The differences between yeast and mammalian metabolism are important factors
influencing the carnitine acyltransferase function in these cells. To summarise, the
differences are as follows: (i) yeast metabolise acetate and ethanol to acetyl-CoA in
the cytosol whereas mammalian cells do not use these compounds as carbon
source; (ii) yeast have the unique glyoxylate cycle functioning in the cytosol or
peroxisome; and (iii) yeast p-oxidation is restricted to the peroxisome whereas
mammalian p-oxidation is located primarily in the mitochondria.
In mammalian cells, p-oxidation of fatty acids in the mitochondria has important
regulatory effects on their activation in the cytosol, which could help explain why
there are no CATs in this compartment. Studies have shown that during high rates of
fatty acid p-oxidation, there is a major increase in acetylcarnitine concentration in the
mitochondria (Zammit, 1981). This results in the efflux of a large amount of
acetylcarnitine from the mitochondria into the cytosol. Hypothetically, if CATs were
present in the cytosol, they would catalyse the formation of large amounts of carnitine
and acetyl-CoA. Subsequently, the limited pool of free CoA would be depleted. In
contrast to yeast, free CoA is needed in the cytosol of mammalian cells for the
activation of fatty acids. After activation, fatty acids can then enter the mitochondria to
be catabolised through p-oxidation. The depletion of free CoA would inhibit p-
oxidation of fatty acids because there would not be enough CoA left for activation.
Moreover, the high concentration of acetyl-CoA in the cytosol would provide building
blocks for the formation of the cytosolic malonyl-CoA. Malonyl-CoA inhibits the
function of outer-mitochondrial carnitine palmitoyltransferase 1, which is essential for
fatty acid oxidation. Therefore, the presence of a cytosolic CAT would be counter
productive in conditions where the cell needs to oxidise large amounts of fatty acids.
Without the cytosolic CAT, as is the case, acetylcarnitine will either leave the cell or
be transported to organelles such as the peroxisome where it can be converted to
acetyl-CoA, thereby avoiding the formation of this compound in the cytosol.
1.3.2 Carnitine palmitoyltransferases
In 1955, work on carnitine acyltransferases was initiated through research showing
that the oxidation of the long-chain fatty acid, palmitic acid, could be performed by
liver homogenates (Fritz, 1955). This finding created interest in the field and later
studies identified carnitine as a mediator of fatty acid oxidation. It was shown that
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carnitine palmitoyltransferase enzymes were required for the transfer of long-chain
acyl-CoA from the cytosol to the mitochondria. In this way, the problem of
impermeability of the mitochondrial inner-membranes to CoA esters could be
overcome (Fritz, 1963). After this work, the field did not draw much attention until it
was discovered in 1973 that a defective carnitine palmitoyltransferase (CPT) could
give rise to debilitating human diseases (DiMauro and DiMauro, 1973). This initiated
a major thrust of research on CPT enzymes, in particular regarding their structure,
function and regulation.
1.3.2.1 Carnitine palmitoyltransferase 1
1.3.2.1.1 Primary structure and topology
The mitochondrial carnitine palmitoyltransferase 1 (CPT1), situated in the outer-
mitochondrial membrane, is by far the most studied CPT. It has an interesting
structure which is important for function and regulation.
There are two isoforms of CPT1, the liver (L) and the muscle (M) isoforms, each
encoded by its own gene. In addition, there has been a recent report indicating that
the mRNAs of the L-CPT1 and M-CPT1 undergo differential splicing, subsequently
resulting in different sized CPTs translated from each of the two genes (Yu et al.,
1998). In rats, the L-CPT1 is found in the liver, kidney, pancreatic cells, ovary,
spleen, intestine and brain while the M-CPT1 is found in the heart, skeletal muscles
and adipose tissue (Brown et al., 1997).
The amino acid sequences of M-CPT1 and L-CPT1 have a similarity of 63% to
each other. There are also regions in both isoforms with high homology to CPT2. The
primary structure of M-CPT1 consists of a short N-terminal domain, two
transmembrane domains separated by a hydrophilic loop and a catalytic C-terminal.
This correlates with the membrane topology determined for L-CPT1 expressed in
hepatic cells (Fraser et al., 1997). The CPT1 secondary structure can be divided into
four domains. The N-terminal and catalytic C-terminal domains are on the cytosolic
side of the membrane. The loop, situated between the two transmembrane regions,
faces the mitochondrial inner-membrane space. Both the acyl-CoA and the inhibiting
malonyl-CoA sites of the CPT1 enzyme face the cytosol (Fraser et al., 1997). An
illustration of the membrane topology and interactions is shown in Figure 3.
Recently, the structure function relationship of CPTs was examined through
heterologous expression of CPTs in the yeasts Pichia pastoris and S. cere visia e.
These organisms are devoid of CPT activity and are able to express mammalian
CPTs functionally, making the analysis of enzyme activity simple. The rat L-CPT1
cDNA was successfully expressed in P. pastoris and it was confirmed in this system
that the enzyme is catalytically active, malonyl-CoA sensitive and reversibly
inactivated by detergents such as Triton-X-100 (de Vries et al., 1997). It is important
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to consider the last point when enzyme activity assays are conducted on enzymes
expressed in yeast as detergents can inhibit their activity. However, in S. cerevisiae
initial expression studies were not conclusive because not enough active enzyme
was expressed to evaluate its properties accurately (Brown et al., 1994). Improved
expression of CPT1 in S. cerevisiae has recently been reported (Prip-Buus et al.,
1998). In this work, comparisons were also made between the CPT1 expressed in
S. cerevisiae and the CPT1 expressed in P. pastoris and rat liver mitochondria
(RLM). The kinetic parameters of the enzymes expressed in the three systems
indicated similar Km values for carnitine. However, the Km and Vmax values for
palmitoyl-CoA were higher for the P. pastoris and S. cerevisiae expressed enzymes
compared to that of the RLM enzyme. Besides the analysis of kinetic parameters, the
successful expression of CPT1 enzymes in yeast can also be used as an effective
system to study structure/function relationships through targeted mutagenesis and
subsequent analysis of function. For instance, the location of the binding sites of
CPT1 for its substrates and the inhibiting malonyl-CoA has been determined using P.
pastoris as an expression system. These sites were mutated and subsequent
analysis revealed which substrate or inhibitor was not able to bind (de Vries et al.,
1997, Zhu et al., 1997a; Zhu et al., 1997b).
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Figure 3. Structure and interactions of the camitine palmitoyltransferase 1 (CPT1) in the
outer-mitochondrial membrane. (A) The enzyme consists of two transmembrane domains
(TM1 and TM2) connected by a loop domain in the inter-membrane space. The cytosolic side
consist of a short N-terminal domain and a long C-terminal domain. Most of the protein is on
the cytosolic side of the membrane and the substrate and malonyl-CoA binding sites are
situated in this region. (8) The N-terminal domain interacts with the C-terminal domain to
maintain the tertiary structure for optimal catalytic activity and sensitivity to malonyl-CoA.
Interactions between the TM1 and TM2 domains can affect catalytic activity (Zammit, 1999).
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Although expression of CPTs in heterologous systems is useful, the foreign
environment can have some negative influences on the enzyme. In order to mimic
conditions in the mitochondrial membrane, CPT1 s have recently been reconstituted
in liposomes and their activity analysed (McGarry and Brown, 2000). Six CPT1 s were
histidine-tagged and expressed in P. pastoris. The enzymes were isolated and
purified using a metal-chelate affinity matrix. The initial isolation procedure from the
yeast made use of Triton X-100, which is known to inhibit CPT1 activity because this
compound disrupts the outer-mitochondrial membrane. Indeed, enzymatic analysis
indicated that CPT1 activity was almost completely abolished. The purified enzyme
was then reconstituted in liposomes and showed a 200 to 400-fold increase in
enzymatic activity. Comparison of the enzymatic activity of CPT1 in liposomes with
that of CPT1 enzyme in rat liver and P. pastoris mitochondria, showed that the
enzyme behaved much more like the native rat liver mitochondrial enzyme that the
heterologous P. pastoris enzyme. These data support the use of this system to study
CPT1 function (McGarry and Brown, 2000).
The study of the structure/function relationship of CPT1 led to the determination
of the specific topology of the enzyme in the outer-mitochondrial membrane and the
factors influencing its function. Two important discoveries were that the substrate and
malonyl-CoA binding sites, as well as the N- and C-terminal domains, face the
cytosol. In addition, it was found that interactions between the N- and C-terminal
domains are important in maintaining the tertiary structure of CPT, which then
ensures optimal activity of the catalytic domains (Zammit et al., 1997). Removal of
only nine N-terminal amino acids resulted in a 60% loss of activity and made the
enzyme malonyl-CoA insensitive (Fraser et al., 1997). Changing the N-terminal
amino acids of CPT1 can also influence the kinetics of the enzyme. This was
demonstrated by replacing the distinctive N-terminal segment of ovine M-CPT1 with
that of rat M-CPT1 (Price et al., 2003). As a result, the Km for the P. pastoris
expressed enzyme was altered for palmitoyl-CoA (decreased) and carnitine
(increased). Other workers focussed on the C-terminal region of M-CPT1 by making
a series of deletions and substitutions in this region and measuring the activity of the
P. pastoris expressed enzymes (Oai et al., 2003). It was shown that leucine-764 is
essential for catalysis. Substitution of leucine with alanine resulted in a 40% loss of
activity while substitution with arginine resulted in 84% loss of activity. Interestingly,
substitution with a valine had no effect on activity. Secondary structure analysis
showed that amino acid residues 744-764 form a coiled-coil alpha helix in the
extreme C-terminal region and that this may be important for folding and subsequent
activity.
Topological effects of the mitochondrial outer- and inner-membrane itself have an
influence on the optimal functioning of CPT1. Previously, it has been indicated that
the inner- and outer-mitochondrial membranes have contact sites between them in
some places, which would then imply possible contact between CPT1 and the inner-
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mitochondrial carnitine palmitoyltransferase, CPT2 (Fraser and Zammit, 1998).
Therefore, it has been proposed that channelling of acetylcarnitine into the
mitochondria takes place through the CPT1/CPT2 contact sites (Zammit, 1999). In
support of this hypothesis, these contact sites represent 5-10% of the surface area of
the outer-mitochondrial membrane but contribute about 40% of both CPT1 and CPT2
activity. Interestingly, the carnitine transporter is not concentrated at the contact sites
but is more randomly distributed around the inner-mitochondrial membrane,
indicating that it might have a more general role in the reverse uptake and outflow of
carnitine and acetylcarnitine (Zammit, 1999)
1.3.2.1.2 Metabolic regulation
In mammals, during starvation and uncontrolled diabetes, the liver increases the
production of ketone bodies. This increase is initiated by a fall in the level of insulin
(due to low blood glucose levels), resulting in a change in the metabolism of liver
cells. In the liver cells, fatty acids can either be synthesised through lipogenesis in the
cytoplasma or oxidised through p-oxidation in the mitochondria. A drop in insulin
shifts the metabolic balance to the desired oxidation of fatty acid reserves, resulting
in the formation of ketone bodies.
A molecule at the centre of this switch in liver cell metabolism is malonyl-CoA,
which is exclusively located in the cytosol. Insulin activates the acetyl-CoA
carboxylase, the enzyme that catalyses the synthesis of malonyl-CoA, thereby
increasing the level of malonyl-CoA in the cytosol. On the one hand, malonyl-CoA is
the precursor for fatty acid synthesis, while on the other hand, it inhibits L-CPT1,
which initiates fatty acid oxidation in the mitochondria (McGarry and Foster, 1980;
McGarry et aI., 1989). During high insulin conditions (high blood glucose), the
concentration of malonyl-CoA increases in the liver cells, thereby inhibiting CPT1.
This increase in malonyl-CoA concentration also makes it availability for lipogenesis,
which results in an increase of fatty acids synthesis for storage as energy reserves.
During low insulin conditions (low blood glucose), the concentration of malonyl-CoA
drops, resulting in less substrate available for lipogenesis and less inhibition of CPT1.
This shifts the metabolic balance to the oxidation of fatty acid reserves. Interestingly,
in these conditions the level of carnitine in the liver also increases, thereby facilitating
the oxidation of fatty acids (McGarry and Foster, 1980; McGarry et al., 1989).
The presence of two distinct CPT1 isoforms in mammalian cells is due to the
different metabolic needs of specific cells. In comparison to liver cells, heart and
muscle cells have a greater need for the oxidation of fatty acids to produce energy.
Therefore, the muscle M-CPT1 isoform is regulated differently from the liver L-CPT1.
M-CPT1 is much more sensitive to malonyl-CoA and has a much higher affinity for
carnitine (McGarry et aI., 1983; Saggerson and Carpenter, 1981). In muscle cells, a
raise in insulin (as a result of high blood glucose) causes the predictable increase in
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malonyl-CoA concentration. Due to the sensitivity of M-CPT1 to malonyl-CoA, the
enzyme is immediately inhibited. Metabolism can then quickly be shifted to glucose
oxidation in the mitochondria via the pyruvate dehydrogenase complex (Saddik et al.,
1993; Stanley et al., 1996). Therefore, the shift to glucose oxidation in muscle cells is
much more sensitive and rapid in conditions of high glucose than is the case for liver
cells.
The central regulatory role that CPTs play in regulating blood glucose levels
through fatty acid oxidation have made them a prime target for developing drugs for
type 2 diabetes. Attempts are being made to design selective inhibitors for L-CPT1.
These inhibitors would inhibit the function of L-CPT1 and thereby decrease fatty acid
oxidation. This would shift metabolism towards glucose oxidation and result in a
decrease in blood glucose levels (Anderson, 1998). However, a major problem with
these CPT1 inhibitors would be their effect on M-CPT1 in the heart cells. In these
cells there is a continuous need for fatty acid oxidation to produce energy, and
therefore inhibition of CPT1 would have severe side effects. A possible solution to
this problem might be to develop CPT1 isozyme specific inhibitors but this appears a
difficult task due to the high protein homology of these enzymes.
1.3.2.2 Carnitine palmitoyltransferase 2
The carnitine palmitoyltranferase 2 (CPT2) is situated on the inner-mitochondrial
membrane facing the mitochondrial matrix (Fraser and Zammit, 1998). The catalytic
C-terminal section of CPT2 has significant homology to the catalytic C-terminal
section of CPT1 but it does not posses the N-terminal and transmembrane domains.
CPT2 is not sensitive to malonyl-CoA inhibition, which may be due to its location in
the mitochondria since the mitochondria and the mitochondrial inner-membrane
space do not contain any malonyl-CoA (Declercq et al., 1987). CPT2 converts
acylcarnitine into acyl-CoA, releasing carnitine, which can be transferred out of the
mitochondria or converted to acetylcarnitine via CAT before transfer out of the
mitochondria (Ventura et al., 1998).
As in the case of CPT1, CPT2 has also been successfully cloned and functionally
expressed in S. cerevisiae and P. pastoris (Brown et al., 1994; de Vries et al., 1997).
In these studies, the site directed mutagenesis of the CPT2 gene indicated that
changes of the histidine residue 372, the aspartate residue 376 and the aspartate
residue 464 to alanine. Expressing these mutated enzymes in S. cerevisiae resulted
in complete loss of CPT2 activity.
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2. Carnitine biosynthesis
One of the first organisms that were shown to biosynthesise carnitine is the
filamentous fungi Neurospora crassa (Fraenkel, 1953). Elucidation of the biochemical
pathway for carnitine biosynthesis started in 1961 when Bremer showed that the
methyl groups attached to the amino group of carnitine originate from methionine and
not from choline. The following year, it was also shown that y-butyrobetaine and not
y-aminobutyric acid or y-dimethylaminobutyrate is the final intermediate before
carnitine is formed (Bremer, 1962). The origin of the carnitine backbone stayed an
enigma for about ten years before investigators showed that labelled lysine is
converted to carnitine in N. crassa (Horne et al., 1971; Horne and Broquist, 1973).
Since then the complete pathway for carnitine biosynthesis has been established, but
surprisingly, the first gene sequence for a carnitine biosynthesis enzyme was only
published in 1998 (Vaz et al., 1998). Today, three of the four genes coding for
carnitine biosynthesis enzymes are known for various organisms (Vaz et al., 1998;
Galland et al., 1999; Vaz et al., 2000; Vaz et al., 2001; Swiegers et al., 2002;
Swiegers et al., unpublished; Chapter 5).
This review focusses on the discovery, the enzymatic and genetic
characterisation, and the methods of analysis of the carnitine biosynthesis enzymes.
One of the long term goals of our group is to develop a de novo carnitine
biosynthesising strain of S. cere visiae , so particular attention will be given to detailed
issues regarding extraction protocols, enzymatic analysis and genetic
characterization, in order to provide a complete reference for future work. The
biochemical pathway and intermediates of carnitine biosynthesis are shown in
Figure 4.
2.1 Enzymes involved in carnitine biosynthesis
In the first step of carnitine biosynthesis, trimethyllysine (TML) is hydroxylated by the
trimethyllysine hydroxylase (TMLH; EC 1.14.11.8) to form 3-hydroxytrimethyllysine
(HTML). The aldolytic cleavage of HTML farms 4-trimethylaminobutyraldehyde
(TMABA) and glycine, in a reaction catalysed by hydroxytrimethyllysine aldolase
(HTMLA; EC 4.1.2.'X'). The dehydrogenation of 4-trimethylaminobutyraldehyde by
trimethyl-aminobutyraldehyde dehydrogenase (TMABA-DH; EC 1.2.1.47) results in
the formation of 4-N-trimethylaminobutyrate (y-butyrobetaine). The last step involves
the hydroxylation, at the 3-position, by y-butyrobetaine hydroxylase (BBH; EC
1.14.11.1). The following sections will describe each of the four enzymes in more
detail. A schematic representation of the enzymes involved in carnitine biosynthesis
is shown in Figure 5.
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Figure 4. The biochemical intermediates of camitine biosynthesis.
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Figure 5. Localisation and fundion of the camitine biosynthesis enzymes in mammalian cells
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2.1.1 Trimethyllysine hydroxylase (TMLH)
The precursor for the first step in carnitine biosynthesis is the molecule
trimethyllysine (TML). The role of lysine in carnitine biosynthesis was first established
in 1971, when it was shown that in a N. crassa lysine auxotroph, radiolabelled lysine
was incorporated into carnitine when the fungi was grown on a carnitine-free
synthetic medium (Horne et al., 1971). In animals, certain lysine residues are post-
translationally trimethylated in proteins such as myosin, actin and histones by protein
lysine methyltransferase (EC 2.1.1.43), and after their degradation, released and
used for carnitine biosynthesis (Labadie et al., 1976; Dunn and Englard, 1981). The
three methyl groups of TML originate from S-adenosylmethionine (Tanphaichitr et al.,
1971 ).
In contrast to animals, free lysine in N. crassa is sequentially methylated to form
trimethyllysine through the action of a S-adenosylmethionine-6-N-L-lysine
methyltransferase (EC 2.1.1-) (Borum and Broquist, 1977). The enzyme is a soluble
monopeptide of 22 kDa and transfers all three methyl groups in a stepwise fashion,
with the second transfer faster than the first and the last transfer the faster than the
second. In this way the formation of partially methylated lysine is prevented. This is in
contrast to animals, where mono- and dimethyllysine can be found in different
proteins, but only trimethyllysine is converted to carnitine (Paik and Kim, 1975;
Labadie et al., 1976). Unfortunately, no genetic information is available for N. crassa
S-adenosylmethionine-6-N-L-lysine methyltransferase, since this gene would be a
prime target for manipulation in order to increase the amount of TML produced.
The first step in the identification of TMLH was made in 1976, when it was shown
that trimethyllysine injected into a rat was secreted in the urine as
hydroxytrimethyllysine (Hoppel et al., 1976). The first report on the hydroxylation of
TML was published in 1978 when it was shown that rat liver mitochondria are
capable of hydroxylating TML to produce 3-hydroxytrimethyllysine (HTML) (Hulse et
al., 1978). Later, Sachan and Hoppel showed that rat kidney homogenates were also
able to hydroxylate TML to HTML and at the same time, Sachan and Broquist
showed that non-mitochondrial cellular fractions of N. crassa were also able to
perform this reaction (Sachan and Broquist, 1980; Sachan and Hoppel, 1980).
These workers confirmed through their enzymatic assays that TMLH is a non-
haem ferrous-iron hydroxylase, which needs a-ketoglutarate, Fe2+ and O2 as co-
factors (Hulse et aL, 1978; Sachan and Broquist, 1980; Sachan and Hoppel, 1980).
In general, non-haem ferrous-iron hydroxylases require the decarboxylation of a-
ketoglutarate to form succinate and CO2. At the active site of the enzyme, the O2
reacts to form an oxo-ferryl intermediate (Fe4+=0) which is used to hydroxylate the
substrate after which the O2 is incorporated into a-ketoglutarate resulting in the
formation of succinate and CO2 (Prescott and Lloyd, 2000).
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In earlier studies, enzymatic assays were based on the conversion of
radiolabelled TMl to TMlH in the presence of the essential co-factors a-
ketoglutarate, Fe2+ and 02. The radiolabelled TMlH was separated through ion-
exchange and radioactivity of the fraction counted with a scintillation counter (Hulse
et al., 1978; Sachan and Hoppel, 1980). In these assays, the importance of reducing
agents such as ascorbic acid and dithiotreitol was shown, probably to keep the iron in
the ferrous state. Sachan and Hoppel showed other miscellaneous factors such as
an increase of 20% activity in the presence of catalase and, interestingly, a 2-fold
increase in specific activity in the presence of Ca2+ when homogenates of kidneys
were used (Sachan and Hoppel, 1980). The role of Ca2+ in stimulating hydroxylation
is not clear but it could assist the transport of TMl or a-ketoglutarate across the
mitochondrial membrane to the site of TMlH. The Ca2+ mediated transport of a-
ketoglutarate in rat and rabbit kidney has been reported (Mason et al., 1977). A non-
radiolabelled TMlH assay was later developed using ion-exchange and HPlC (Davis
et al., 1984). Recently, an assay using HPlC-electrospray tandem mass
spectrometry (ESMS) was developed for the determination of TMl and other
carnitine biosynthesis metabolites in urine (Vaz et al., 2002). The urine is first
derivatised to remove interfering compounds and the carnitine biosynthesis
metabolites are then separated by ion-pair, reversed-phase HPlC and detected by
ESMS. Detection limits were 0.05-0.1 urnol/l.,
Before the work by Vaz et al., (2001), there was no sequence information
available for TMlH. The enzyme had previously been purified to homogeneity from
kidneys but was shown to be very unstable in the particular conditions used, being
rapidly inactivated (Henderson et al., 1980). In humans, TMlH activity was shown to
be present in liver, muscle, heart and brain but the highest activity was present in the
kidney (Rebouche and Engel, 1980). Using a different method, TMlH was purified
from rat kidney using liquid chromatography and the enzymatic activity was
preserved by the addition of the reducing agents ascorbate and dithiotreitol, as well
as by addition of glycerol during purification and storage at -80°C (Vaz et al., 2001).
Using gelfiltration and blue native PAGE analysis, it was also shown that TMlH is an
87 kDa enzyme. However, a 43 kDa protein was present in the final purification step
and determination of the protein sequence by quadruple time-of-flight MS, indicated
that TMlH acts as a homodimer. The short peptide sequences generated by MALDI-
TOF MS allowed the identification of the corresponding gene from Expressed
Sequence Tag databases and a rat eDNA of 1218 bp, coding for a protein with a
calculated mass of 47,5 kDa, was cloned (Vaz et al., 2001). Heterologous expression
of the rat eDNA in COS cells and subsequent enzymatic analysis through HPlC-
ESMS, confirmed that the gene encodes a TMlH. Interestingly, expression of the
gene in S. cerevisiae did not result in any TMlH activity. This could be due to the
mitochondrial localisation of TMlH. To confirm the localisation of TMlH in the
mitochondria, subcellular centrifugation was performed and the TMlH activity fraction
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and immuno-reactive material showed that rat TMlH is exclusively located in the
mitochondria. Through studying the inactive expressed TMlH in S. cere visiae , it was
shown that only a 43 kDa mature protein was present, indicating post-translational
modification, probably during import into mitochondria where the mitochondrial import
machinery removes the N-terminal presequence. The improper function of this
process is possibly the reason for the inactive state of the TMlH expressed in
S. cerevisiae. Recently, a TMlH gene was cloned from N. crassa and the 1413 bp
cDNA was successfully expressed in S. cere visiae , showing high TMlH activity
(Swiegers et al., 2002). Contrary to mammalian TMlH, the N. crassa TMlH is
cytosolic, probably explaining the high activity of the heterologous protein (Sachan
and Broquist, 1980).
The submitochondrial localisation of mammalian TMlH will have serious
consequences for the substrate flow and regulation of carnitine biosynthesis. If
mammalian TMlH is located inside the mitochondria, transport systems would be
needed to shuttle TMl into the mitochondria and hydroxy-TMl product out in order
for the biosynthesis pathway to continue in the cytosol, where the rest of the
enzymes are located. However, an important aspect is that TMl in mammals is
derived from the hydrolysis of TMl-containing proteins, including the mitochondrial
cytochrome c. It is the hypothesis of this reviewer that cytochrome c could be
hydrolysed in the mitochondria and free TMl used as substrate for TMlH. In
contrast, N. crassa is able to trimethylate free lysine using a cytosolic enzyme and
therefore the cytosolic location of its TMlH.
The TMlH proteins cloned from human, mouse, rat and N. crassa have very high
homology to each other and to butyrobetaine hydroxylases, BBH, the last enzyme in
carnitine biosynthesis. The homology of these two enzymes will be discussed in
section 2.1.4.
2.1.2 Hydroxytrimethyllysine aldolase (HTMLA)
The second enzyme in the carnitine biosynthesis pathway, hydroxytrimethyllysine
aldolase (HTMLA), converts hydroxy-TMl to trimethylaminobutyraldehyde and
remains enigmatic. No protein sequence or genetic information is known for this
enzyme. Rebouche and Engel (1980) generated the only concrete data available for
this enzyme by showing that in human tissue extracts, HTMLA activity was almost
exclusively contained in the cytosolic fractions. The highest HTMLA activity was
found in liver. To date, the enzyme could not be extracted to purity.
It could be that HTMLA is similar to the aldolase serine hydroxy-
methyltransferase (SHMT; EC 2.1.2.1). SHMT is a pyridoxal-phosphate dependent
enzyme that catalyses the reversible interconversion of serine and tetrahydrofolate to
glycine and methylene tetrahydrofolate, generating one-carbon units for methionine,
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thymidylate and purine synthesis in the cytoplasma (Girgis et al., 1998). Two
isoforms for SHMT exist, of which one is located in the cytosol, while the other is
located in the mitochondria. Both these isoforms have been purified to homogeneity
from rat liver and have been shown to catalyse the aldolytic cleavage of some ~-
hydroxyamino acids (Ogawa and Fujioka, 1981). The human eDNA for SHMT have
been isolated and cloned through functional complementation of an E. coli glyA
mutant using a human eDNA library. The eDNA for the mitochondrial and cytosolic
enzymes encode proteins of 474 aa, and 483 aa, respectively (Garrow et al., 1993).
It has been indicated that a pyridoxal-phosphate (a derivative of vitamin B6)
enzyme is involved in carnitine biosynthesis, supporting the possible similarity of
HTMLA to SHMT. It was shown that in the presence of a vitamin B6 antagonist,
carnitine biosynthesis decreases (Dunn et al., 1982). Like most aldolases, SHMT
also uses pyridoxal-phosphate as co-factor. However, the relation of HTMLA to
SHMT has not been established to date. It could also be that another specific
aldolase might be the HTMLA.
2.1.3 Trimethylaminobutyraldehyde dehydrogenase (TMABA-DH)
Kaufman and Broquist (1977) were the first to suggest that y-trimethylamino-
butyraldehyde (TMABA) is converted by an aldehyde dehydrogenase to form
butyrobetaine. Using isotope-labelling experiments in N. crassa, they showed that
TMABA is an intermediate of carnitine biosynthesis. Later, perfusion experiments
showed TMABA being absorbed by rat liver and converted to carnitine via y-
butyrobetaine (Zaspel et al., 1980). At the same time, it was shown that TMABA-
dehydrogenase activity was present in the cytosolic fraction of homogenates
prepared from liver, kidney, brain, heart, and muscle (Rebouche and Engel, 1980).
Concurrently, the TMABA-DH was purified from cytosolic fractions of bovine liver,
and it was shown to have maximum activity with TMABA, converting it to y-
butyrobetaine (Hulse and Henderson, 1980). The later workers demonstrated the
activity of the pure TMABA-DH by spectrophotometrical measurement of NADH
formation. The reaction was started by addition of TMABA to the buffered reaction
mixture containing NAD+ and an increase in absorbance was measured at 340 nm
(Hulse and Henderson, 1980).
Recently, the human TMABA-DH was identified and shown to be identical to the
human aldehyde dehydrogenase 9 (ALDH9)(EC 1.2.1.19) (Vaz et al., 2000). The
human ALDH9 is a cytosolic NAD+-dependent dehydrogenase belonging to the
human aldehyde dehydrogenase gene family (Yoshida et al., 1998). ALDH9 is
involved in the synthesis of the well-known neurotransmitter y-aminobutyric acid
(GABA) (Lin et al., 1996; Kikonyogo and Pietruszko, 1996). GABA is synthesised
through oxidation of y-aminobutyraldehyde (the same structure as TMABA without
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the trimethyl groups) by ALDH9. Betaine is also synthesised through ALDH9 from
betaine aldehyde. This compound can serve as a methyl donor in the synthesis of
methionine and regulates osmolarity in the kidney (Petronini et al., 1992; Barak et al.,
1996).
The human TMABA-DH (ALDH9) was identified by purification of the TMABA-DH
enzyme, which was then subjecting to peptide sequencing (Vaz et al., 2000). The
sequences were screened on the Genome Databases and the ALDH9 gene
identified. The cDNAs of human ALD9 was retrieved from an EST database and
cloned into an E. coli maltose binding protein (MBP) fusion expression vector. The
clones were transformed into E. coli and the MBP-ALDH9 purified through an affinity
column. Purified rat liver TMABA-DH and the MBP-TMABA was subjected to kinetic
analysis. The Km and Vmax values for both enzymes were the same. The affinity for
TMABA was shown to be the highest showing a VmaxlKm of 20.83, compared to the
values for aminobutyraldehyde and betaine aldehyde, both at 0.71 (Vaz et al., 2000).
Because the TMABA-DH enzyme is not only specific for carnitine biosynthesis,
homology searches with the protein produces high similarities with different aldehyde
dehydrogenases. Although the ALDH9 heterologous protein was functionally
expressed in E. coli, it has not been functionally expressed in S. cerevisiae.
2.1.4 Butyrobetaine hydroxylase (BBH)
The last step in carnitine biosynthesis involves the hydroxylation of y-butyrobetaine to
L-carnitine by the y-butyrobetaine hydroxylase (BBH). This enzyme was first isolated
in crude extracts of rat liver by Lindstedt (1967). Of all the enzymes in the carnitine
biosynthesis pathway, BBH is the most studied. Lindstedt showed in preliminary
experiments that the enzyme requires molecular oxygen and ferrous iron and that the
reaction is stimulated by ascorbate. In these early experiments, carnitine production
was measured using radiolabelled y-butyrobetaine in the reaction mixture (Lindstedt,
1967). Further experiments by the same group revealed that another co-factor is
needed, namely a-ketoglutarate (Lindstedt and Lindstedt, 1970).
The BBH protein was later purified from the bacteria Pseudomonas sp. AK 1 by
ion-exchange, adsorption and molecular-sieving chromatography. By using
isoelectric focussing and equilibrium sedimentation, it was shown that the enzyme
was purified to homogeneity. Equilibrium centrifugation was used and the molecular
mass was determined to be 95 kDa (Lindstedt et al., 1977). In this work, enzyme
activity was determined by measuring the 14C02 formed from radiolabelled a-
ketoglutarate in the presence of co-factors and a-ketoglutarate. The enzymatic
mechanism catalysed by BBH involves the incorporation of one atom of molecular
oxygen into carnitine and the other into succinate (Lindblad et al., 1969).
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In 1993, the first molecular work on a carnitine biosynthesis enzyme was done
through sequencing the protein sequence of the Pseudomonas sp. AK 1 BBH
through Edman degradation (Ruetschi et al., 1993). In this work, it was shown that
the BBH enzyme functions as a dimer with two polypeptide chains, one of 383
residues and the other of 382 residues with molecular masses of 43 321 Da and
43207 Da, respectively. These two peptides are identical, except for the presence or
absence of an N-asparagine residue and contain cysteine residues and 13 histidine
residues, amino acids that have been implicated in iron binding.
The BBH enzyme is solely localised in the cytosol (Lindstedt and Lindstedt, 1970;
Lindstedt et al., 1982; Galland et al., 1999; Vaz et al., 1999b). The BBH is expressed
in various organs such as liver, kidney, brain and possibly testis. Interestingly, BBH
activity is found in kidney extracts of human, cat, cow, rabbit, hamsters and Rhesus
monkeys but not in kidney extracts of sheep, dogs, mice, rats and Cebus monkeys
(Erfle, 1975; Englard and Carnicero, 1978; Englard, 1979; Lindstedt et al., 1982). It is
interesting that BBH activity is found in the human brain but not in the brains of any
other mammal (Rebouche and Engel, 1980). The reason for the differential
expressions is not clear.
Recently, the human cDNA encoding BBH was identified (Vaz et al., 1998). The
gene was identified through purification to homogeneity of the protein from rat liver.
The protein was then subjected to N-terminal sequencing using Edman degradation.
The amino acid sequence was used to screen the genome database and led to the
identification of a human cDNA containing an open reading frame of 1161 bp coding
for a protein of 387 amino acids with a predicted molecular mass of 44.7 kDa. The
cDNA was cloned into a yeast expression vector and the BBH enzyme
heterologously expressed in the yeast S. cere visiae. Enzyme activity was determined
by using the homogenate of the transformed yeast and the measurement of carnitine
in a radioisotopic assay. High activity was obtained in excess of 1 nmol/min/mg. The
enzyme did not contain any peroxisomal or mitochondrial targeting signals,
supporting the cytosolic location of BBH. Using the full-length cDNA as probe in
Northern blot analysis, the expression of BBH in different human tissues could be
studied. Expression of the BBH cDNA was found in kidney, liver and brain but not in
heart, skeletal muscle, colon, thymus, spleen, small intestine, placenta, lung and
peripheral blood leukocytes. Highest expression was found in kidney and the lowest
in the liver. Expression in brain was very low (Vaz et al., 1998).
Galland and co-workers cloned and characterised the rat liver BBH (Galland et
al., 1999). The cDNA contained an open reading frame of 1161 bp encoding a
protein of 387 amino acids with a molecular weight of 44.5 kDa. The rat BBH is
expressed in the liver, and, contrary to humans, also in the testis and the epididimus.
The size of the mRNA in the epididimus (4.5 kb) and testis (3.5 kb) is bigger than the
mRNA in the liver (1.9 kb), which could be due to alternative splicing. Interestingly,
BBH was only expressed in the adult rats after weaning of the baby rats (Galland et
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al., 1999). This corresponds to data shown for human liver, showing low BBH activity
at birth and high activity in adults. However, high BBH activity is found in kidneys at
birth (Olson and Rebouehe, 1987).
Recently, the BBH gene of N. crassa was cloned and expressed in S. cerevisiae.
The enzyme was able to endogenously synthesize carnitine in transformed yeast
grown on media containing y-butyrobetaine. Interestingly, the carnitine-dependent
strain, !1cit2, was able to grow on non-fermentable carbon sources containing y-
butyrobetaine when the BBH was expressed in yeast, indicating that carnitine
biosynthesis takes place. The presence of intracellular carnitine was confirmed using
electrospray mass spectrometry (Swiegers et al., unpublished; Chapter 6)
The BBH enzymes have high protein homology to each other and to the first
carnitine biosynthesis enzyme, TMLH. This is because both enzymes are non-haem
ferrous-iron hydroxylases, requiring the same co-factors, a-ketoglutarate, Fe2+ and
molecular oxygen. BLASTp searches with BBH and TMLH does not find similarities
with other proteins, indicating that these enzymes form a separate family of a-
ketoglutarate dependent, non-haem ferrous-iron hydroxylases. Two homologous
proteins are found in humans, rats, mouse, Caenorhabditis elegans, Drosophila
melanogaster and N. crassa. Interestingly, in S. cerevisiae, a single weak
homologous protein encoded by YHL021c is found. However, this gene does not
encode for a TMLH or BBH (Swiegers et al., unpublished; Chapter 5). Alignments of
BBH and TMLH proteins are shown in Figure 6.
The filamentous fungi N. crass a was important in establishing the biochemical
pathway for carnitine biosynthesis. The fungal genome contains two homologues
genes, one coding for TMLH and the other coding for BBH (Swiegers et al., 2002;
Swiegers et al., unpublished). An important area of research in future would be the
studying of organisms with disruptions in carnitine biosynthesis enzymes. In this
instance, N. crassa would be a good candidate for these studies.
2.2 Regulation of carnitine biosynthesis
In order to genetically engineer microorganisms to over-produce carnitine, a good
understanding of the regulation of the biosynthesis pathway would be essential.
However, nothing is known about the regulation of carnitine biosynthesis in carnitine
producing yeast and filamentous fungi. This section of the review therefore focuses
on the regulation of carnitine biosynthesis in human, rat and mouse models.
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2.2.1 Regulation by intermediates
In 1986, Rebouche and workers showed that trimethyllysine (TML) is rate limiting for
carnitine biosynthesis in rats. In these experiments, rats that were given TML (but no
dietary carnitine) excreted more carnitine in the urine than those that were not fed
TML. The rate of carnitine excreted also increased with increasing doses of TML. An
increase in carnitine secretion of up to a 100-fold was measured and even at the
highest levels of oral TML supplementation, carnitine excretion still increased
(Rebouche et al., 1986). Earlier, Rebouche also showed that administration of y-
butyrobetaine to rats could increase levels of carnitine excretion up to 65-fold
(Rebouche, 1983). These results suggest that the availability of TML limits the rate of
carnitine biosynthesis and that carnitine biosynthesis from TML is not regulated by
end-product feedback mechanisms.
In animals, TML is derived from the hydrolysis of proteins containing
trimethylated lysine residues (Labadie et al., 1976; Dunn and Englard, 1981). In
humans, the liver and muscles together can produce up to 2 urnol of TML in a day
through protein hydrolysis, sufficient for carnitine biosynthesis (Rebouche, 1982). In
contrast to animals, free lysine in N. crass a is sequentially methylated to form TML
(Borum and Broquist, 1977). However, there is some evidence suggesting that the
carnitine biosythesis enzymes are to some extent being regulated by the
intermediates and precursor. Rebouche showed that activity of BBH in rat liver
decreases when the diet of rats was supplemented with carnitine. Also, BBH activity
increases when rats are fed butyrobetaine (Rebouche, 1982). It is however not clear
if this regulation occurs on an enzymatic or gene expression level. The high level of
carnitine biosynthesis seen in the experiments where carnitine precursors are added
to the diet suggests that the ability of the carnitine biosynthesis enzymes is much
greater than required under physiological conditions. Therefore, in mammalian
systems, the amount of TML available determines the level of carnitine synthesised.
2.2.2 Pharmacological, hormonal and physiological regulation
Epileptic patients treated with valproic acid tend to suffer from carnitine deficiency. In
rats this was confirmed experimentally by showing that the administration of 1.2
mmollkg valproic acid resulted in decreased levels of carnitine in the liver. However,
an increase in the level of butyrobetaine was measured. This would suggest that
valproic acid regulates the BBH enzyme directly. However, in vitro experiments could
not confirm this hypothesis. Physiological experiments showed that valproic acid
reduces the amount of the BBH co-factor, a-ketoglutarate, thereby explaining why
there is less carnitine synthesised in the presence of valproic acid (Farkas et al.,
1996).
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The compound 3-(2,2,2-trimethylhydrazinium) propionate (THP or mildronate)
inhibits carnitine biosynthesis. It was shown that THP treatment reduced levels of
carnitine in the hearts of paced work-performing guinea pigs. Interestingly, THP
treatment also protected guinea pigs hearts against hypoxic damage in this study.
These findings suggest that THP could be used for the treatment of patients with
damaged hearts (Dhar et al., 1996).
The hypolipidemie drug, clofibrate, which stimulates the production of
peroxisomes, has been shown to greatly increase liver carnitine and acylcarnitine
levels (Paul et al., 1986). In these experiments it was shown that the increase in liver
carnitine levels is a direct effect of the increase in carnitine biosynthesis because
there was no change in carnitine levels in other tissues and the same amount of
carnitine was secreted in the urine. However, clofibrate treatment did increase the
level of TML secreted in the urine, suggesting that the increase in carnitine
biosynthesis is due to the increased availability of TML.
The hormone thyroxine produced by the thyroid gland has been shown to
increase levels of carnitine in the liver (Pande and Parvin, 1980). It was shown that in
rats fed 6 mg thyroxine per kg of diet for 10 days, the level of carnitine in the liver
doubled, as did the activity of BBH. Recently, it has been shown that the thyroid
hormone regulates carnitine levels through modification of the BBH enzyme, resulting
in altered Vmax values, and through the regulation of BBH gene expression (Galland
et al., 2002).
Physiological conditions such as starvation also have a significant effect on
carnitine biosynthesis. In the livers of starved rats, the oxidation of long-chain fatty
acids was significantly enhanced and the level of carnitine also increased drastically
(McGarry et al., 1975). Starvation results in increased fatty acid oxidation, which is
mediated by higher levels of carnitine. It is however not clear if this is due to
increased carnitine biosynthesis or due to redistribution of carnitine from other
tissues. During starvation, the body also retains carnitine by excreting much less in
the urine (Sandor and Hoppel, 1989).
In future, the regulation of carnitine biosynthesis in yeast and fungi such as
N. crassa would be an interesting field of study. These organisms could act as model
systems to study the molecular regulation of carnitine biosynthesis and the possible
effects of different drugs and chemicals on the enzymes of carnitine biosynthesis.
Researching the possible metabolic reason why some yeast biosynthesise carnitine
and others not will also be a fascinating new field.
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3. Carnitine in human disease
3.1 Carnitine palmitoyltransferase deficiency
In humans, the carnitine palmitoyltransferases CPT1 and CPT2 are essential for fatty
acid oxidation. Therefore, mutations in the genes coding for these enzymes result in
severe physiological effects, depending on the site of mutation. Carnitine
palmitoyltransferase deficiency is a human disease with debilitating symptoms and
inherited defects that are due to mutations in both CPT1 and CPT2 have been
described. The outer-mitochondrial CPT1 enzyme deficiency is found in rare cases,
while the inner-mitochondrial CPT2 deficiency is more abundant. The reason for the
small amount of cases of CPT1 deficiency could be due to the lethality caused by
mutations in this enzyme. The first case of CPT1 deficiency was reported relatively
recently (Bougneres et al., 1981). Clinical presentation of the illness includes
hypoketoic hypoglycemia in infants, which can be fatal if left untreated (Bonnefont et
al., 1999). During fasting, the symptoms of patients with L-CPT1 deficiency can be
enhanced. In these conditions, glucose needs to be generated in the liver through
gluconeogenesis, which depends on fatty acid oxidation through the CPT system. As
a result of a deficient CPT1 enzyme, the process becomes inefficient and blood
glucose levels drop drastically (hypoglycemia). The reduced capacity of liver fatty
acid oxidation also explains the abundant formation of ketone bodies (hypoketoic)
(Bougneres et al., 1981). The condition can be treated by administration of
triacylglycerols (fatty acids that do not need the CPT system for oxidation) or by
maintaining a high carbohydrate and low fat diet. Recently, it has been reported that
women carrying a foetus with L-CPT1 deficiency can develop acute liver failure as a
consequence (Innes et al., 2000).
In 1998, the basis for L-CPT1 deficiency was first characterised on the molecular
level (Ijlst et al., 1998). The human L-CPT1 cDNA has previously been cloned
(Britton et al., 1995). The L-CPT1 cDNA was cloned from a patient suffering from L-
CPT1 deficiency and expressed in S. cerevisiae under the GAL 1 promotor.
Enzymatic analysis of the heterologously expressed L-CPT1 revealed that it only had
2% activity when compared to the wild type heterologously expressed L-CPT1
enzyme. Sequencing of the defective L-CPT1 revealed an A to G missense mutation
at position 1361 resulting in the change of the aspartate at position 454 to a glycine.
In the patient's fibroblasts, an immunoblot revealed a reduced size in the defective L-
CPT1, suggesting that the mutation causes the instability of the protein (Ijlst et al.,
1998). Later, these findings were confirmed through expression of mutant L-CPT1 in
COS cells and subsequent determination of the proteins stability (Brown et al., 2001).
In these experiments, mutant L-CPT1 cDNAs of six different patients were expressed
in COS cells. The mRNA levels of the six expressed cDNAs were similar to wild type
expressed cDNA but immunoblots indicated lower levels of each mutant protein
compared to wild type protein.
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To date, only 30 families with L-CPT1 deficient enzymes have been described.
Interestingly, no patients have so far been described for deficient muscular M-CPT1.
This may be linked to the vital role it plays in heart muscle, and a deficient form of M-
CPT1 may therefore be lethal in all cases.
In contrast to the limited amount of CPT1 deficiencies, more and more cases of
inner-mitochondrial CPT2 deficiency are being reported. It is believed that CPT2
deficiency is the most common cause for abnormal lipid metabolism in humans. The
disease was first described in 1973 and since then more than 200 families have been
identified with this defect (Di Mauro and Di Mauro, 1973). The disease usually
manifests after fasting, heavy exercise or infection resulting in symptoms of muscle
pain due to impaired fatty acid oxidation and is often accompanied by renal failure.
Additional clinical phenotypes have been described in infants, in particular hypoketoic
hypoglycemia, liver failure, heart problems and sudden death (Taroni et al., 1992;
North et al., 1995; Bonnefont et al., 1996; Yamamoto et al., 1996).
A number of disease causing mutations in the gene coding for CPT2 have been
identified to date. Taroni et al. (1993) identified the first and also most common
mutation in CPT2. The mutant CPT2 gene contains a C to T transition at position
439, which changes amino acid 113 from serine to leucine. Expression of the mutant
CPT2 in COS cells indicated significant decrease in activity compared to wild type
expressed CPT2. The mutant CPT2 was expressed at the same level as wild type
but the mutant protein was unstable, resulting in reduced activity (Taroni et al., 1993).
Verderio and workers identified a number of additional mutations causing CPT2
deficiency. A proline to histidine substitution was identified in residue 50 of the CPT2
enzyme of five patients. This mutation occurs in the very conserved leucine-proline
motive of the family of carnitine acyltransferases. Another rare mutation, resulting in
an aspartate to asparagine substitution in position 553, was found in one patient.
Both types of mutations were expressed in COS cells and resulted in a significant
decrease in CPT2 activity compared to wild type. Biochemical analysis showed that
the proline to histidine mutation does not affect the binding of substrate but rather the
stability of the protein, resulting in loss of activity (Verderio et al., 1995).
Recently, novel splice site mutations were identified in the genomic gene of
CPT2 (Smeets et al., 2003). In this work, a novel splice-site mutation in the splice-
acceptor site of intron 2 was found resulting in a 25 bp deletion. In other work,
analysis of CPT2 from a patient identified the common serine to leucine substitution
at residue 113 on one allele and on the other allele, a novel 4 bp deletion starting at
codon 515 thereby creating in a premature stop codon (Deschauer et al., 2002).
The continuous study of the CPT1 and CPT2 mutants could eventually lead to
the development of new treatments for genetic diseases of this nature. Especially
important is the structure/function relationship of the wild type and mutant CPTs. The
possibility of developing drugs that could stabilise the enzymes would be one way of
treating this illness. The expression of the protein in heterologous systems with no
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CPT activity, such as S. cerevisiae and P. pestoris. would be of great value and
possibly lead to the development of high-throughput screening assays for the
identification of new drugs.
3.2 Carnitine translocase deficiency
In humans, carnitine is only biosynthesised in the liver, kidney and to a lesser extent
in the brain. It is however essential in organs such as muscles and the heart.
Therefore, an adequate system needs to be in place in order to transfer carnitine to
these tissues and into the cells (Rebouehe, 1992). These tissues take up carnitine
from the blood through active transport. Active transport is also involved in the uptake
of carnitine from food sources in the intestine and also for renal reabsorbtion in the
kidneys (Engel et al., 1981; Rodrigues-Pereira et al., 1988)
Defects in the carnitine transport system result in a severe illness known as
systemic carnitine deficiency. In patients with this disease, plasma and carnitine
tissue levels are very low due to excessive renal and intestinal wastage coupled with
decreased renal reabsorbtion in the kidneys. Patients with this disease develop
symptoms of myopathy (muscle wastage) and cardiomyopathy (heart muscle
wastage), especially under conditions of starvation when fatty acids become an
essential fuel (Tanphaichitr and Leelahagul, 1993). Administration of high doses (in
excess of 1 g/day) of carnitine is life-saving for these patients and counters the effect
of increased renal secretion of carnitine.
Investigation of the cells of patients with systemic carnitine deficiency indicated a
deficient carnitine uptake system (Eriksson et al., 1989; Tein et al., 1990). Tamai and
co-workers cloned the first gene coding for a carnitine transporter using a human
kidney eDNA library. The gene was named OCTN2 and encodes a polypeptide of
557 amino acids and is highly expressed in kidney, skeletal muscle, heart, and
placenta. The eDNA was expressed in HEK293 cells and resulted in highly efficient
sodium dependent carnitine transport. The transporter showed a high affinity for
carnitine with a Km of 4.34J.lM. The OCTN2 transporter is strongly inhibited by
acetylcarnitine and butyrobetaine, possibly indicating its role in the transport of these
compounds (Tamai et al., 1998).
Recently, mutations in the OCTN2 gene have been identified from patients
suffering from systemic carnitine deficiency (Nezu et al., 1999). Three unrelated
patients were investigated. In one patient, a deletion of a 113 bp region containing
the start codon of OCTN2 was identified. In the OCTN2 gene of the second patient,
two separate mutations cause a frame shift and a premature stop codon. In the third
patient, the OCTN2 gene had a splice-site mutation also resulting in a premature stop
codon. At the same time it was shown by Vaz and co-workers that mutations in the
OCTN2 gene are indeed responsible for systemic carnitine deficiency. In this work,
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fibroblasts of patients were transformed with a wild type OCTN2 cDNA that restored
the ability of these cells to transport carnitine and increased carnitine transport 12-
fold. In the three patients tested, two patients had an A to G mutation at position 632
resulting in a tyrosine residue in amino acid position 211 changing to a cystein and
one patient had a C to T nonsense mutation in position 844 resulting in a arginine
changing to a stop codon in amino acid position 282 (Vaz et al., 1999a). Recent
studies have indicated that the OCTN2 transporter is located in the plasma
membrane of cells where it can facilitate the import of carnitine into the cells (Tamai
et al., 2001).
The human inner-mitochondrial membrane carnitine/acetylcarnitine transporter,
CACT, has also been identified (Huizing et al., 1997). The neonatal
carnitine/acetylcarnitine deficiency caused by mutations in CACT has severe
phenotypes and in most cases result in death. Analysis of the mutant CACT from an
affected sibling revealed a 13 bp insertion at position 388 resulting in the skipping of
exon 3 and 4 (Yang et al., 2001). In this sibling, CACT enzyme activity was
completely absent. Recently, a novel peroxisomal carnitine transporter, OCTN3, was
identified and implicated in Crohn's disease (Lamhonwah et al., 2003).
In future, unicellular organisms such as yeast could be used in studying carnitine
transporters. The gene coding for the plasma membrane transporter in S cerevisiae
has been identified as the gene known to code for a general amino acid transporter,
AGP2 (van Roermund et al., 1999). Deletion of this gene in the Scit? genetic
background abolished growth on fatty acids in the presence of carnitine, which
confirmed its role in carnitine transport. Intracellular carnitine measurements
confirmed that carnitine transport was blocked. In this work and that of other groups,
the inner-mitochondrial carnitine/ acetylcarnitine translocase encoded by CRC1 was
also identified, (Palmieri et al., 1999, van Roermund et al., 1999, Swiegers et al.,
2001). Deletion of CRC1 in the !1cit2 background displayed the same phenotype as
the AGP2 deletion, showing no growth on oleic acid, even in the presence of
carnitine, indicating its vital role in the transport of carnitine and acetylcarnitine across
the mitochondrial inner-membrane (van Roermund et al., 1999; Swiegers et al.,
2001). The AGP2 and CRC1 deletion strains of S. cerevisiae could be used for
structure/ function analysis of human OCTN2 and CACT.
It is clear that mutations in the genes involved in carnitine transport in humans
have severe and debilitating consequences. Interestingly, no case of defects in
carnitine biosynthesis genes has ever been identified in humans.
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3.3 Carnitine in disease treatment
Besides the use of carnitine to treat systemic carnitine deficiency, it has recently
found use in the symptomatic treatment of various unrelated diseases. In the
treatment of systemic carnitine deficiency, a large dose of carnitine is needed to
counter the effect of excessive renal secretion. However, in other diseases, carnitine
is used in different quantities and in some cases derivatised before use
Because of its role in the enhancement of energy production and removal of toxic
metabolites during ischemia, it has been suggested that carnitine could be used for
the treatment of various cardiac diseases (Retter, 1999). A natural derivative of
carnitine, propionyl-L-carnitine, has been shown to improve myocardial (heart
muscle) contraction in different experimental models of heart failure. It seems that the
beneficial effect of this compound is due to its action on muscle and heart
metabolism by increasing the pyruvate flux to the Krebs cycle, especially under
conditions of increased workload (Ferrari and Giuli, 1997). Exogenous carnitine
treatment has also been shown to be beneficial in other heart conditions such as
congestive heart failure, arrhythmia and acute ischemia (Retter, 1999). Some
molecular links have been found regarding the prevention of skeletal muscle
myopathy by carnitine during heart failure (Vescovo et al., 2002). In this study,
treatment of rats with carnitine revealed the inhibition of caspases and tumor necrosis
factor-a (TNF-a), both components known to induce apoptosis, suggesting that
carnitine inhibits apoptosis. Indeed, previous work has shown that carnitine regulates
the activity of caspases and also prevents doxorubicin-induced apoptosis in cardiac
myocytes (Andrieu-Abadie et al., 1999; Mutoba et al., 2000).
Carnitine has also recently found use for the symptomatic treatment of immune-
mediated diseases such as AIDS and chronic fatigue syndrome. Patients suffering
from AIDS often present a degree of carnitine deficiency due to the malabsorbtion of
carnitine and the possible negative effect of anti-retroviral drugs on tissue carnitine
levels (Famularo and De Simone, 1995). Another immune disease called chronic
fatigue syndrome is characterised by persistent debilitating fatigue. Most patients
have a deficiency in acetylcarnitine levels in the serum and it has been proposed that
there is a relation between acetylcarnitine levels and the onset and severity of this
disease (Kuratsune et aI., 1994). In both of these diseases, treatment with carnitine
was shown to be beneficial to patients.
Acetylcarnitine is also currently under investigation for the treatment of the neuro-
degenerative Alzheimer's disease. In these conditions acetylcarnitine is proposed to
have a beneficial effect due to its role in brain energy and phospholipid metabolism
(Pettegrew et al., 2000). In support of the role of carnitine in the nervous system, it
has been shown that acetylcarnitine increases the survival time of rat sensory
neurons (Formenti et al., 1992).
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The last few years L-carnitine has also been extensively used as a weight loss
agent due to its role in fatty acid oxidation. In addition, due to its role in energy
metabolism, it is also widely used as an energy booster, mostly in nutritional
supplements. Many other nutritional products today contain added carnitine, as do
most soy-based commercial infant formulas. However, carnitine is found in high
concentrations in foods such as meat and milk, with the highest concentrations found
in meat. In fruits and vegetables, carnitine is found in low quantities, making carnitine
supplementation beneficial for vegetarians (Carter et al., 1995).
Interestingly, the common bakers yeast, S. cerevisiae, does not biosynthesise
carnitine (Swiegers et al., 2001). It will be a great nutritional benefit if this yeast could
be engineered to produce carnitine in large quantities, adding value to food products
such as bread and beverages such as beer and wine.
4. Conclusion
Although the research results that will be discussed in Chapters 3-6 are based on the
metabolism of the yeast S. cerevisiae and the filamentous fungi N. crassa, this
literature review indicates how little information on carnitine metabolism and function
is available for these organisms. However, the review does state what is currently
known about carnitine in these organisms and also points out the application in
particular of S. cerevisiae in the various experiments designed to elucidate the
function of carnitine in mammalian cells, e.g. the expression and analysis of human
CPTs in yeast.
It is also of broader interest for the yeast researcher to understand the important
differences in carnitine metabolism of mammalian versus yeast cells. This review
highlighted the important metabolic role of carnitine in mammalian cells. It is clear
that in the yeast system, much can still be learned regarding carnitine
acyltransferases, carnitine translocases and carnitine biosynthesis. In S. cerevisiae,
only five genes have been identified to date for their involvement in the carnitine
shuttle and not much is known about their regulation. Of particular interest is the role
of the three CATs in the metabolism of non-fermentable carbon sources (Swiegers et
al., 2001) (discussed in Chapter 3). In contrast to yeasts, the mammalian system has
only one gene coding for a peroxisomal and mitochondrial CAT. This review has
offered possible explanations for these differences but this has to be verified
experimentally.
Chapters 4 and 5 relates the attempts by our laboratory to try and introduce this
pathway in the metabolism of S. cerevisiae. This review has looked in depth into what
is known regarding carnitine biosynthesis in order to state the obvious challenges in
engineering a endogenously carnitine producing yeast but also to serve as a
reference for future work in this field. As the reader would have noticed, very little is
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known about carnitine biosynthesis, especially on the molecular level. Information on
carnitine biosynthesis in unicellular eukaryotes is almost non-existent. The section on
the regulation of carnitine biosynthesis in mammalian systems may help to engineer
a yeast strain for optimal carnitine production. Of particular interest is the finding that
trimethyllysine appears to be the limiting factor in carnitine biosynthesis in mammals.
The importance of carnitine in human health was also highlighted by this review.
The severe and debilitating consequences of mutations in genes involved in carnitine
dependent metabolic activities is striking. An attempt was also made to indicate the
use of yeast such as S. cerevisiae to study the mutant CPTs as an easy and effective
method of analysis. The possible use of yeast in the high-throughput screening of
drugs for treatment of carnitine related illnesses appears promising. The role of
carnitine and its derivatives in the treatment of various diseases indicates that there
is still much to be learned about the metabolic and physiological function of this
molecule. The use of carnitine for disease treatment and nutritional supplementation
supports the potential commercial value that a carnitine biosynthesising strain of
S. cerevisiae would have for the health and well being of human beings.
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1. Abstract
L-Carnitine is required for the transfer of activated acyl-groups across intracellular
membranes in eukaryotic organisms. In Saccharomyces cerevisiae, peroxisomal
membranes are impermeable to acetyl-CoA, which is produced in the peroxisome
when cells are grown on fatty acids as carbon source. In a reversible reaction
catalysed by carnitine acetyltransferases (CATs), activated acetyl groups are
transferred to carnitine to form acetylcarnitine which can be shuttled across
membranes. Here we describe a mutant selection strategy which specifically selects
for mutants affected in carnitine-dependent metabolic activities. Complementation of
three of these mutants resulted in the cloning of three CAT encoding genes: CAT2,
coding for an carnitine acetyltransferase associated with the peroxisomes and the
mitochondria; YAT1, coding for the carnitine acetyltransferase which is presumably
associated with the outer mitochondrial membrane and YER024w (YAT2), which
encodes a third, previously unidentified carnitine acetyltransferase. The data also
show that (i) L-carnitine and all three CATs are essential for growth on
non-fermentable carbon sources in a strain with a disrupted CIT2 gene, that (ii) Yat2p
contributes significantly to total CAT activity when cells are grown on ethanol, and
that (iii) the carnitine-dependent transfer of activated acetyl groups plays a more
important role in cellular processes than previously realised.
2. Introduction
Carnitine is synthesised by most eukaryotic organisms from lysine as a precursor and
methionine or S-adenosyl methionine as a methyl donor (Bieber, 1988). In humans,
endogenic synthesis occurs mainly in liver tissues, but is complemented through
dietary uptake. Systemic or tissue specific carnitine deficiencies, the latter frequently
Stellenbosch University http://scholar.sun.ac.za
~~ Chapter 3: Research Results I 46
due to genetic defects in the plasma membrane carnitine transport system, are
debilitating, sometimes life-threatening diseases, highlighting the importance of
carnitine in cellular metabolism (Pons and De Vivo, 1995).
Recent data, on the other hand, suggest that the yeast Saccharomyces
cerevisiae may be unable to synthesise carnitine (van Roermund et al., 1999).
Furthermore, wild-type strains appear not to require carnitine under any of the
conditions investigated thus far (van Roermund et al., 1995, 1999). However,
enzymatic activities that require carnitine, in particular carnitine acetyltransferases
(CATs), are present in S. cerevisiae, and a plasma membrane transport protein,
encoded by AGP2, that allows the up-take of carnitine from the extracellular
environment has been identified (van Roermund et al., 1999).
The only well-defined molecular role of carnitine in eukaryotic organisms is to
facilitate the transfer of activated acyl groups across intracellular membranes. In
mammalian cells, this role entails the transfer of long-chain fatty acids to the
mitochondria for ~-oxidation, as well as the transport of activated medium- and
short-chain organic acids from the peroxisomes to the mitochondria (Bieber, 1988). In
S. cerevisiae, the role of carnitine consists in the transfer of activated acetyl groups of
peroxisomal or cytoplasmic origin to the mitochondria (Schmalix and Bandlaw, 1993;
van Roermund et al., 1995). This process is referred to as the carnitine shuttle, and
involves the transfer of the acetyl-moiety of acetyl-CoA, which can not cross
organellar membranes, to a molecule of carnitine, the subsequent transport of the
acetylcarnitine across membranes and finally the reverse transfer of the acetyl group
to a molecule of free CoA for further metabolism.
The transfer of acetyl groups from acetyl-CoA to carnitine and vice versa is
catalysed by CATs (Bieber, 1988). Two genes coding for these enzymes have been
identified in S. cerevisiae. The first gene, CAT2, codes for a CAT found in the
peroxisomes and mitochondria and contributes >99% of the total CAT activity in
galactose grown cells (Kispal et al., 1993). The second gene, YAT1, codes for a CAT
presumably associated with the outer surface of the mitochondria and contributes an
estimated 5% to the total CAT activity in acetate and ethanol grown cells (Schmalix
and Bandlaw, 1993).
When yeast grow on fermentable carbon sources, no clearly identifiable
peroxisomal structures can be detected, but when grown on fatty acids such as oleic
acid, a proliferation of peroxisomes is observed (Veenhuis et al., 1987). Peroxisomes
are required for yeast to catabolise fatty acids, since they are the sole site for
~-oxidation, the fatty acid degradation pathway which results in the formation of
acetyl-CoA in the peroxisome (Kunau et al., 1988). Van Roermund et al. (1995)
showed that S. cerevisiae uses two pathways to further utilise this product. The first
pathway is the previously described carnitine shuttle, where peroxisomal CAT is
thought to catalyse the transfer of the activated acetyl from CoA to carnitine. The
acetylcarnitine is transferred to the mitochondria where mitochondrial CAT catalyses
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the reverse reaction to form carnitine and acetyl-GoA to enter the tricarboxylic acid
(TGA) cycle for energy production. The second pathway utilising peroxisornally
produced acetyl-GoA is the glyoxylate cycle, a modified version of the TGA cycle,
which, at least in part, takes place in the peroxisome. This cycle results in the net
synthesis of the G4 compound succinate from two molecules of acetyl-GoA, which
can then be further utilised for anabolic and catabolic purposes (van Roermund et al.,
1995).
The existence of two pathways to further utilise peroxisornally produced
acetyl-GoA explains the absence of growth defects on oleic acid media of strains
lacking either the CIT2 gene, which encodes the first enzyme of the glyoxylate cycle,
or the CAT2 gene, encoding the peroxisomal and inner mitochondrial membrane
associated GAT. However, a strain disrupted for both CIT2 and CAT2 is unable to
grow in these conditions (van Roermund et al., 1995), implying that the two pathways
can complement each other.
Besides its importance for the acetyl shuttle mechanism between peroxisomes
and mitochondria during growth on fatty acids, carnitine also plays a role when yeast
cells are grown on other non-fermentable carbon sources like acetate and ethanol.
The catabolism of these compounds results in the production of acetyl-GoA in the
cytosol which needs to be transferred to the mitochondria for the production of
energy. The transfer can take place through the formation of acetylcarnitine in the
cytosol and the subsequent transfer thereof to this cellular compartment (Schmalix
and Bandlow, 1993; Stemple et al., 1998).
Besides the two GAT-encoding CAT2 and YAT1 genes and the carnitine
transporter-encoding AGP2 gene, only one additional gene required for a functional
carnitine shuttle, CRC1, which encodes a carnitine/acetylcarnitine translocase
located in the inner mitochondrial membrane (Palmieri et al., 1999; van Roermund et
al., 1999), has thus far been identified. Other genes, which should include
translocases located in the peroxisomal and outer mitochondrial membrane, have yet
to be identified.
In order to characterise additional carnitine shuttle-specific genes in
S. cerevisiae, and to analyse the metabolic implications of carnitine-related activities,
this paper describes a selection strategy resulting in the isolation of mutants affected
specifically in carnitine-dependent metabolic activities. Six mutants, called GPAM for
carnitine pathway affected mutants, where isolated using this strategy. We
furthermore describe the isolation of the genes affected in 5 of the selected mutants
through functional complementation. Two of the mutants were complemented by
CRC1, while three of the mutants were affected in genes encoding carnitine
acetyltransferases, corresponding to the previously identified CAT2 and YAT1 genes,
as well as a newly identified GAT, which is encoded by ORF YER024w and was
named YAT2 because of its more significant homology with YAT1. While the cloning
of CAT2 and CRC1 was expected, since the phenotype had been described and the
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genes had also been identified in the screen described by van Roermund et al.
(1999), no such phenotype has yet been described for YAT1 and YAT2. Our data
furthermore show (i) that carnitine is essential for growth on all non-fermentable
carbon sources tested in a strain with a disrupted CIT2 gene; (ii) that S. cerevisiae
contains three CAT-encoding genes that are essential in these same conditions and
are unable to cross-complement each other; (iii) that YER024w encodes a previously
non-identified CAT which contributes 50% percent to total CAT activity in
ethanol-grown cells. Taken together, the data highlight that carnitine plays a more
important role in the metabolism of non-fermentable carbon sources than previously
realised.
3. Materials and methods
3.1 Yeast strains culture conditions
Yeast strains used in this study derive from FY23 and are isogenic to S288C (Table
1). Yeast were either grown on rich YPD [1% (w/v) yeast extract, 2% (w/v) peptone,
2% (w/v) glucose] or on minimal YND media, containing 0.67% (w/v) YNB without
amino acids (Difco) and 2% (w/v) glucose. Three different media with oleic acid as
sole carbon source were used: (i) VNO [0.67% (w/v) YNB without amino acids and
0.1% (v/v) oleic acid]; (ii) YNOC [VNO media supplemented with L-carnitine
(10 mg/I)]; and (iii) YNOY [VNO media supplemented with 0.1% (w/v) yeast extract].
Media containing acetate (YNA), ethanol (YNE) and glycerol (YNG) were made with
0.67% (w/v) YNB without amino acids and 3% (v/v) of each carbon source. These
media were also supplemented with L-carnitine to a concentration of 10 mgll (YNAC,
YNEC and YNGC). Amino acids (20 mgll) were added to all media according to the
specific requirements of each strain.
3.2 DNA manipulations and construction of plasm ids
All plasmids used in this study are listed in Table 1 and primers in Table 2. Standard
DNA techniques were applied as described by Sambrook et al. (1989). Sequencing
was carried out on an ABI PRISM™ automated sequencer. The CIT2 gene was
amplified by PCR using genomic DNA from strain FY23 as template and primers
CIT2F1 and CIT2R1 (Table 2). A 3.4 kb Hindlll-EcoRI fragment, containing the CIT2
gene with its promoter and terminator, was cloned into the Hind III and EcoRI sites of
the plasmid YEplac112 (using the Hind III and EcoRI sites introduced in the primers
CIT2F1 and CIT2R1). The same fragment was also cloned into the HindIII and EcoRI
sites of the plasmid YCplac33. The YEplac112-CIT2 plasmid was used for the
construction of the CIT2 disruption casette. The major part of the open reading frame
(ORF) of the CIT2 gene was deleted by replacing an internal 1185 bp Spel-Bali
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Table 1. Strains and plasmids used in this study
Strains and ~Iasmids Genot:i~e Source or reference
Strains:
FY23 MA Ta leu2 trp1 ura3 Winston et al. 1995
FY23t.cit2 MA Ta leu2 ura3 cit2::TRP1 This study
PSY142 MA Ta leu2 lys2 ura3
PSY142t.cit2 MA Ta leu2 lys2 cit2::URA3 Kispal et al. 1988
FY23t.cat2 MA Ta trp1 ura3 cat2::LEU2 This study
FY23t.cit2t.cat2 MA Ta ura3 D.cit2::TRP1 cat2::LEU2 This study
FY23t.yat1 MATa trp1 ura3 t.yat1::LEU2 This study
FY23t.cit2t.yat1 MATa ura3 t.cit2::TRP1 yat1::LEU2 This study
FY23t.yat2 MATa trp1 ura3 yat2::LEU2 This study
FY23t.cit2t.yat2 MA Ta ura3 t.cit2:: TRP1 t.yat2::LEU2 This study
Plasm ids:
YCplac33 CEN4 URA3 Gietz and Sugino 1988
YCplac33-CA T2 CEN4 URA3 CA T2 This study
YCplac33-CIT2 CEN4 URA3 CIT2 This study
YCplac33- YAT1 CEN4 URA3 YAT1 This study
YCplac33- YAT2 CEN4 URA3 YAT2 This study
YDp-L LEU2 Berben et al. 1991
YDp-W TRP1 Berben et al. 1991
YEplac112 2J! TRP1 Gietz and Sugino 1988
YEplac112-CIT2 CEN4 TRP1 CIT2 This study
pBluescript II SK+ Stratagene
PGEM-T-easy Promega
PGEM- T-easy-CA T2 This study
PGEM-T-easy-CAT2 (PIE) This study
pt.cat2 t.cat2::LEU2 This study
pt.cit2 t.cit2:: TRP1 This study
pt.yat1 t.yat1 ::LEU2 This study
~t.lat2 t.y_at2::LEU2 This study
fragment with a 0.8 kb fragment containing the TRP1 gene, isolated from plasmid
YDp-W. A 1.6 kb Apal-Stul fragment containing the disruption cassette was isolated
and transformed into haploid wild-type FY23 cells. Trp+ transformants were selected
and the disruption of the chromosomal CIT2 locus confirmed by analysing the PCR
product obtained from genomic DNA, using the primers CIT2F1 and CIT2R1. The
CAT2 gene was amplified by the polymerase chain reaction (PCR) method using
genomic DNA from strain FY23 as template and primers CAT2F1 and CAT2R1. The
PCR product was cloned into pGEM-T Easy plasmid using the Promega pGEM-T
EasyVector System (Promega). A 3890 bp Pstl-EcoRI fragment containing the CAT2
gene with its promoter and terminator sequences was cloned into the Pstl and EcoRI
sites of the plasmid YCplac33. This fragment was also cloned into the Pstl and EcoRI
sites of pGEM-T Easy to create plasmid PGEM-CAT2 (PIE). This plasmid was used
for the construction of a disruption cassette, where a 595 bp BamHI-Bg/ll fragment,
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internal to the CAT2 ORF, was replaced by a 1.6 kb fragment containing the LEU2
gene isolated from plasmid YDP-L. A 4.1 kb Oral fragment containing the disruption
cassette was transformed into FY23 and FY23fl.cit2 strains. Leu+ transformants were
screened and the disruption of the chromosomal CAT2 locus confirmed by PCR
through analysing the PCR product obtained from genomic DNA, using the primers
CAT2F1 and CAT2R1.
Table 2. Oligonucleotides used in this study
Oligonucleotide Seguence
CAT2F1
CAT2R1
CIT2F1
CIT2R1
YAT1F1
YAT1R1
YAT2F1
YAT2R
5'-GACACTGTTCGCCAAA TTTCG-3'
5'-ATAAGCAAGGCACAATATCC-3'
*5'-AGGT AAGCTTCTCGCTT AGGGTGCGG-3'
*5'-GAGGAA TTCATCAGGT AAAGTTTCCTCGACC-3'
5'-ATCAGCATCAGCATCAGC-3'
5'-AGAGGT AATCCAAACGACG-3'
5'-ATGGATGCTACGGCTTTAGTCG-3'
5'-CAA TGGCAAA TCTGGTCCGGG-3'
'Underlined sequences indicate introduced restrictions sites
3.3 Random mutagenesis of yeast strain
Transformants FY23fl.cit2 cells were grown in YPD to an optical density (OD600) of
0.1 corresponding to ca. 3x106 cells/ml. Approximatly 4x108 cells were centrifuged
and washed twice with sterile water. The cells were suspended in 2 ml 0.1 M sodium
phosphate buffer pH 7.0 and treated with 2% (v/v) ethylmethanesulfonate (EMS) for
1 hour at 30°C. The reaction was stopped by adding 1 ml of a 5% (w/v) sodium
thiosulphate solution. The survival rates, corresponding to the percentage of cells
able to form colonies on rich YPD medium after mutagenesis, were on average 30%.
Approximately 30 000 colonies were washed of the YPD agar plates and dilutions
were plated on glucose medium (YND). Single colonies (11 000) were picked and
streaked in a grid-like fashion on YND agar plates and were allowed to grow for 2-3
days before being replica-plated onto oleic acid media supplemented with L-carnitine
(YNOC). A total of 114 mutants impaired for growth on YNOC agar plates were
selected.
3.4 Cloning and disruption of YAT1 and YER024w
The growth defect of the selected mutant strains on VNO plates was complemented
by transforming these strains with a S. cerevisiae genomic library (ATCC 77162),
selecting transformants on glucose containing YND agar plates and selecting
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complemented strains through replica-plating on YNOC agar plates. Complementing
plasm ids were isolated and transformed into E. coli DH5a and retransformed into the
S. cerevisiae mutants to confirm complementation on YNOC agar plates. Genomic
inserts were sequenced and the genes YAT1 and YER024w were identified. The
YAT1 gene, with promoter and terminator sequences, was subeloned as a 3962 bp
Hind III-EcoRI fragment into the Hind III and EcoRI sites of the plasmid YCplac33.
Transformation of the YCplac33- YAT1 plasmid into the original mutant
complemented the growth defect on YNOC agar plates. A portion of the ORF of the
YAT1 gene was deleted by removing the 565 bp Sacl fragment by digesting the
YCplac33- YAT1 plasmid with Sacl, followed by a religation of the plasmid, resulting
in the exclusion of the 565 bp Sacl fragment from the plasmid. Using this plasmid, the
1.6 kb fragment containing the LEU2 gene, isolated from plasmid YDp-L, was cloned
into the BamHI site of the truncated YAT1 ORF. A 2.6 kb Ball fragment containing the
disruption cassette was isolated and transformed into haploid wild-type FY23 and
haploid FY23L'lcit2. Leu+ transformants were selected and the disruption of the
chromosomal YAT1 locus confirmed by PCR through analysing the PCR product
obtained from genomic DNA using the primers YAT1 F1 and YAT1 R1. The YER024w
gene was subeloned as a 3264 bp Xbal-Hindlll fragment into the Xbal and Hindiii
sites of the plasmid YCplac33. Transformation of the YCplac33- YER024w plasmid
into the original mutant complemented the growth defect on YNOC agar plates. The
YCplac33- YER024w plasmid was used and a part of the ORF of YER024w gene was
deleted by replacing the 871 bp Pstl-BbrPl fragment with a 1.6 kb fragment
containing the LEU2 gene, isolated from plasmid YDp-L. A 4.0 kb Xbal-Hindlll
fragment containing the disruption cassette was isolated and transformed into
haploid wild-type FY23 and haploid FY23L'lcit2. Leu+ transformants were selected
and the disruption of the chromosomal YAT1 locus confirmed by PCR obtained from
genomic DNA using primers YAT2F1 and YAT2R1.
3.5 CAT assays
The L-carnitine UV-test supplied by Roche Diagnostics (Mannheim, Germany) was
adapted for measuring CAT activity. For this purpose, L-carnitine was provided in
excess at 400 mg/I in all the samples. Strains were grown in 3% (v/v) ethanol to an
00600 of 1.0. A volume of 40 ml of the culture was centrifuged for 5 min at 5000 rpm.
The cells were washed once with water and placed into 1.5 ml Eppendorf tubes and
centrifuged for 3 min at 5000 rpm. The pellet was suspended in 200 ul of cold 0.05%
(v/v) Triton X-100. Glass beads (0.16 g) were added to the suspension and cells
were vortexed for 10 min at 8°C. The suspensions (100 ul) were transferred to new
Eppendorf tubes and centrifuged for 3 min at 5000 rpm. The supernatant was used
for CAT assays. The amount of NADH consumed during the reaction was measured
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spectrophotometrically at 340 nm. The consumption of NADH was linearly correlated
to the time of reaction and the gradient of the graph directly correlated with the
amount of CAT enzyme added. Samples containing either no L-carnitine or known
amounts of CAT enzyme were used as controls. All reactions were carried out in
triplicate.
4. Results
4.1 A Acit2 strain is dependent on carnitine for growth on acetate,
ethanol, glycerol and oleic acid
In order to phenotypically select for mutants affected specifically for
carnitine-dependent metabolic activities, parts of the glyoxylate cycle, which creates
a bypass for all known carnitine-dependent activities, have to be blocked. In a strain
without a functional CIT2 gene, mutations in the carnitine shuttle system should
indeed result in a growth defect on oleic acid media, but should not affect growth on
fermentable carbon sources. To create the appropriate genetic background, the CIT2
gene, encoding the glyoxylate cycle-specific citrate synthetase which catalyses the
condensation of acetyl-CoA with oxaloacetate to form citrate, was disrupted. In this
b..cit2mutant strain, the flow of acetyl groups into the glyoxylate cycle is blocked, and
the strain will be dependent on the carnitine shuttle to transfer acetyl groups from the
peroxisomes to the mitochondria.
The CIT2 gene was disrupted in the FY23 genetic backgound. As expected, the
strain did not present any growth defects on minimal media containing glucose,
whether supplemented with carnitine or not. However, when oleic acid was used as
sole carbon source, the strain was unable to grow on YNB-based minimal media in
the absence of carnitine, but grew as well as the wild-type in the presence of
carnitine. In the absence of carnitine, the strain also failed to grow on minimal media
containing acetate (YNA), ethanol (YNE) or glycerol (YNG) as sole carbon source
(Figure 1 and Table 3). This contradicts previously published data by Kispal et al.
(1993), which showed that a PSY142 S. cerevisiae with a disrupted CIT2 locus was
able to grow on minimal media containing glycerol as sole carbon source. Other
groups have also reported that a t1cit2 strain is able to grow on some of the above
cited carbon sources (Kim et al., 1986; van Roermund et al., 1999), but these groups
use 0.1% yeast extract to complement their growth media. Our selection strategy and
phenotype verification was carried out in media containing only carnitine as
supplement. Yeast extract indeed contains sufficient amounts of carnitine to
complement the carnitine requirements of yeast (van Roermund et al., 1999).
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YNE YNEC
FY23 WT PSY142 WT FY23 WT PSY142WT
FY23Acit2 PSY142Aclt2 FY23Acit2 PSY142Acit2
Figure 1. Growth of wild-type (WT) and f1cit2 mutant strains on ethanol media with (YNEC)
and without L-carnitine (YNE). Plates were incubated at 30° for 10 days.
Table 3. Phenotypes of strains on different carbon sources in the presence and absence of
carnitine
Strains YNO YN/O/NE/G YN/OC/AC/EC/GC
FY23 + + +
PSY142 + + +
FY23t-..cit2 + +
PSY142t-..cit2 + +
FY23t-..cit2t-..cat2 +
FY23f1cat2 + + +
FY23t-..cit2f1yat1 +
FY23f1yat1 + + +
FY23t-..cit2t-..yat2 +
FY23t-..~at2 + + +
Strains were streaked on YND and incubated at 30°C for 2 days after which it was replica-plated on
the different media and incubated for 4-10 days at 30°C (growth +/ no growth -)
The data show that the growth of the !1cit2 strains on non-fermentable carbon
sources is dependent on extracellular carnitine in the FY23 and PSY142 laboratory
strains (Figure 1 and Table 3), which suggests that these strains are unable to
synthesise carnitine. This was confirmed through electrospray-masspectrometry (ES-
MS) measurements of intracellular carnitine levels in strain FY23 grown on oleic acid
which showed that carnitine is only present in the cells when it is supplied in the
growth media (data not shown). Taken together with the previously published
observation by van Roermund et al. (1999) showing that another laboratory strain,
BJ1991, was unable to synthesise carnitine, the data suggest that S. cerevisiae is
unable to synthesise carnitine.
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4.2 Selection of mutants affected in the carnitine shuttle
The mutagenesis of the /icit2 strain resulted in the isolation of a total of 114 mutants
defective for growth on oleic acid media supplemented with L-carnitine (YNOC) from
a total of 11000 colonies. However, most of these mutants are expected to be
affected in genes coding for proteins involved in peroxisome biogenesis, p-oxidation,
fatty acid import and other pathways independent of the carnitine shuttle but required
for fatty acid utilisation. Such mutants should still be unable to grow on oleic acid
even when a functional glyoxylate cycle has been re-established. To select CPAM
mutants specifically affected for the carnitine pathway, the 114 strains were
individually transformed with a centromeric plasmid containing a functional CIT2
gene, restoring the glyoxylate cycle in all the mutants. Only mutants with functional
peroxisomes and fatty acid utilisation pathways would be able to grow on YNOC
medium after transformation with CIT2, indicating that the mutations resulting in the
defective growth on this medium before transformation with CIT2 affect genes acting
in the carnitine shuttle bypass. A total of six mutants able to grow after
retransformation with CIT2 were isolated (CPAM 1-6).
To verify if the mutants were affected in any of the previously identified carnitine-
related genes whose mutation results in related phenotypes, all mutants were
transformed with centromeric plasmids containing either CAT2, AGP2 or CRC1. One
of the mutants, CPAM-3, was complemeted by CAT2, while two mutants, CPAM-4
and CPAM5, were complemeted by CRC1. These data confirm the high specificity of
the selection screen. However, none of the mutants could be complemented by a
plasmid carrying AGP2.
4.3 The cloning of YAT1 and YER024w
The genes mutated in strains CPAM-2 and CPAM-6 were cloned through functional
complementation with a S. cerevisiae genomic DNA library. A total of approximately
10000 transformed colonies were screened for each strain, and four and three
complementing plasmids were isolated for CPAM-2 and CPAM-6, respectively. In
both cases, one of the isolated plasm ids showed a restriction map identical to the
chromosomal region containing CIT2, and sequencing of these plasm ids confirmed
that they indeed contained a genomic copy of the gene. This result was expected
since functional complementation of the /icit2 genetic background of the mutant
strains is sufficient to establish normal growth in all conditions. The other plasmids
isolated from each of the mutants contained genomic fragments with partially
overlapping restriction maps. The overlapping restriction fragments were subeloned
and sequenced. Sequence analysis of plasm ids isolated from CPAM-2 showed that
the overlapping fragment contained the gene YAT1, which codes for the carnitine
acetyltransferase presumably associated with the outer mitochondrial membrane
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(Schmalix and Bandlow, 1993). This is the first description of a phenotype associated
with this gene. CPAM-5, on the other hand, was complemented by a fragment of
DNA containing ORF YER024w. The predicted protein sequence encoded by
YER024w displays significant homology with Yat1 p, and to a lesser degree with
Cat2p. We therefore named the gene YAT2.
4.4 Phenotypes of CAT2, YAT1 and YAT2 deleted strains
To verify the observed phenotypes in null mutants of CAT2, YAT1 and YAT2, the
genes were disrupted in strains FY23 and FY23ócit2. The ócat2, óyat1 and óyat2
strains grew similar to the wild-type strain on all carbon sources tested. However, the
double mutant strains ócit2/ócat2, ócit2lóyat1 and ócit2/óyer024w did not grow on
any of the non-fermentable carbon sources tested (Figure 2 and Table 3), but grew
normally on glucose media. The deletion of any of the three genes therefore yielded
identical phenotypes to the primary mutants. The data indicate that in the absence of
the glyoxylate cycle citrate synthetase, all carnitine acetyltransferases are essential
for growth on non-fermentable carbon sources, including oleic acid, acetate, ethanol
and glycerol. Transformation of the ócit2/ócat2, ócit2lóyat1 and ócit2lóyer024w
strains with plasm ids carrying CAT2, YAT1 or YAT2 did not lead to any
cross-complementation, indicating that, despite the high sequence similarity, each of
the genes encodes for a highly specific activity.
'NT
Acit2
Ayat1
Acit2Ayat1
Ayat2
Acit2Ayat2
Acat2
Acit2Acat2
YNOC YNGC
'NT
Acit2
Ayat1 Acat2
Ayat2
Figure 2. Growth of wild-type (WT) and mutant strains on oleic acid (YNOC) and glycerol
(YNGC) media with L-carnitine. Strains were replica-plated on YNOC from a YNO master
plate and incubated at 30° for 10 days. Strains were streaked on YNGC and incubated at
30° for 8 days.
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4.5 Sequence analysis
The predicted amino acid sequence encoded by the YAT2 ORF displays a significant
homology with the two known S. cerevisiae carnitine acetyltransferases, Yat1 p [29%
identity, 45% similarity over 500 amino acids (aa)] and Cat2p (19% identity, 38%
similarity over 600 aa), as well as with carnitine acyltransferases from other
organisms, where similarities range from 30-40 % (data not shown). Interestingly, the
highest similarity between Yat2p and any other protein found in the databases is with
FacC, a carnitine acetyltransferase of Aspergillus nidulans which has been
suggested to represent a cytosolic CAT (Stemple et al., 1998). It is also interesting to
note that both Yat1 pand Yat2p show a higher degree of sequence similarity with
mammalian palmitoyl transferases then with the S. cerevisiae Cat2p.
Further analysis of the Yat2p protein sequence indicated the presence of a single
acetyltransferase domain, found in a similar position as in Yat1 p, while Cat2p has two
acetyltransferase domains (Elgersma et al., 1995). No distinct signal sequences,
which might target Yat2p to specific cellular compartments in the cell, were detected
in the sequence. The identical phenotypes of the three mutants and the sequence
homologies strongly suggests that YAT2 encodes a third CAT in S. cerevisiae.
4.6 YAT2 encodes a CAT contributing 50 % to total CAT activity on
ethanol media
In order to verify that YAT2 indeed encodes a CAT, total CAT activity was measured
in a S. cerevisiae FY23 wild-type strain and compared with the isogenic L1.yat2mutant
when grown on ethanol. In these conditions, the mutant showed an approximately
50% reduction in total CAT activity (Figure 3). These data confirm that YAT2 indeed
encodes a functional CAT, which contributes a significant percentage to total CAT
activity when cells are grown on ethanol.
5. Discussion
In this study, mutants affected in carnitine-dependent metabolic pathways were
isolated. The strategy was based on the finding that there are only two pathways
through which peroxisomally produced acetyl-CoA can be utilised for further
metabolism. One pathway depends on the carnitine shuttle, while the other depends
on the production of glyoxylate cycle intermediates from peroxisomally produced
acetyl-CoA and the subsequent transport thereof. By blocking this pathway through
the disruption of the CIT2 gene, we have created a strain that is dependent on the
presence of carnitine when acetate, ethanol, glycerol and oleic acid are used as sole
carbon sources. These data confirm that laboratory strains of S. cerevisiae are
unable to neo-synthesise carnitine.
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Figure 3. Comparison of CAT activity in wild-type (wt) and ~yat2 strains. Cells were grown to
OD600 of 1 in 3% ethanol media and equal amounts of cells were harvested for mechanical
disruption. The amount of NADH consumed during the reaction is directly correlated to the
amount of acetylcarnitine formed by CAT. The dotted lines represents the control experiment
of the wild type (...) and the ~yat2 (---) strains when no carnitine was added to the reaction
mixture. The values indicate the average of three independent experiments.
In our study, six mutants affected in carnitine-dependent metabolic pathways
were isolated. The genes affected in five of these mutants were identified through
complementation. Three mutants were affected in genes encoding CAT enzymes: the
CAT2 gene codes for the peroxisomal and mitochondrial CAT (Kispal et al., 1993;
Elgersma et al., 1995), while YAT1 codes for a CAT associated with the outer
mitochondrial membrane (Schmalix and Bandlow, 1993). We show that YAT2 codes
for a third, previously unidentified CAT with significant homology to Yat1p, as well as,
to a slightly lesser degree, to Cat2p and CATs of other organisms.
Besides CAT2 and YAT1, two additional genes encoding carnitine-dependent
metabolic activities had previously been identified in S. cerevisiae: (i) AGP2, which
codes for a plasma membrane carnitine transporter (van Roermund et al., 1999) and
(ii) CRC1, coding for the carnitine acetylcarnitine translocase of the inner
mitochondrial membrane (Palmieri et al., 1999; van Roermund et al., 1999). All these
genes, with the exception of AGP2, which also acts as a general amino acid
transporter, are specifically involved in the transfer of acetyl groups in and out of
organelles via the carnitine shuttle. In the selection screen used by van Roermund et
al. (1999), ten mutants were selected and could be grouped into only three
complementation groups, indicating a rather satisfying level of saturation of the
mutant selection procedure. The affected genes were identified as CAT2, AGP2 and
CRC1/CAC. In our study, we identify, in addition to CAT2 and CRC1, the genes
YAT1 and YER024w (YAT2). The five analysed mutants therefore yielded four
different genes, and none of the mutants was complemented by AGP2, suggesting
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that mutant selection did not saturate the screen. An explanation for the discrepancy
between the data by van Roermund et al. (1999) and the data presented here
probably resides in the difference in the two selection strategies. The two strategies
differ in the composition of the oleic acid media used for mutant selection, which is
either supplemented with carnitine alone (this study) or 0.1% (w/v) yeast extract (van
Roermund et al., 1999). While yeast extract contains sufficient amounts of carnitine
to meet the requirements of the cells, we also observed that its use in the oleic acid
medium (YNOY) resulted in some "background" growth on solid media of all the
strains disrupted for CIT2 together with any of the three carnitine acetyltransferase
genes (data not shown), making selection of the mutants more difficult. This could be
one of the reasons for the absence of YAT1 and YAT2 in the mutant selection screen
applied by these authors. Figure 4 shows a schematic representation of the function
and localisation of all known proteins involved in carnitine-dependent metabolic
activities. It is worthwhile noting that, in addition to the genes and proteins identified
to date, there are theoretically two additional, as yet unidentified, proteins required for
a functional carnitine shuttle, i.e. the translocases which should be located in the
peroxisomal and outer mitochondrial membranes.
Agp2p l Acetyl-CoA ....- ....- ....- Acetatel Ethanol
Carnitine
~ p-oxidalion
Acetyl-CoA + Carnitine
1Cat2p
CoA-SH + Acetylcarnitine -j-----
Carnitine +Acetyl-CoA
Cat2p i
CoA-SH + Acetylcarnitine
Yat1p
TCA Cycle
MITOCHONDRIUMPEROXISOME
Yat2p?
Figure 4. Representation of the known proteins involved in carnitine-dependent metabolic
activities. In a t:.cit2 strain, the cell depends on the carnitine shuttle to transfer acetyl groups
to the mitochondria for energy production. Agp2, Cat2p, Crc1p, Yat1pand Yat2p are all
essential in a t:.cit2 strain for growth on fatty acids. The subcellular localisation of Yat2p is
not yet known.
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The carnitine-dependent phenotype of the tlcit2 strain sheds new light on the
importance of the glyoxylate cycle. The glyoxylate cycle is indeed required for
anabolic purposes on these carbon sources (Kornberg, 1966). It has been proposed
that the reason for the survival of the tlcit2 strain on these media is that
mitochondrially produced citrate can be recruited by the peroxisome for use in the
glyoxylate cycle (Kispal et al., 1988; van Roermund et al., 1995). Mutations in the
genes coding for the glyoxylate cycle enzymes isocitrate lyase (lCL 1) and malate
synthetase (MLS1), on the other hand, renders the strains inviable even on acetate
media containing carnitine (McCammon, 1996). These enzymes are responsible for
the formation of glyoxylate and succinate from isocitrate and of malate from
glyoxylate and acetyl-CoA, respectively. These enzymatic activities are unique to the
glyoxylate cycle, and glyoxylate can therefore not be recruited from other metabolic
pathways, possibly explaining why strains without Icl1p and Mls1p cannot grow on
acetate media.
It is important to take note of the role of carnitine in the metabolism of the yeast
when investigating certain genes. In previously published work on the CIT2 gene,
media containing non-fermentable carbon sources including acetate and glycerol
have been supplemented with yeast extract (Kim et al., 1986; Kispal et al., 1988). We
show that the reported lack of a phenotype of the tlcit2 strain in these conditions is
due to the presence of carnitine in yeast extract. A discrepancy however exists
between data presented by Kispal et al. (1988) indicating that strain PSY142~cit2
grows normally on a minimal glycerol media that does not contain carnitine, and our
data, which clearly show that carnitine is required for growth on glycerol media (YNG
and YNGC).
The data presented here also shed new light on the importance of CATs in the
metabolism of S. cere visia e. We show that all three of these enzymes are essential in
a ~cit2 strain, and that they play an important role in the metabolism of acetate,
ethanol, glycerol and oleic acid. Based on our current knowledge of the carnitine
shuttle (Figure 4), it is unclear why three CAT enzymes are essential in all the
conditions investigated. It suggests that the physiological importance of carnitine in
yeast has been underestimated thus far. Besides the shuttle, carnitine has been
suggested to play an important role in the regulation of the availability of free
CoA-SH. Considering the highly compartmentalised distribution of CoA, this
regulation might require specifically compartmentalised and independently regulated
CAT activities. Furthermore, the proper channelling of activated acetyl groups into
either anabolic pathways or catabolic energy metabolism is essential during growth
on non-fermentable carbon sources, and might require the presence of three
independently regulated CATs.
The significant homology of Yat2p with the cytosolic carnitine acetyltransferase of
A. nidulans, FacC, the absence of distinct signal sequences in the protein and the
high percentage of total CAT activity due to Yat2p in ethanol media suggest that this
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enzyme could be a cytosolic carnitine acetyltransferase. Cytosolic CAT activity has
been detected in S. cerevisiae by Kispal et al. (1993), and no CAT responsible for
this cytosolic activity has been identified. Further characterisation of the expression of
YAT2 as well as Yat2p's cellular localisation and activity patterns, will cast some light
on the role of this protein in the carnitine-dependent metabolic activities in
S. cerevisiae.
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1. Abstract
The biosynthesis of L-carnitine in eukaryotic organisms was first elucidated in the
ascomycete Neurospora crassa. The first step of the pathway is catalysed by E-N-
trimethyllysine hydroxylase (TMLH), which converts E-N-trimethyllysine into ~-
hydroxy-N-E-trimethyllysine in a reaction dependent on a-ketoglutarate, Fe2+ and
oxygen. Here we report on the cloning of the N. crassa TMLH cDNA and its
functional expression in Saccharomyces cerevisiae. The TMLH eDNA contains an
open reading frame (ORF) of 1413 base pairs encoding a predicted polypeptide of
471 amino acids. The Michaelis-Menten constants of the heterologously expressed
enzyme were determined for E-N-trimethyllysine, a-ketoglutarate, Fe2+ and
correspond to 0.33 mM, 133 JlM and 46 JlM, respectively.
2. Introduction
L-Carnitine (3-hydroxy-4-N-trimethylaminobutyrate) is required for the transfer of
activated acyl groups across intracellular membranes. In most eukaryotic systems,
carnitine is an essential component of the mitochondrial carnitine cycle, which is
responsible for the transfer of activated long-chain fatty acids into the mitochondria
for ~-oxidation (Bieber, 1988). In the yeast Saccharomyces cerevisiae, carnitine is
essential for the transfer of activated acetyl groups from the peroxisome or the
cytoplasm to the mitochondrion, since the peroxisomal, and presumably also the
mitochondrial membranes are not permeable to acetyl-CoA (van Roermund et al.,
1999). Since S. cerevisiae does not synthesise carnitine, a strain with a non-
functional glyoxylate cycle is dependent on extracellular carnitine for growth on non-
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fermentable carbon sources (Swiegers et al., 2001). Most eukaryotes, on the other
hand, are able to synthesise carnitine from g-N-trimethyllysine (TML) (Lindstedt and
Lindstedt, 1970; Kaufman and Broquist, 1977; Bremer, 1983) TML is provided by the
lysosomal hydrolysis of proteins that contain this amino acid as a result of the
post-translational modification of lysine residues. In the first step of the carnitine
biosynthesis, TML is hydroxylated to p-hydroxy-g-N-trimethyllysine by g-N-
trimethyllysine hydroxylase (TMLH, EC 1.14.11.8) (Rebouche and Engel, 1980;
Bremer, 1983). Subsequently, P-hydroxy-g-N-trimethyllysine, is cleaved into
y-trimethylamino-butyraldehyde and glycine by p-hydroxy-g-N-trimethyllysine aldolase
(Rebouche and Engel, 1980; Bremer, 1983). The aldehyde is then oxidised by y-
trimethylaminobutyraldehyde dehydrogenase to form y-butyrobetaine (Hulse and
Henderson, 1980; Rebouche and Engel, 1980; Bremer, 1983). Finally, y-
butyrobetaine is hydroxylated at the 3-position by y-butyrobetaine hydroxylase to
form L-carnitine (Englard 1979; Rebouche and Engel, 1980; Bremer, 1983).
The identity of the intermediate metabolites of the carnitine biosynthesis pathway
was first elucidated in the filamentous fungus Neurospora crassa, using isotope-
labelling experiments (Kaufman and Broquist, 1977). More recently, enzymes
required for the catalysis of three of the four reactions required for carnitine
biosynthesis have been characterised at the molecular level, either in rat, mouse or
man (Vaz et al., 1998; Galland et al., 1999; Vaz et al., 2000; Vaz et al., 2001).
However, none of the N. crassa carnitine biosynthesis enzymes has so far been
characterised at the molecular level. Here we report the identification of the N. crassa
cDNA encoding TMLH, the first enzyme of carnitine biosynthesis. TMLH is a non-
heme ferrous-iron dioxygenase that requires a-ketoglutarate, Fe2+ and molecular
oxygen as cofactors (Hulse et al., 1978; Sachan and Broquist, 1980; Sachan and
Hoppel, 1980; Stein and Englard, 1982). Based on homology with the recently
identified rat TMLH, the putative TMLH ORF was amplified by the polymerase chain
reaction (PCR) from a cDNA library, and cloned into an S. cerevisiae expression
vector. High TMLH activity could be measured in Iysates of transformed yeast,
allowing for the determination of the kinetic constants of the enzyme for
E-N-trimethyliysine, a-ketoglutarate, and Fe2+.
3. Materials and methods
3.1 Cloning and expression of the N. crassa TMLH in S. cerevisiae
The predicted coding sequence of the hypothetical protein CAC18241 (Genbank™),
which is derived from the N. crassa genome sequence of DNA linkage group V,
Cosmid contig 99H12 position 13250-15449, was used to design nucleotide primers
NC-TMLH-F (5'-gatcgaattc ATG AGA CCG CM CGG GTA GGG GCA-3') and NC-
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TMLH-R (5'-gatcgaattc TCA TTT TCC GCT GGT TIC TIT CCG-3'). These primers
were used to amplify the putative open reading frame (ORF) from a N. crassa cDNA
yeast expression library (Fungal Genetic Stock Center, Kansas, USA) using the PCR
technique (Brunelli and Pall, 1993). Using the introduced EcoRI sites, the PCR
product was cloned downstream of the constitutive PGK1 promoter of the yeast
expression vector pHVXl1 (Volschenk et al., 1997). The correct orientation of the ORF
was confirmed by restriction analysis. The construct was transformed into the yeast
strain FY23i1cit2 (Swiegers et al., 2001) using the lithium acetate procedure (Becker
and Guarente, 1991). Transformed yeast cells were grown on minimal glucose
medium (6.7 g L-1 yeast nitrogen base, 20 g L-1 glucose and amino acids as required
at 20 mg L-\ Spheroplasts were prepared using zymolyase according to Franzusoff
et al. 1991, lysed in a 10 mM sodium phosphate buffer, pH 7.4, containing 140 mM
NaCl, 1 mM OTT and 1 g/litre Triton X-100 and TMLH activity was measured as
described below.
3.2 TMLH assay
The amount of p-hydroxY-E-N-trimethyllysine that was enzymatically produced from E-
N-trimethyllysine was determined by HPLC tandem MS as described by Vaz et al.
2001. For the measurement of the dependency of TMLH on E-N-trimethyllysine, a-
ketoglutarate and Fe2+, only the concentration of these components was varied. To
obtain a reliable Km value, the enzyme sample was diluted so that the substrate
consumption was below 10%.
4. Results and Discussion
4.1 Cloning and sequence analysis of N. crassa cDNA
A putative N. crassa TMLH-encoding gene was identified by database searches
based on the homology of the derived protein sequence (CAC 18241) to known
mammalian TMLHs. The predicted coding sequence of this hypothetical protein was
used to design primers overlapping with the putative start and stop codons. Using a
N. crassa cDNA library as template, a PCR product of 1.6 kb was amplified.
Sequencing of the product revealed a smaller than expected ORF of 1413 bp,
encoding a protein of 471 amino acids, which corresponds to a calculated molecular
mass of 52.6 kDa (EMBL accession no. AJ421151). Alignment with the genomic
sequence indicated that the coding sequence consists of eight exons, and that the
coding sequence of CAC18241 had been predicted incorrectly, with several intron
splice sites having been missed or miss-assigned. This also explains the smaller than
expected size of the ORF encoded by the cDNA, with primer NC-TMLH-R hybridising
in fact to the sequence 206-226 bp downstream of the newly identified stop codon.
The protein sequence derived from the cDNA also aligns better with published TMLH
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protein sequences than the previously suggested sequence. The protein indeed has
high homology to the three confirmed TMLH proteins identified in rat, mouse and
human [13] and also to the last enzyme of carnitine biosynthesis, y-butyrobetaine
hydroxylase (BBH), which is also a dioxygenase. The positional identity to mouse
and human TMLH is 33%, and 32% to rat TMLH (Figure 1). The protein contains a
unique and unusual 11 residue poly-P region (residues 278-288). This region could
separate two protein domains and should have a major effect on the tertiary structure
of the enzyme. X-ray crystallisation studies will be pursued to elucidate the effect of
this region. No significant homologies to other dioxygenase enzymes were found,
indicating that the TMLH and BBH carnitine biosynthesis enzymes form a separate
group of highly conserved enzymes.
Ncrassa TMLH 1
Rat TMLH 1
consensus 1
Ncrassa TMLH 51
Rat TMLH 42
consensus 51
Ncrassa TMLH 101
Rat TMLH 75
consensus 101
Ncrassa TMLH 151
Rat TMLH 125
consensus 151
Ncrassa TMLH 199
Rat TMLH 175
consensus 201
MRPQVVGAILRSRAVVSRQP~RTHIFAAVTVAKSSSPAQNSRR8FSSSF
---------MKRGDIAHGLR~GFKSLFPFSLHWCHTASKSVNC8WHQHE
** *
Ncrassa TMLH 249 P
Rat TMLH 224
consensus 251
Ncrassa TMLH 299
Rat TMLH 251
consensus 301
Ncrassa TMLH 349
Rat TMLH 291
consensus 351
Ncrassa TMLH 398
Rat TMLH 341
consensus 401
Ncrassa TMLH
Rat TMLH
consensus
RR~YEPK~EITAEGLELSPPQAVTGGKRTVLPNF~N8mCTK8v~QD8
DH~ELQY~STVMR-----------------FDYV~H8mSAS8Y~SK8
* * **** ** * * *
L~NFN8FAIPSDDH~TKVEATKENVTVQ~S~NmTST~PWPF~SFYLTSN
H~SLD8AsVDLCDK~KTIRLDESTLFFT~P~GmvTR~DLDW~VKNSYEG
** * *.* * * * * *
ARGHENDQIS~GSEAGS--RP~T~P~PRVMASDQ8vADLTAMIKEF8FC
QKQEVIQPRV~NAKLYQDAQL~S~D~QGFLETKE8LKKFLQNFLLY8IA
** *.* * * *
~KDT~HDDPDV8RQ~LEmIAFamv8H~GFYD~P~LAMA~N~
~ENVmp-TQEH8EK~RmvSLamE8I~RMWY~S~FSRG~K~
** * * * * ** * ** ** * ***** ***
~~~~~~~~~I~~13a:llti~~~~~:~B:~;~~I~~:~i:~~~;~~
** ****** ** * ** * * * *
ITIAPDK-LYmv~ELNEDTG~HRVmw~D~G~PFGEKYSPSE~E~A
QCHNHMIGVGmI~NIYPWNK~YLlmY~Y~A~INTVPYDVVRR~A~H
. *.* . ** *.** **.* ** *
448 ~FISRwmNTNYPRSEVLPRVTG
391 ~~NTAmILGLHA---------
451 *** *
Figure 1. Alignment of TMLH amino acid sequences. The deduced protein sequence
encoded by the N. crassa TMLH-encoding cDNA (EMBL accession no. AJ421151) was
aligned with the sequence of the rat TMLH protein. The N. crassa sequence contains an
unusual, 11-residue poly-P region (residues 278-288) in the TMLH protein.
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4.2 Expression of N. crass a TMLH in S. cerevisiae
To confirm that the identified sequence indeed encodes a TMLH, the ORF was
cloned into the multiple copy expression vector pHVXII between the constitutive
PGK1 promoter and the PGK1 terminator, and transformed into strain FY23~cit2.
TMLH activity measurement in the homogenate of a yeast transformant containing
the putative TMLH cDNA revealed high TMLH activity, whereas the strain
transformed with the pHVXII vector without insert showed no activity (Figure 2). The
gene was subsequently named cbs-1 for carnitine biosynthesis. Contrary to rat
TMLH, heterologously expressed N. crassa TMLH is therefore active in yeast. Rat
TMLH is localised in the mitochondria and undergoes post-translational processing,
probably after import into the mitochondria (Vaz et al., 2001) whereas N. crassa
TMLH is a cytosolic enzyme (Kaufman and Broquist, 1977). These differences in
post-translational modification and localisation may explain the difference in activity in
S. cerevisiae.
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Figure 2. Detection of j3-hydroxY-E-N-trimethyllysine by HPLC tandem MS. Levels of e-N-
trimethyllysine and j3-hydroxy-e-N-trimethyllysine, the substrate and product of TMLH activity,
respectively, were measured after 60 minutes incubation in cellular extracts. Peak 1
corresponds to e-N-trimethyllysine and peak 2 to j3-hydroxy-e-N-trimethyllysine. (A) Extract
from S. cerevisiae strain transformed with vector pHVXl1 without insert. (B) Extract from
S. cerevisiae strain transformed with vector pHVXII containing inserted TMLH ORF. The
trace represents the total ion current of the transitions m/z 247>142 (peak 1, e-N-
trimethyllysine) and m/z 263>158 (peak 2, j3-hydroxy-e-N-trimethyllysine).
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4.3 Characterization of heterologously expressed N. crassa TMLH
The Km values for the substrate E-N-trimethyllysine, as well as the co-factors
a-ketoglutarate and Fe2+, were determined using Lineweaver-Burk double-reciprocal
plots. The Km values for the three compounds were found to be 0.33 mM, 133 JlM
and 46 j..tM, respectively (Figure 3). The Km value for E-N-trimethyllysine is
significantly lower than the previously reported values of 1.1 mM (Vaz et al., 2001)
and 1.6 mM (Sachan and Hoppel, 1980) for rat TMLH. On the other hand, the Km
values for a-ketoglutarate and Fe2+in rat TMLH, which were determined to be 109 j..tM
and 54 j..tM,respectively, are similar to those reported here (Vaz et al., 2001).
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Figure 3. Km curve and Lineweaver-Burke plot for (A) E-N-trimethyllysine, (B) a-
ketogluterate, and (C) Fe2+.
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1. Abstract
L-Carnitine is a quaternary ammonium compound that plays an essential role in the
transfer of activated acyl-residues across intra-cellular membranes. Most eukaryotes
can neo-synthesise carnitine, but recent data show that this is not the case in the
yeast Saccharomyces cerevisiae. The filamentous fungus Neurospora crassa was
one of the first organisms used to identify the precursor and intermediates of the
carnitine biosynthesis pathway. In this organism, the precursor trimethyllysine is
converted in a four-step process to carnitine. In the last step of this pathway, y-
butyrobetaine is hydroxylated to form carnitine in a reaction catalysed by y-
butyrobetaine hydroxylase (BBH). A novel plate screen has been developed for the
identification of carnitine producing strains of yeast. Using this screen, a genomic
fragment encoding the N. crassa y-butyrobetaine hydroxylase was identified and the
gene designated cbs-2. We show that a yeast expressing cbs-2 is able to
endogenously produce carnitine from y-butyrobetaine and that expression of this
gene is able to rescue the growth defect on non-fermentable carbon sources of the
carnitine-dependent /::"cit2strain.
2. Introduction
L-Carnitine (3-hydroxy-4-N-trimethylaminobutyrate) is a quaternary ammonium
compound that was first discovered in muscle extracts in 1905 (Bremer, 1983). In
1952, it was shown that the mealworm Tenebrio molitor is dependent on carnitine for
survival, generating new interest in this molecule, which was named vitamin Br
(Carter et al., 1952). Later investigations showed that most eukaryotic organisms
could synthesise L-carnitine from trimethyllysine as a precursor (Vaz and Wanders,
2002). Nevertheless, carnitine deficiencies occur and they are debilitating diseases,
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frequently due to genetic mutations (Bonnefont et al., 1999; lahjouji et al., 2001).
Such diseases are characterised by low levels of carnitine in either the serum or in
specific tissues. In most cases, patients respond favourably to exogenous dietary
supplementation of carnitine (Pons and De Vivo, 1995). In recent times, L-carnitine
has also been used for symptomatic treatment in cases of diseases, such as chronic
fatigue syndrome, coronary vascular disease, hypoglycemia and muscular
myopathies (Kelly, 1998). In addition, carnitine is widely used in nutritional products,
such as energy drinks, weight loss supplements and baby formulae (Carter et al.,
1995)
In mammalian cells, carnitine is an essential component of the mitochondrial
carnitine cycle that is responsible for the transfer of activated long-chain fatty acids
into the mitochondria for ~-oxidation (Bieber, 1988). In the yeast Saccharomyces
cere visiae , on the other hand, ~-oxidation occurs solely in the peroxisomes (Kunau et
al., 1988). Van Roermund et al. (1995) showed that exogenous carnitine was
essential for growth on fatty acids as sole carbon source in the absence of the
glyoxylate cycle citrate synthase, Cit2p. later, Swiegers et al. (2001) showed that in
the Llcit2 strain, carnitine is essential for growth on all non-fermentable carbon
sources. Therefore, S. cerevisiae is unable to biosynthesise carnitine endogenously
but relies on exogenous carnitine, which is transported into the cell by the general
amino acid membrane transporter Agp2p (van Roermund et al., 1999; Swiegers et
al.,2001).
Mammals, plants and some fungi are able to biosynthesise carnitine from £-N-
trimethyllysine (TMl) (Lindstedt and Lindstedt, 1970; Kaufman and Broquist, 1977;
Bremer, 1983). In mammals, TMl is provided by the lysosomal hydrolysis of proteins
that contain this amino acid as a result of the post-translational modification of lysine
residues (Bremer, 1983). However, in Neurospora crassa, free lysine is trimethylated
in the cytosol (Borum and Broquist, 1977). In the first step of carnitine biosynthesis,
TMl is hydroxylated to ~-hydroxy-£-N-trimethyllysine by £-N-trimethyllysine
hydroxylase (TMLH; EC1.14.11.8) (Rebouche and Engel, 1980; Bremer, 1983).
Subsequently, ~-hydroxy-£-N-trimethyllysine is cleaved into y-trimethylamino-
butyraldehyde and glycine by ~-hydroxy-£-N-trimethyllysine aldolase (Rebouche and
Engel, 1980; Bremer, 1983). The aldehyde is then oxidised by y-
trimethylaminobutyraldehyde dehydrogenase to form y-butyrobetaine (Hulse and
Henderson, 1980; Rebouche and Engel, 1980; Bremer, 1983). Finally, y-
butyrobetaine is hydroxylated at the 3-position by y-butyrobetaine hydroxylase to
form L-carnitine (Figure 1) (BBH; EC 1.14.11.1) (Englard, 1979; Rebouche and
Engel, 1980; Bremer, 1983).
The identity of some of the intermediate metabolites of the carnitine biosynthesis
pathway was first elucidated in the filamentous fungus Neurospora crassa, using
isotope-labelling experiments (Kaufman and Broquist, 1977). The genes encoding
the enzymes required for the catalysis of three of the four reactions required for
71
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carnitine biosynthesis have been characterised at the molecular level, either in rat,
mouse or man (Vaz et al., 1998; Galland et al., 1999, Vaz et al., 1999; Vaz et al.,
2000; Vaz et al., 2001). The first gene for carnitine biosynthesis, TMLH, was recently
cloned in our laboratory from N. crassa cDNA and functionally expressed in
S. cerevisiae. (Swiegers et al., 2002). Here we report the identification and cloning of
a genomic fragment, which we named cbs-2, encoding a N. crassa y-butyrobetaine
hydroxylase (BBH) and its functional expression in S. cerevisiae. A novel plate
screen was used to identify genomic fragments of N. crassa that could functionally
express BBH. We show that the wild type strain transformed with the cbs-2 gene can
use exogenous y-butyrobetaine from the growth media to biosynthesise carnitine. In
addition, the presence of the cbs-2 gene in the carnitine-dependent strain I1cit2 could
rescue the growth defect of this strain on non-fermentable carbon sources in the
presence of y-butyrobetaine. This is the first report of an S. cerevisiae strain that can
biosynthesise carnitine.
y-Butyrobetaine
L-Carnitine
Figure 1. Hydroxylation of y-butyrobetaine to L-carnitine by y-butyrobetaine hydroxylase.
3. Materials and methods
3.1 Yeast strains and plasm ids
FY23 (MATa leu2 trp1 ura3) was used as a wild-type strain (Winston et al., 1995).
The FY23L1cit2 (MA Ta leu2 ura3 cit2:: TRP1) was used as the glyoxylate citrate
synthase deficient strain (Swiegers et al., 2001). A 2016 bp fragment was cloned
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from N. crassa genomic DNA using the primers NcBBH-F (5'-GATCAGATCT ATG
AAA GTC GAC AAG GAA GCC GGC AA-3') and NcBBH-R (5'-GATCAGATCT TTA
TGC GTT CCA GTT CAC CGT GCC CAA-3') with introduced restriction sites.
Genomic DNA was extracted from strain PPRI 333S (National Collection of Fungi,
Agricultural Research Council, Pretoria, South Africa). The fragment was cloned into
expression vector pHVXl1 into the Bglll site under the regulation of the PGK1
promoter (Volschenk et al., 1997) Sequencing was done using the ABI-Prism
sequencer. The S. cerevisiae gene YHL021c was amplified by PCR from genomic
DNA from strain FY23 using the primers YHL-F (5'-GATCGAATTC ATG CTA AGA
TCA AAT TTA TGC AGA GGA-3') and YHL-R (5'-GATCCTCGAG TTA TTT GTA
CTG AGG AAA CTT CTC TTC-3') with introduced restriction sites. The fragment was
cloned into expression vector pHVXII into the Bglli site under the yeast PGK1
promoter. Constructs were transformed into the yeast strains using the lithium
acetate procedure (Becker and Gaurente, 1991).
3.2 Media and growth conditions
Escherichia coli carrying plasm ids were grown in Luria Bertani (LB) broth with 10 mgll
ampicillin. Yeast strains were grown in YPD (1% yeast extract, 2% bactopeptone, 2%
glucose), synthetic glucose medium (6.7 gil yeast nitrogen base without amino acids,
2% glucose, amino acids as required), synthetic glycerol medium (6.7 gil yeast
nitrogen base without amino acids, 3% glycerol, amino acids as required). Media was
prepared using double distilled water.
3.3 Intra-cellular carnitine extraction
Transformants were grown on synthetic glucose medium for two days and then
inoculated in 100 ml synthetic glycerol medium with 10 mgll y-butyrobetaine and
grown for 4 days at 30°C. Cells were harvested by centrifuging 5 min at 5000 rpm
and washed with 40 ml double distilled water and harvested again using the same
procedure. Cells were resuspended in 1 ml double distilled water, transferred to a
1.5 ml microcentrifuge tube and harvested at 12 000 rpm for 2 min. Wet weight was
determined by weighing the cells and the microcentrifuge tube after all the
supernatant was removed by pippeting. The cells were resuspended in 0.2 ml double
distilled water. The cells were disrupted by adding 0.16 g glass beads and vortexed
for 30 min at SoC. The cells were then vortexed for 10 min at 12 000 rpm and 0.1 ml
of the supernatant added to 0.9 ml acetonitrile and stored at -20°C. Before ES-MS
analysis, the solution was centrifuged for 10 min at 12 000 rpm to remove all protein
precipitates and the supernatant used for analysis.
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3.4 HPLC-electrospray mass spectrometry
Mass spectrometry was performed on a Micromass (Manchester, UK) Quattro triple
quadropole mass spectrometer fitted with an electrospray ionisation source. Solvent
A (acetonitrile/water/formic acid: 30170/0.05 (v/v/v) was used as a carrier solvent and
was supplied to the ionisation source by a LKB/Pharmacia (Sweden) pump. For
direct injection of the carnitine and acetylcarnitine standards, the flow rate was
20 !-II/min and 5 !-IIof the standard was injected through a Rheodyne injection valve.
The molecular ion ([M+H]+) of carnitine and acetylcarnitine was observed using a
capillary voltage of 3.5 kV, source temperature of 80°C and a cone voltage setting of
20 V. To obtain the fragment pattern of carnitine and acetylcarnitine, the molecular
ion was dissociated in the fragmentation cell by collision-induced dissociation at an
argon pressure of 2.8X10-3 mbar applying collision energy of 20 eV. The resultant
fragments were scanned in the second analyser. Quantitation of carnitine and
acetylcarnitine in the incubation samples was accomplished by LCMSMS. A Luna
C18 150X2 mm (31J)column was used for separation, with solvent A as the mobile
phase at a flow rate of 100 !-II/min delivered by the above mentioned pump. Five
microliter of sample was injected by a Waters 747 autosampler. The eluent from the
column was directed into the electrospray ionisation source of the mass
spectrometer. The capillary voltage, cone voltage, argon pressure and collision
energy were as mentioned above. Detection was by multiple reaction monitoring,
using the molecular ions of carnitine and acetylcarnitine as precursor ions and the
fragments at m/z = 43 and m/z = 85 as product ions, respectively. Chromatographic
peaks representing carnitine and acetylcarnitine were integrated and the
concentration in the incubation samples were calculated from a dilution range of
known concentrations of standard carnitine and acetylcarnitine in distilled water and
diluted to a final concentration of 90/10 (v/v): acetonitrile/15 mM Tris.HCI. The
calculations were automatically performed by the Quantify program of MassLynx and
expressed as ng/ml.
4. Results
4.1 Identification of a N. crass a BBH homologue
BBH protein sequences from different organisms are highly homologous to each
other and to TMLH protein sequences. BBH and TMLH are part of a family of (J.-
ketoglutarate-dependent, non-haem ferrous iron dioxygenases (Vaz and Wanders,
2002). However, when the BBH and TMLH proteins are compared to other proteins
using BLAST searches (NCBI), reduced homology is found, indicating that these
enzymes form a separate class of dioxygenases.
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Searching the N. crassa Genome Database (NCGD) resulted in the identification
of 2 putative proteins with high homology to human, rat and mouse BBH protein
sequences (http://www-genome. wi.mit.ed u/annotation/fu ngi/neu rosporal). The fi rst
corresponds to the TMLH previously cloned and identified in our laboratory, whereas
the second was a novel gene encoding a hypothetical protein (NCU06891.1). The
BBH homologous gene predicted by the NCGD consists of 5 predicted exons totalling
3786 bp and translating a hypothetical protein of 1262 aa. This is in strong contrast to
the other known BBH proteins of humans, rats, mice and Pseudomonas, the length of
which varies between 340-380 aa. However, homology to BBH proteins is only found
for the protein sequence translated by the last exon (exon 5) as described in the
feature map of the hypothetical protein on the NCGD. The other translated exons do
not show homology to any known protein.
Using the N. crassa genomic DNA, a 2013 bp fragment (encoding a putative
protein of 671 aa which includes the entire area of BBH homology), was cloned into a
yeast expression vector, pHVXII under regulation of the PGK1 promotor. Sequencing
confirmed that the correct genomic area was cloned. Homology of the 671 aa
putative protein to other known BBH proteins from humans, mouse and
Pseudomonas are shown in Figure 2. However, the 671 aa putative proteins
contained a 111 aa N-terminal and 110 aa C-terminal flanking regions without any
homology to known BBH proteins. The C-terminal domain contains a six-fold repeat
of the sequence "PKVEE". Some 'additional' internal sequences, which contained
GGGG repeats, was also present within the BBH homologous area, similar to what
was observed for the N. crassa TMLH where an 11 residue poly P region and an
"AAAAA" are found within the TMLH homologous area (Swiegers et al., 2002).
4.2 Screening of carnitine producing transformants
A large-scale screen was developed to identify microorganisms producing carnitine.
The screen is based on the carnitine-dependent t..cit2 strain, which, after thorough
washing, is plated as a mat on a synthetic agar medium containing a non-
fermentable carbon source (e.g. ethanol) and no carnitine. On such plates, growing
colonies of microorganisms that biosynthesise carnitine produce a zone due to the
complementation of the t..cit2 mutant by carnitine. In this way, various
microorganisms that produce carnitine were identified, including the yeasts Yarrowia
lipolytica, Rhodotorula graminis and Candida curvata (Figure 3B). Endogenous
carnitine biosynthesis by these strains was verified through intracellular
carnitine/acetylcarnitine measurements using a novel HPLC-electrospray mass
spectrometry (ESMS) method that is described in the 'Materials and Methods'.
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Figure 2. Alignment of the 671 aa expressed N. crassa BBH homologue to human,
Caenorhabditis elegans and Pseudomonas BBH proteins.
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Figure 3. Carnitine large-scale plate screen. (A) Strains were grown on glucose synthetic
medium and streaked on a 2% ethanol synthetic medium agar plate with 10 mg/I y-
butyrobetaine and with a thin mat of ,1.cit2cells grown on synthetic glucose medium, which
were washed twice with sterile distilled water before plating. Cells were grown for 10 days at
30°C. The production of L-carnitine by the strain expressing a functional BBH results in the
secretion of carnitine, which complements the surrounding ,1.cit2 strains and resulted in the
formation of a zone. (B) Carnitine secretion plate assay for identification of endogenous
biosynthesis and secretion of carnitine. Yeast were grown on glucose synthetic medium
before they were streaked onto a 2% ethanol synthetic medium agar plate with a thin mat
,1.cit2cells. Cells were grown for 10 days at 30°C. Yeast strains with endogenous L-carnitine
biosynthesis and secretion could be identified by the zone formation (DS, 04 and 02). (DS)
Yarrowia lipolytica; (04) Rhodotorula graminis; (02) Candida curvata. The controls were the
S. cerevisiae laboratory strain FY23 (A1) and industrial commercial wine strain VIN13 (A2).
Other non-zone forming yeast represents a various collection of different genus and species.
To improve visual detection of zones, plates were transilluminated with light and photos
taken. Biosynthesis of carnitine in zone forming strains was verified using electrospray mass
spectrometry as described in the 'Materials and Methods'.
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By adapting this large-scale screen, we could screen S. cerevtsiee strains
encoding functional BBH genomic fragments. As in the previous case, washed I1cit2
cells are plated on a non-fermentable carbon source but in this instance, y-
butyrobetaine was added to the media to provide the necessary intermediate.
Transformed wild type strains forming zones would indicate functionally expressed
BBH due to the formation of carnitine from y-butyrobetaine and its subsequent
secretion into the growth medium. Expressing the 2013 bp genomic fragment from
the hypothetical protein NCU06891.1, resulted in the formation of a zone (Figure 3A).
We concluded that the gene encoded a BBH and therefore named the gene cbs-2 for
"carnitine biosynthesis gene no. 2".
4.3 Complementation of the carnitine-dependent ~cit2 strain by
BBH
The pHVXII-cbs-2 construct encoding the 671 aa BBH homologue was transformed
into FY2311cit2 in order to see if the transformed strains were able to grow on medium
containing the precursor y-butyrobetaine. The transformants were streaked on
synthetic glycerol media with and without y-butyrobetaine. Strain FY2311cit2
transformed with the cbs-2 construct, grew in the presence of y-butyrobetaine,
whereas the FY2311cit2 transformed with the vector did not grow on any of the media
tested (Figure 4A). Wild type strain FY23 grew normal on both glycerol media tested.
The growth effect on glycerol agar plates were also clearly demonstrated on glycerol
liquid media where the FY2311cit2 strain transformed with the cbs-2 construct grew
almost like the wild type strain and the FY2311cit2 strain transformed with the vector
alone did not grow (Figure 4B). Interestingly, the FY23 wild type transformed with
cbs-2 grew slightly better than the FY23 wild type transformed with vector alone
indicating that production of carnitine can be advantageous for the cell or that y-
butyrobetaine may be slightly toxic to the cell. These data suggest that the y-
butyrobetaine in the growth medium is taken up by the I1.cit2 strain and converted to
carnitine endogenously, which allows the carnitine shuttle to function and therefore
promote the production of energy and subsequent growth. To confirm this conclusion,
carnitine and acetylcarnitine measurements were done using ESMS. Intra-cellular
carnitine measurements were made after wild type strains were grown on synthetic
medium containing glycerol and synthetic medium containing glycerol with y-
butyrobetaine. No carnitine could be measured in FY23 wild type and FY23
transformed with cbs-2 in synthetic glycerol medium. When y-butyrobetaine was
added, the FY23 transformed with cbs-2 gene showed high amounts of carnitine and
acetylcarnitine, indicating that carnitine was produced and the carnitine shuttle was
active (Figure 5). No carnitine could be measured in the FY23 wild type strain
transformed with the vector alone, in the presence of y-butyrobetaine. A total of 897
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ng/gWW of intracellular carnitine and 1151 ng/gWW intracellular acetylcarnitine was
measured. S. cerevisiae only has carnitine acetyltransferase activity, so
acetylcarnitine is the only carnitine ester that can be formed (Swiegers et aI., 2001).
Carnitine production of cbs-2 transformed strains could also be confirmed in glucose
containing medium.
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Figure 4. (A) Strains were grown for 4 days at 30°C on synthetic glycerol (3%) medium and
synthetic glycerol medium with 10 mgll y-butyrobetaine. (8) Growth curves of strains and
transformants: FY23 wild type strain (.); FY23Llcit2 strain (Ll); FY23 wild type strain with
cbs-2 (.); FY23Llcit2 strain with cbs-2 (0). Each strain was grown in 100 ml of synthetic
glycerol (3%) medium plus 10 mgll y-butyrobetaine at 30°C.
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4.4 S. cerevisiae does not contain genes involved in carnitine
biosynthesis
In contrast to most eukaryotic organisms, S. cerevisiee cannot endogenously
biosynthesise carnitine (van Roermund et al., 1999; Swiegers et al., 2001). However,
in this work we show that some other yeasts are able to endogenously biosynthesise
this compound de novo. To date, all carnitine biosynthesising organisms (including
human, rat, mouse, Caenorhabdifis elegans, Drosophila melanogasfer and
N. crassa) have two enzymes with unique function, TMLH and BBH, which are easily
identified based on protein homology. However, S. cerevisiae has only one putative
protein, encoded by YHL021c, which has weak homology to the known BBH and
TMLH proteins. The Yhl021cp has 22% and 27% identity to human BBH and TMLH
proteins, respectively. We cloned YHL021c into the yeast expression vector pHVXII
and transformed the /::,.cif2strain. Overexpression of YHL021c did not complement
the growth defect of the /::"cif2strain on non-fermentable carbon sources containing y-
butyrobetaine.
A B
1m 204 IJlJ J 8., UU204 00:> ss 00'CO
I.
I'l
II(
! \
Cl
DO
lf,) 00 &3nu
15200:> 4300
200 13m 0[1600 eoo:; 1)1) 4.((1
Figure 5. Measurement of intracellular carnitine and acetylcarnitine using electrospray mass
spectrometry. (A) FY23 wild type strain with cbs-2 and (B) FY23 wild type strain was grown
on synthetic glycerol (3%) medium with 10 mgll y-butyrobetaine for 4 days at 30°C after
which cells were harvested and intracellular carnitine and acetylcarnitine levels were
determined. Carnitine has a parent ion of 162 and the daughter fragment of 43 was
measured. Acetylcarnitine has a parent ion of 204 and a daughter ion of 85 was measured.
The level of intracellular carnitine measured for cbs-2 transformed cells were 897 ng/g\JIMI
and acetylcarnitine 1151 ng/gWW.
Stellenbosch University http://scholar.sun.ac.za
~",J:..r1 Chapter 5: Research Results III 81
We also investigated the possibility that expression of both BBH and TMLH could
restore biosynthesis of carnitine from trimethyllysine. The two carnitine biosynthesis
enzymes involved in the second reaction, 3-hydroxy trimethyllysine aldolase
(HTMLA), and third reaction, 4-trimethyl aminobutyraldehyde dehydrogenase
(TMABADH), are indeed thought to perform other additional biochemical functions
not related to carnitine biosynthesis (Vaz and Wanders 2002). This raises the
possibility that similar enzymes may be present in S. cerevisiae. The precursor of the
carnitine biosynthesis pathway, TML, is present in S. cerevisiae (Bieber, 1988).
However, co-transformed strains with both cbs-1 (TMLH) and cbs-2 (BBH) did not
produce any carnitine. Taking all of this together, it is clear that S. cerevisiae has no
genes involved in carnitine biosynthesis and that most probably all four biosynthesis
genes will need to be introduced in order for endogenous carnitine biosynthesis to
take place.
5. Discussion
In this study, a S. cerevisiae strain was genetically engineered that could
biosynthesise carnitine from y-butyrobetaine. A N. crassa genomic fragment was
cloned that expressed a functional BBH, which could biosynthesise carnitine from y-
butyrobetaine. In addition, the BBH could suppress the growth defect of the carnitine-
dependent b..cit2 strain when cells were grown on glycerol synthetic medium
containing y-butyrobetaine.
The hypothetical protein predicted by the NCGB is significantly larger than other
known BBH proteins. In future, it will be the focus of our laboratory to establish the
role of the upstream and downstream sequences (which was not cloned in this work)
of the hypothetical NCU06891.1 gene. However, it might be that due to errors in the
sequencing of the N. crassa genome, stop codons are present, which will result in a
predicted protein that is much smaller. We are currently sequencing the complete
NCU06891.1 genomic fragment.
We concluded that to develop a de novo carnitine biosynthesising strain of
S. cerevisiae, probably all four genes encoding biosynthesis enzymes would need to
be introduced. In contrast to TMLH and BBH, TMABADH proteins are homologous to
a large variety of dehydrogenases, making the cloning of this gene from N. crassa
through homology searches more difficult. In addition, the HTMLA has not been
characterised at the molecular level. This creates particular problems for future work
in this field. The use of N. crassa biosynthesis mutants might overcome these
problems and could lead to the identification of the complete set of genes involved in
carnitine biosynthesis.
The use of the large-scale selection screen could be useful to isolate carnitine
overproducing mutants through monitoring the zone sizes. It can also be used to
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identify the novel carnitine biosynthesis genes from a variety of organisms. The use
of carnitine producing strains of S. cerevisiae will increase the nutritional value of
foods such as bread and beverages such as beer and wine. In addition, carnitine has
recently been shown to protect S. cerevisiae from stress conditions (Lee et al., 2002).
This would be an additional advantage to S. cerevisiae strains producing carnitine de
novo.
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Regulation of respiratory growth by Ras:
The glyoxylate cycle mutant, Acit2, is
suppressed by RAS2
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Regulation of respiratory growth by Ras: The glyoxylate
cycle mutant, f1cit2, is suppressed by RAS2
Jan H. Swiegers 1, Isak S. Pretorius/ and Florian F. Bauer"
'Institute for Wine Biotechnology, Department of Oenology and Viticulture, University of
Stellenbosch, Victoria Street, Stellenbosch, ZA 7600, South Africa. 2The Australian Wine
Research Institute, Waite Road, Urrbrae, Adelaide, SA 5064, Australia
1. Abstract
In the yeast Saccharomyces cerevisiae, the cytosolic glyoxylate cycle is required for
anaplerotic reactions and gluconeogenesis during growth on non-fermentable carbon
sources. In these conditions, the glyoxylate cycle and the carnitine shuttle are also
the only two pathways through which extra-mitochondrial activated acetyl groups can
be further metabolised for energy production in the mitochondria. As a consequence,
deletion of the cytosolic glyoxylate cycle citrate synthase, encoded by CIT2, causes a
severe growth defect on non-fermentable carbon sources in the absence of carnitine.
Screening of the t:.cit2 mutant with an overexpression cDNA library of Neurospora
crassa, resulted in the isolation of the Ras gene, ras-1, as a suppressor.
Subsequently, it was shown that the t:.cit2 mutant could also be suppressed by
overexpressing the native S. cerevisiae RAS2 gene. In wild type strains,
overexpression of RAS2 resulted in enhanced proliferation of cells grown on medium
with glycerol as sole carbon source while the constitutively active RAS2va/19 allele
caused a growth defect. However, in the t:.tpk1 strain, this proliferation effect was
blocked. In this study, it was shown that overexpression of RAS2 nevertheless
activates the cAMP/PKA pathway but that activation is not as severe as in the case of
the RAS2va/19 allele. In strains grown on medium containing glycerol as sole carbon
source, overexpression of RAS2 upregulated mitochondrial citrate synthase activity
while in the t:.ras2 mutant, activity was downregulated. We propose that RAS2
overexpression results in a combination of general upregulation of the mitochondrial
machinery and an increase in mitochondrial citrate/citrate synthases, which together,
complement the metabolic requirements of the t:.cit2 mutant.
2. Introduction
In Saccharomyces cerevisiae, Ras signals via the cAMP/protein kinase A (PKA)
pathway to regulate cellular metabolism in response to the type of carbon source
available for utilisation (Broach and Deschenes, 1990; Thevelein, 1994). Two Ras
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proteins are present in yeast and are encoded by RAS1 and RAS2 (DeFeo-Jones et
al., 1983; Powers et aL, 1984; Dhar et al., 1984; Toda et al., 1985). Regulatory
signals are transmitted by Ras by shuttling between the inactive GOP-bound form
and the active GTP-bound form through the activity of the guanine nucleotide
exchange factor, Cdc25p, and the GTPase activating proteins Ira1pand Ira2p
(Tanaka et al., 1989; Tanaka et al., 1990a; Tanaka et al., 1990b; Jones et al., 1991).
The GTP-bound Ras protein stimulates adenylyl cyclase, Cyr1 p, which synthesises
cyclic AMP, thereby increasing intracellular concentrations of cAMP (Toda et al.,
1985; De Venditis et al., 1986; Field et al., 1988). High cAMP concentrations
stimulates the binding of cAMP to the PKA regulatory subunit, Bcy1 p, thereby
releasing the catalytic subunits, Tpk1 p, Tpk2p and Tpk3p, which subsequently
phosphorylate a variety of proteins involved in cellular metabolism and regulation
(Matsumoto et al., 1982; Toda et al., 1987b; Broach and Deschenes, 1990;
Thevelein, 1994; Robertson et al., 2000). Intracellular cAMP is degraded by cyclic
nucleotide phosphodiesterases, Pde1p and Pde2p (Sass et al., 1986; Nikawa et al.,
1987).
The effect of Ras activation on levels of cAMP appears most apparent when
strains growing on non-fermentable carbon sources are switched to glucose media
(Mbonyi et ai, 1990). In these conditions a rapid and significant increase in cAMP
levels are observed, as much as a 50-fold increase after 1-2 min. However, cAMP
levels rapidly decline and, after a relatively short time, near basal levels are reached
(Nikawa et al., 1987). After the cAMP spike, the basal levels of cAMP required for
continuous growth on glucose is slightly higher than the basal level of cAMP required
for growth on non-fermentable carbon sources. Indeed, the level of cAMP must drop
in order for the cell to adapt its metabolism from fermentative growth to respiratory
growth (Russel et al., 1993).
The absence of Ras2p downregulates the Ras/cAMP/PKA pathway (decrease of
intracellular cAMP concentrations) and this results in a severe growth defect on non-
fermentable carbon sources (Fraenkel, 1985; Tatchell et al., 1985; Toda et al., 1985).
On fermentable carbon sources e.g. glucose, the absence of Ras2p or Ras1 p has no
effect on growth, however, when they are both absent, the strain is not viable
(Kataoka et al., 1984; Tatchell et al., 1984). Hyperactivation of the Ras/cAMP/PKA
pathway (increase of intracellular cAMP concentrations), through the presence of the
constitutively active RAS2va/19 allele, also results in a severe growth defect on non-
fermentable carbon sources (Kataoka et al., 1984; Toda et al., 1985; Nikawa et al.,
1987). In addition, hyperactivated Ras strains show distinctive phenotypes that
include reduction in glycogen and trehalose levels, heatshock sensitivity, nutrient-
starvation sensitivity, pronounced pseudohyphal differentiation and invasive growth
(Toda 1987a, Engleberg 1994; Pan and Heitman; 1999; Stanhill et al., 1999). The
same phenotypes, including a growth defect on glycerol, are observed in strains
without the PKA regulatory unit, Bcy1 p, where the Tpk's are permanently liberated
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and therefore constitutively active (Toda et aI., 1985; Toda et al., 1987a). Thus, it is
clear that Ras2p/cAMP/PKA pathway is an important regulator of respiratory growth
on non-fermentable carbon sources. It has also been shown on the non-fermentable
carbon source lactate, that hyperactivation of the cAMP/PKA pathway (e.g.
RAS2va/19) or constitutive activation of PKA (e.g. I1bcy1) results in an increase in
mitochondrial enzyme content, while a loss of Ras activity (e.g. I1ras2), results in a
decrease in mitochondrial enzyme content (Dejean et al., 2002). The specific
molecular targets involved in the mitochondrial upregulation remain to be identified.
The glyoxylate cycle is an essential metabolic process required for growth on
non-fermentable carbon sources. The cycle is a modified version of the TCA cycle,
incorporating two acetyl-CoA units per cycle and releasing succinate (Kornberg,
1966). The succinate produced by the glyoxylate cycle is transferred to the
mitochondria in order to supply the TCA cycle with C4 intermediates (van Roermund
et al., 1995). The carnitine shuttle also supplies the TCA cycle with carbon units. In
this shuttle, acetyl-CoA combines with carnitine to form acetylcarnitine, which is
transported into the mitochondria where the acetylgroup is released to form acetyl-
CoA, which can then enter the TCA cycle (Bremer, 1983). Because of the
impermeability of the mitochondrial membrane to acetyl-CoA, the glyoxylate cycle
and the carnitine shuttle are the only two pathways through which the carbon groups
of cytosolic and peroxisomal acetyl-CoA can be transferred to the mitochondria (van
Roermund et al., 1995; Swiegers et al., 2001). In the absence of carnitine (and
therefore the carnitine shuttle), the glyoxylate cycle citrate synthase mutant, I1cit2,
has a severe growth defect on glycerol (Swiegers et al., 2001). In this mutant, the
inflow of acetyl-CoA into the glyoxylate cycle is blocked. However, because the
glyoxylate cycle is required for gluconeogenesis and anaplerotic reactions, growth of
the I1cit2 mutant on non-fermentable carbon sources when supplemented with
carnitine implies that the glyoxylate cycle is still functional. Therefore, it has been
proposed that in this mutant, citrate is recruited from the mitochondria in order to
keep the glyoxylate cycle functioning (van Roermund et al., 1995).
The genomes of filamentous fungi are more complex than the relatively simple
genome of S. cerevisiae. In addition, the metabolic pathways of filamentous fungi
and the regulation thereof differ from that of S. cerevisiae, in which glucose
fermentation is mostly favoured. The Neurospora crassa genome has recently been
sequenced and it revealed the interesting complexity of this organism's genetic
make-up (Galagan et al., 2003). Of all the predicted proteins, more than 40% have no
clear homologues in other eukaryotic organisms and of the more than 1400 genes
with high homology to plants and animals, over 500 genes have no homology to
genes in S. cerevisiae (Hynes, 2003). It would therefore be interesting to see if some
of these genes would be able to suppress the S. cerevisiae metabolic I1cit2 mutant
when grown on synthetic medium with glycerol as sole carbon source.
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Here we present data showing that both N. crassa ras-1 and RAS2 could
suppress /!'cit2 strains when grown on synthetic media with glycerol as carbon
source. We show that overexpression of RAS2 and ras-1 enhances the ability of
yeast to proliferate on glycerol medium in general. Interestingly, the RAS2
proliferation effect is more pronounced in the /!'cit2 strain, suggesting communication
between the mitochondria and the glyoxylate cycle. We confirm the role of the PKA
pathway in this process by showing that in the absence of Tpk1 p, the growth
enhancement caused by RAS2 overexpression is blocked. Differences in glycogen
levels and flocculation phenotypes suggest that the overexpression of RAS2
activates the cAMP/PKA pathway but less severely than in the case of the RAS2va/19
allele. Furthermore, our data show that overexpression of RAS2 increases and Sres?
decreases mitochondrial citrate synthase activity of cells grown on glycerol. We
propose that a combination of the upregulation of mitochondrial capacity and
increase in mitochondrial citrate/citrate synthases, complements the metabolic needs
of the /!'cit2 mutant. Therefore, the suppression does not act directly on the glyoxylate
cycle but reflects the indirect effects resulting from general mitochondrial
upregulation.
3. Experimental procedures
3.1 Yeast strains and plasm ids
FY23 (MATa leu2 trp1 ura3) was used as a wild-type strain while the FY23/!'cit2
(MATa leu2 ura3 cit2::TRP1) was used as the glyoxylate citrate synhase deficient
strain (Winston et al., 1995; Swiegers et al., 2001). The RAS2 gene was cloned by
PCR from plasmid YCP50-RAS2 using the primers RAS2F(EcoRI) 5'-GATCGAATTC
ATG CCT TTG AAC AAG TCG AAC A-3' and RAS2R(Xhol) 5'-GATCCTCGAG TTA
ACT TAT AAT ACA ACA GCC AC-3' with introduced restriction sites (underlined).
The gene was subcloned into pGEM-T-easy (Promega) and cloned into the
EcoRI/Xhol sites of expression vector pHVXII between the PGK1 promoter and
terminator (Volschenk et al., 1997). Transformation of yeast was done using the
lithium acetate procedure (Becker and Gaurente, 1991). The RAS2va/19 allele was
supplied by David Engelberg (plasmid B2562). The pYPGE15 ras-1 plasmid was
isolated from PG15 cDNA library (Fungal Genetic Stock Center, Kansas City, KS,
USA) (Brunelli and Pall, 1993). This library is based on the pYPGE15 plasmid; 2
micron, URA3 and the cDNA's were cloned under regulation of the constitutive PGK1
yeast promoter. The FY23/!,ras2 strains was prepared by transforming the PCR
product of the disruption cassette of strain BY4742óras2 (Euroscarf) using the
primers RAS2-Fp AGT GGG TGG TGT GGC TAA TC and RAS2-Rp CAT CGT CGT
CTT CCT CG. Other strains used were BY4742wt, BY4742/!'tpk1, BY4742/!,tpk2 and
BY4742Mpk3 (Euroscarf) and disruptions were verified using PCR.
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3.2 Media and growth conditions
Yeast were grown in rich 2% glucose medium (YPD), synthetic glucose medium
(SCD); 6,7 g/I yeast nitrogen base without amino acids (Difco) and 2% glucose.
Synthetic glycerol medium (SCG) contained 6.7 g/I yeast nitrogen base without
amino acids (Difco) and 3% glycerol. Amino acids were supplied according to the
requirement of each strain.
3.3 cDNA library screen
A N. crassa cDNA yeast expression library (Fungal Genetic Stock Center, Kansas
City, KS, USA) was used to transform the FY23/).cif2 strain using the lithium acetate
method (Becker and Guarente, 1991). About 40 000 transformants were replica
plated on YNG medium. Plates were incubated for two weeks at 30°C. Clones that
grew were isolated and the plamids isolated. Isolated plasm ids were retransformed
into the FY23/).cif2 strain to confirm the phenotype. Sequencing was done using the
ABI-Prism automated sequencer.
3.4 Citrate synthase and citrate assay
Strains were grown in selective media and 4 ml of the culture was harvested and the
supernatant decanted. The culture was centrifuged and the remaining supernatant
removed by pipetting . The cells were resuspended in 200 JlI ice cold Triton-X-100
(0.05%); Tris-HCI 0.1 M solution and 150 JlI glass beads were added. The
suspension was vortexed rigorously at aoc for 15 min and aDOJlI ice cold water was
added. A volume of 25-50 JlI was used for enzyme analysis. Citrate synthase (EC
4.1.3.7) activity was determined by monitoring at 412 nm the oxidation of coenzyme
A (produced by citrate synthase activity) by 5,5'-dithiobis-2-nitrobenzoic acid (DTNB)
as a function of time using a photometer (Srere, 1969). The enzyme activity was
calculated using an extinction coefficient of 13600 M-1 ern" at 412 nm. One citrate
synthase unit was equal to 1 urnole of DTNB reduced per minute per mg wet weight
For intracellular citrate determination strains were grown on selective SCD
medium for 4a hours and 40 ml harvested through centrifugation for 5 min at
5 000 rpm. Cells were washed with 10 ml distilled water, harvested and resuspended
in 1 ml distilled water to be transferred to a microcentrifuge tube. After centrifuging for
1 min at 12 000 rpm and removal of the supernatant, 0.5 g of glass beads were
added and 0.3 ml Triton-X-100. Rigorous vortexing was applied for 30 min at aoc.
The microcentrifuge tubes with cell suspension were centrifuged 10 min, 12 000 rpm
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at 4°C to remove the debries. The supernatant was used to assess the citrate
content using the Citric Acid Enzymatic UV test kit (Roche).
3.5 cAMP assay
The BiotrakTM cAMP competitive enzyme-immunoassay system was used to
determine intracellular levels of cAMP (Amersham Pharmacia Biotech). Strains were
grown in selective media and a total of 10-40 ml of cells were harvested depending
on the growth stage (Figure 3C). Cells were resuspended in 1 ml water and
transferred to a microcentrifuge tube. The cells were harvested and the wet weight
determined. The cells were resuspended in 300 )lI lysis buffer 1B (Amersham) and
150 )lI glass beads added. The suspension was vortexed for 30 min at 8°C and then
spun down 10 min at 4°C. The supernatant (100 )lI per sample) was used for
analysis.
4. Results
4.1 Cloning of heterologous suppressors of Acit2
We used the N. crassa cDNA yeast expression library to screen for suppressors of
the D.cit2 mutation in S. cerevisiae (Brunelli and Pall, 1993). The library was
transformed into the D.cit2 mutant and transformants selected on SCD media.
Approximately 40 000 transformants were replica-plated onto SCG plates without
carnitine. After two weeks, four growing colonies were isolated and the plasm ids
were retrieved and sequenced. Two plasm ids contained cDNA that was identified as
the res-t gene, the N. crassa homologue to yeast RAS1 and RAS2 (NCBI accession
no. X53533 protein id. CAA37612.1) (Atschuier et al., 1990). The other two
suppressors were identified as coding for an ATPase but was not investigated
further. No citrate synthase homologues were isolated indicating that the library was
not saturated. The res-t gene codes for a protein of 213 aa. The translated protein
has 59% and 57% identity to yeast RAS1 and RAS2 respectively. Retransformation
of the res-t clone confirmed the suppression of D.cit2 (Figure 1). Transformation of
the plasmid into a S. cerevisiae D.ras2 strains suppressed the growth defect of this
mutant on non-fermentable carbon sources indicating the functionality of the N.
crassa ras-1 gene in S. cerevisiae (data not shown). The interchangability of Ras
proteins between organisms is well known and this is the first time it has been shown
for N. crass a (Kataoka et al., 1985; Parrini et aL, 1996).
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4.2 Yeast RAS2 suppresses the ~cit2 growth defect
The identification of a Ras gene as a suppressor of !1cit2 was a surpnsinq but
interesting find. In order to assess if this suppression was exclusively linked to the
N. crass a Ras, or if the S. cerevisiae native Ras genes could also suppress the !1cit2
mutant, the RAS2 gene was cloned into the multiple-copy expression vector pHVXl1
under the regulation of the PGK1 promoter. The FY23!1cit2 strain was transformed
with pHVXII-RAS2, grown under selective conditions in SCD medium, serially diluted
and spotted on 3% SCG agar plates. After 8 days a clear suppression of the growth
defect of the !1cit2 mutant was observed in pHVXII-RAS2 transformed strains, similar
to the suppression of !1cit2 by N. crassa ras-1 overexpression (Figure 1). However,
the constitutively active RAS2va/19 could not suppress the !1cit2 mutant.
A B
WtNc ras-I
Wt
cit2
cit2RAS2
«atusr""
Figure 1. Suppression of !lcit2 by Ras on glycerol. (A) Suppression of the !lcit2 phenotype
by Neurospora crassa ras-1. Strains were grown on SCD to avoid carnitine carry-over from
rich media and then streaked on SCG and grown for 14 days at 30eC. (B) Suppression of the
!lcit2 phenotype by RAS2. Strains were grown on SCD solid media and then for 2 days on
SCD liquid media to stationary phase. Strains were serially diluted to equal cell counts and
then spotted on SCG media and grown for 8 days at 30eC.
The suppression of the !1cit2 phenotype by overexpression of both ras-1 and
RAS2 takes a few days to present itself clearly. The reason for this could be that
transformants of !1cit2 need to be streaked on synthetic glucose medium twice and
then on synthetic glycerol medium, which results in very slow growth on the glycerol
media of wild type strains in general. This step has to be taken because of the
sensitivity of the !1cit2 mutant to complementation by trace amounts of carnitine. For
example, glycerol media containing very small amounts of yeast extract or peptone
complement the !1cit2 phenotype fully due to the large quantities of carnitine present
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in these extracts. The suppression was also more prominent when transformants
were spotted on amino acid selective glycerol plates.
4.3 RAS2 and ras-1 overexpression improves proliferation on
glycerol
Ras is involved in a complex array of cellular processes and control mechanisms for
metabolic regulation. Therefore, because of the far-reaching influence of Ras on
metabolism, we determined if the suppression was specific to the I1cit2 mutant, or if it
could be due to a general enhancement of proliferation on glycerol. The Ras genes
were overexpressed in FY23 wild type and the growth monitored on glucose and
glycerol (Figure 2). Indeed, overexpression of Ras in wild type cells improved the
proliferation on minimal glycerol media. The wild type strains with overexpressed Ras
reached a much higher optical density on glycerol at stationary phase compared to
wild type. However, on glucose media, the opposite was observed. Strains with
overexpressed Ras had a lower optical density at stationary phase compared to wild
type. This would indicate that the high biomass yield reached at stationary phase is
not a general effect present on all carbon sources.
The enhancement of proliferation by RAS2 overexpression is in contrast to the
well-known growth defect caused by the RAS2va/19 allele on glycerol. Indeed, FY23
wild type strains harbouring the RAS2va/19 allele showed a growth defect on glycerol
media and reduced biomass yield at stationary phase (Figure 2). Interestingly, the
highest optical density reached at stationary phase for strains growing on glycerol
was observed in the FY2311cit2 strains with RAS2 overexpressed. In this case,
carnitine was added to complement the I1cit2 mutant's growth on glycerol. However,
adding carnitine to the FY23 wild type and the wild type overexpressing RAS2, did
not change the optical density reached at stationary phase. Also, the I1cit2 mutant
grew similar to wild type when carnitine was added. Therefore, the effect is not
related to carnitine but to RAS2 overexpression in the I1cit2 background. For the
I1cit2 strain grown on glycerol medium containing carnitine (SCG + carnitine), a 2 fold
increase in optical density at stationary phase was shown when RAS2 was
overexpressed. In the same conditions and in wild type, only a 1.3 fold increase in
optical density was observed when RAS2 was overexpressed. This would indicate
regulatory effects between Ras2p and Cit2p. Indeed, it has been shown previously
that RAS2 regulates the retrograde response, which is the communication between
the mitochondria and the nucleus in response to mitochondrial dysfunction or
damage (Kirchman et aL, 1999). The CIT2 gene is known to be upregulated in
response to mitochondrial dysfunction or damage (Liao et al., 1991). In our case, the
absence of CIT2 allows RAS2 to enhance proliferation on glycerol significantly better
than when CIT2 is present.
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Figure 2. Proliferation effects of RAS2 overexpression. FY23 strains were grown in 100 ml
synthetic medium with 2% glucose (A) and synthetic medium with 3% glycerol (B).
Precultures were grown in SeD media for 1 day and inoculated at 00600 of 0.05 for glucose
growth curves and 00600 of 0.2 for glycerol growth curves. Symbols are as follows: Wild type
strain (A); Wild type strain with RAS2 overexpressed (.); Wild type strain with Nc-rest
overexpressed (0); Wild type strain with RAS2va/19 (ó): Ilcit2 strain (0); Ilcit2 strain with RAS2
overexpressed (.). Strains were transformed with vector pHVXII or pHVXII-RAS2 and
growth curves were done in triplicate.
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4.4 RAS2 overexpression results in increased cAMP/PKA activity
The RAS2va/19 allele translates a Ras protein that is locked in the GTP bound form
and therefore constitutively activates the Ras/cAMP/PKA pathway through elevated
intracellular cAMP concentrations (Toda et al., 1985; Nikawa et al., 1987). A large
amount of Ras2p in the cell would not necessarily mean higher activity as would be
the case for most enzymes. The level of activation of the cAMP/PKA pathway would
depend on the relative amount of GTP bound Ras2p and not on the total amount of
Ras2p present In addition, various forms of regulation might influence this Ras2p-
GTP/Ras2p-GDP ratio when these proteins are in abundance. Previous reports have
indicated that overexpression of RAS2 does not result in significant elevation of
intracellular cAMP, thereby implying limited activation of the PKA pathway (Sun et al.,
1994; Colombo et al., 1998).
In this work we show that overexpression of RAS2 results in a decrease in
glycogen content. However, the reduction in glycogen levels were less than in the
case of RAS2va/19 (Figure 3A). Also, RAS2 overexpressed strains were sensitive to
nutrient starvation (data not shown).
We also observed a flocculation phenotype in minimal glucose media when
RAS2 was overexpressed (Figure 38). The Ras pathway is known to act on related
phenotypes such as pseudohyphal differentiation and invasive growth (Mosch et al.,
1999; Pan and Heitman et al., 1999). For instance, FL011, which has been
implicated in flocculation and invasive growth, is known to be upregulated when the
Ras/cAMP/PKA pathway is activated (Pan and Heitman, 1999). We further showed
that the !1tpk2 strain blocked the flocculation phenotype in RAS2 overexpressed
strains (data not shown). The blocking of invasive growth in Ras activated strains by
the !1tpk2 deletion has previously been shown, confirming the correlation (Pan and
Heitman, 1999). As expected, RAS2va/19 also caused flocculation on synthetic
glucose media. However, the flocculation was much more intense for strains with
RAS2va/19.
To finally implicate RAS2 overexpression in the activation of the cAMP/PKA
pathway, we measured intracellular cAMP in S288c isogenic strains grown on
glucose and glycerol media. Cells harvested in late stationary phase growing on
glycerol showed a clear increase in intracellular cAMP levels when RAS2 was
overexpressed (Figure 3C). In addition, we also confirmed the hypothesis that a
lower basal level of cAMP is required for growth on glycerol compared to glucose.
The drop in cAMP in cells moving from exponential to stationary phase in glucose
was also confirmed (Russel et al., 1993) Interestingly, cAMP was much higher in late
stationary phase of glycerol grown cells compared to exponentially grown cells
(Figure 4C).
Collectively, all these data would therefore indicate that overexpressing RAS2
does result in the activation of the cAMP/PKA pathway.
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Figure 3. Activation of the cAMP/PKA pathway by RAS2va and overexpression of RAS2.
(A) lodene/iodide staining of transformants. Transformants were grown on SeD medium for
2 days and then spotted on SeD medium and grown for 5 days at 30oe. A solution of 0.2%
iodine/0.4% potassium iodide was gently poured over the colonies and photographs taken 3
minutes later. The darker the colour, the more glycogen is present and lighter the colour, the
less glycogen is present (8) Flocculation phenotypes. Strains were grown in SeD media for
one day at 300e on a rotating wheel and photographs taken. Optical densities did not vary
more than 10%. (C). Intracellular cAMP measurements. Strains were grown on SeD and
SeG media and harvested in log phase (L) or late stationary phases (S). Intracellular cAMP
was measured as described in 'Materials and Methods'.
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4.5 The RAS2 proliferation effect is blocked in the ~tpk1 mutant
Ras2p can signal, independently of cAMP/PKA, through the MAPK cascade to
promote filamentous growth and cell integrity (Lee et al., 1999; Mosch et al., 1999;
Pan et al., 2000). Here we show that the proliferation effect of RAS2 overexpression
does act through the cAMP/PKA pathway. We overexpressed RAS2 in BY4742
strains (Euroscarf), which carry deletions in the catalytic subunits encoded by TPK1,
TPK2 and TPK3. The growth of these strains was then monitored in glycerol media
(Figure 4A).
In these conditions, the ~tpk3 strains showed a significant reduction in biomass
yield at stationary phase compared to wild type. However, RAS2 overexpression in
Mpk3 resulted in growth similar to wild type overexpressing RAS2. Therefore, RAS2
also suppresses the growth defect on glycerol of the Mpk3 strain. The ~tpk2 strain
grew the same as the wild type strain. The Mpk2 strain also grew identical to wild
type when RAS2 was overexpressed in both strains. The Mpk1 strain had a higher
biomass yield at stationary phase compared to the wild type strain. However, RAS2
overexpression did not result in the high biomass yield observed for the wild type,
Mpk2 and Mpk3 strains when RAS2 was overexpressed. However, on synthetic
glucose the characteristic reduction in biomass yield at stationary phase was
observed for Mpk1 when RAS2 was overexpressed (as for all the other strains used)
(Figure 4B). This would indicate that RAS2 overexpression confers its proliferation
effect of cells grown on glycerol through Tpk1 p.
4.6 Overexpression of RAS2 increases mitochondrial citrate
synthase activity and intracellular citrate content
The ~cit2 mutant may be suppressed on non-fermentable carbon due to the leakage
of mitochondrial citrate synthase and/or citrate to the cytosol. The S. cerevisiae
genome encodes for three citrate synthases; the cytosolic Cit2p and the
mitochondrial Cit1p and Cit3p (Kim et al., 1986, Rosenkranz et al., 1986; Jia et al.,
1997).
In order to determine if Ras increases citrate synthase activity, enzyme assays
were done on glucose and glycerol grown cells. On glycerol grown cells, RAS2
overexpression increased citrate synthase activity and in the ~cit2 mutant citrate
sythase activity almost doubled, indicating that the mitochondrial citrate synthase is
upregulated (Figure 5). In contrast, the opposite effect was seen on glucose where
citrate synthase activity decreased when RAS2 was overexpressed. On glucose
grown cells, no significant change in citrate synthase activity was monitored for the
~ras2 strain, but a significant drop in activity was seen when the strain was grown on
glycerol medium. Interestingly, the RAS2va/19 strain showed increased citrate
synthase activity in wild type cells grown on glycerol and decreased activity in wild
type cells grown on glucose, similar to RAS2 overexpression but in both cases more
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pronounced. However, RAS2va/19 could not suppress the !::"cit2mutant and caused a
growth defect in wild type cells grown on glycerol (Figure 1 and Figure 2).
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Figure 4. Proliferation effect of RAS2 overexpression in Mpk strains. (A) Growth of BY4742
strains on SeD. Precultures were grown in SeD media for 1 day and inoculated at an 00600
of 0.2 to start the measurement of the growth curves. Symbols are as follows: Wild type
strain (.); wild type strain with RAS2 overexpressed (0); Mpk1 strain (M; Mpk1 strain with
RAS2 overexpressed (.'-); Mpk2 strain (.); Mpk2 strain with RAS2 overexpressed (0); !::,.tpk3
strain (.) Mpk3 strain with RAS2 overexpressed (<». Strains were transformed with vector
pHVXl1 or pHVXII-RAS2 and growth curves done at least in triplicate. (B) The average
stationary phase 00600 reached for SeD grown BY4742 strains.
Intracellular citrate levels are an indication of respiratory activity in yeast. Citrate
concentrations were therefore determined in RAS2 overexpressed strains. The level
of citrate in a wild type strain was 93 ~g/gWW and in !::"cit2strains 46 ~g/gWW. When
RAS2 was overexpressed citrate levels increased in wild type 2-fold to 201 ~g/gWW
and 2.5-fold more in the !::"cit2strain at 117 ~g/gWW. Therefore, levels of citrate in the
!::"cit2strains with overexpressed RAS2 were even higher than in wild type strains.
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From these data, it is clear that RAS2 tightly regulates citrate synthase activity in
the cell. This seems to be part of a regulatory circuit involved in upregulation of
mitochondrial biogenesis and mitochondrial enzyme content. Therefore, possible
leakage of mitochondrial citrate synthases and citrate from the mitochondria to the
cytosol are probably part of general increase in respiratory and proliferation capacity
of RAS2 overexpressing cells grown on glycerol.
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Figure 5. Citrate synthase activity of Ras affected strains. FY23 strains were grown in SCO
(white bars) and SCG (black bars) media. For the !lcit2 stains, carnitine was added to
complement growth on glycerol medium. The !lras2 and RAS2va/19 strains were inoculated at
00600 of 0.5 in SCG to allow growth to 00600 of 1. The SeD strains were grown for 24 hours
and the SCG strains were harvested at 00600 of 1-1.5. Citrate synthase activity was
measured as described in 'Materials and Methods'.
5. Discussion
In this work, we have identified the N. crassa ras-1 gene as a suppressor of the
S. cerevisae !lcit2 mutant when grown on glycerol medium. We subsequently
showed that the native RAS2 gene could also suppress the !lcit2 mutant when
overexpressed. Further investigation indicated that RAS2 overexpression in cells
grown on glycerol: (i) enhances biomass yield of wild type; (ii) activates the
cAMP/PKA pathway; and (iii) upregulates mitochondrial citrate synthase activity. We
further showed that the increase in biomass yield in wild type cells grown on glycerol
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and overexpressing RAS2 is blocked in the Mpk1 mutant. Recently, Tpk1 p has been
implicated in respiratory growth through its apparent regulation of iron content in the
mitochondria (Robertson et al. 2000). In the same work, Tpk1 p has also been shown
to regulate Bat1 p expression, which is involved in the regulation of stationary phase.
Together, these data implicate the important role of Tpk1 p in growth on non-
fermentable carbon sources.
We also compared the effect of RAS2va/19 with that of RAS2 overexpression and
found that both result in: (i) a decrease in glycogen content; (ii) nutrient starvation
sensitivity; (iii) the flocculation of cells grown on glucose; (iv) a decrease in biomass
yield and citrate synthase activity for wild type cells grown on glucose medium; and
(v) an increase in citrate synthase activity of wild type cells grown on glycerol. In
support of the last point, it has previously been shown that cAMP addition increases
GIT1 expression and citrate synthase activity in cells grown on the non-fermentable
carbon source lactate (Dejean et al., 2002). However, we show that all these
phenotypes were more pronounced in the case of strains with the RAS2va/19 allele.
Surprisingly, in reciprocal effects, RAS2 overexpression enhanced proliferation and
biomass yield of cells growing on glycerol compared to the decreased proliferation
and biomass yield of cells with RAS2va/19 in these conditions.
The importance of the Ras/cAMP/PKA regulatory pathway in respiratory growth
on non-fermentable carbon sources is well known. Most of the deletions in this
pathway result in growth defects on glycerol (e.g. ó.ras2, ó.bcy1, ó.ira1ó.ira2), as does
constitutive activation of the RAS2va/19 allele. In this work we also investigated the
BY4742 strains with a deletion in the cAMP phosphodiesterase genes POE1 and
PDE2. We found that deletion of POE2 (but not POE1) displays a growth defect when
grown on glycerol medium (data not shown). Therefore, over- and underactivation of
the Ras/cAMP/PKA pathway results in growth defects on non-fermentable carbon
sources. Indeed, recent data indicate that the Ras/cAMP/PKA pathway plays a much
more important role on non-fermentable carbon sources than on fermentable carbon
sources (Robertson et al., 2000). In addition, it has been shown that activation of the
cAMP pathway increases mitochondrial enzyme content when the cells are grown on
the non-fermentable carbon source lactate (Dejean et al., 2002).
In our work, and in contrast to the growth defects exhibited by the ó.ras2 mutant,
we show that RAS2 overexpression enhances proliferation on glycerol. Other
examples of these reciprocal effects are the effect of RAS2 overexpression on life
span extension vs. the effect of ó.ras2 on life span curtailing (Sun et al., 1994). On
the other hand, it has previously been shown that RAS2va/19 overexpression and
ó.bcy1 curtails life span (Sun et al., 1994; Pichova et al., 1997). These findings lead
researchers in the field to propose that RAS2 overexpression acts independently of
the cAMP/PKA pathway (Sun et al., 1994). However, later, the same workers
indicated that overexpression of RAS2 can reverse the effect of chronic stress on life
span strictly through the cAMP/PKA pathway (Shama et al., 1998). Our data on
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proliferation of cells on glycerol as a sole carbon source correlate with these
observations. In our case, we show that RAS2 overexpression enhances proliferation
of cells growing on glycerol in contrast to the growth defect of flras2 in these
conditions. We show that the RAS2 overexpression proliferation effect is mediated by
the cAMP/PKA pathway. Recent data indicate that RAS2va/19 can act independently
of the cAMP/PKA pathway to generate reactive oxygen species and lock respiration
in a non-phosphorylating state (Hlavata et al., 2003). These cAMP/PKA independent
effects of RAS2va/19 may contribute to the growth defect of cells grown on glycerol.
This is supported by the fact that, on non-fermentable carbon sources, both RAS2va/19
and RAS2 overexpression result in an increase in mitochondrial enzyme content
(including citrate synthase activity and ATPase activity) (Dejean et al., 2002; Mabuchi
et aL, 2000). However, we show that RAS2 overexpression and not RAS2va/19,
improves proliferation of cells grown on glycerol. The more pronounced activation of
the cAMP/PKA pathway by RAS2va/19 may also be responsible for the adverse effect
regarding growth on glycerol. This is supported by the phenotype of the flbcy1
mutant, showing that constitutively active PKAs result in a growth defect on glycerol.
Therefore, RAS2 overexpression might activate the cAMP/PKA at the right level in
order to alter the mitochondrial machinery in a positive way to promote growth and
proliferation on glycerol.
In support of our data, it has been shown that the ATPase mutant (atp1-2), which
has a growth defect on glycerol, could be suppressed by overexpression of RAS2 on
a multi-copy plasmid under its native promotor (Mabuchi et al., 2000). It was also
shown that RAS2 overexpression increases ATPase activity and deletion of RAS2
decreases ATPase activity of cells grown on glycerol medium. This correlates with
our data regarding citrate synthase activity. In our case, ATPase activity should also
increase when RAS2 is overexpressed in cells grown on glycerol medium. The high
biomass yield achieved in these conditions would support this notion, as more ATP
would be required for this process. In conclusion, it is clear that RAS2 overexpression
in S. cerevisiae alters the mitochondrial metabolism and regulation in a way that
supports growth on glycerol.
We propose that the suppression of the flcit2 mutant on glycerol by RAS2
overexpression is a combination of indirect effects related to mitochondrial capacity.
The overexpression of RAS2 in cells grown on glycerol results in: (i) enhanced
proliferation of wild type strain and flcit2 strain; and ii) increase in citrate synthase
activity in wild type strain and flcit2 strain. However, in both cases the effects were
much more pronounced in the flcit2 strain. It would therefore seem that there is some
type of communication between the glyoxylate cycle and Ras2p with regards to
mitochondrial regulation, which allows the cell to upregulate its mitochondrial
machinery, even better than is the case for wild type. This could result in citrate
synthase/citrate leakage to the cytosol, alteration in metabolic pools of the
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mitochondria, and superior respiratory growth machinery, which together, would
suppress the growth defect of the ~cit2 strain when grown on glycerol medium.
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1. Concluding remarks and future perspectives
At the start of this research programme, components of the carnitine shuttle had to
be identified. Work by van Roermund et al. (1995) provided important insights and
allowed the design of a specific genetic screen for the isolation of genes involved in
carnitine-dependent metabolism. A key contributor to the selection strategy and work
described in Chapters 3-6 was the use of the tlcit2 mutant, carrying a deletion of the
glyoxylate cycle specific citrate synthases gene. The deletion of this gene caused the
strain to be completely dependent on exogenous carnitine for growth on non-
fermentable carbon sources, an ideal genetic background to isolate carnitine shuttle
mutants. Mutants in three of the four genes known to be involved in carnitine
metabolism were identified. This included a novel gene, YER024w, that we named
YAT2. Assays confirmed that YAT2 encodes a carnitine acetyltransferase (CAT) and
that it contributes greatly to CAT activity in cytosolic enriched fractions (Swiegers et
al., 2001). We speculated that YAT2 encodes a cytosolic CAT, similar to the recently
identified cytosolic CAT of Aspergillus nidulans, FacC (Stemple, 1998). Kroppenstedt
and co-workers later showed through green fluorescence protein (GFP) fusions that
Yat2p is indeed located in the cytosol (Kroppenstedt et al., unpublished). It is not
clear why there is a need for a cytosolic CAT in yeast and fungi but it could be that it
is required for metabolism of carbon sources such as ethanol and acetate, which
results in the production of acetyl-CoA in the cytosol (Schmalix and Bandlow, 1993;
Stemple et al., 1998).
It was shown that all three CATs are essential in the carnitine-dependent tlcit2
strain. Therefore, deletion of CAT2, YAT1 or YAT2 renders the carnitine shuttle non-
functional. Kroppensted and co-workers also showed that over-expression of any of
the three CATs does not result in cross-complementation, indicating that each CAT
performs a very specific metabolic function (Kroppenstedt et al., unpublished). In
future, it would be important to uncover the specific role of each CAT in S. cerevisiae.
It may be that these CATs can be involved in other functions besides the role in
transferring acetyl groups to the mitochondria. In particular, the role CAT could play
in the regulation of acetyl-CoN CoA pools, as was shown for human carnitine
acyltransferases (Bremer, 1983). Or, in a less defined manner, the effect on osmotic
stress resistance, similar to what was shown for the effect of carnitine in protecting
microorganisms (Verheul et al. 1997; Verheul et al. 1998; Angelidis et al. 2002;
Mendum and Smith, 2002; Wemekamp-Kamphuis et al. 2002; Angelidis et al. 2003).
Indeed, Font-Sala and co-workers showed that carnitine results in stress resistance
and osmotolerance in S. cerevisiae (Font-Sala et al., unpublished). In support of this,
it has recently been shown that the carnitine plasmamembrane transporter, Agp2p, is
induced upon osmotic shock (Lee et al., 2002). Although the metabolic reasons for
these stress resistance effects are not clear, transcriptional data derived in these
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conditions may supply some clues. Indeed, it was recently shown that the CAT2 gene
is strongly induced during heat shock (Gasch et al. 2000).
The CATs have also been implicated in various other cellular processes. In work
done in the laboratory of SG Oliver (University of Manchester) it was shown that
YAT2 was highly expressed during stationary phase (personal communication). Also,
Lorenz and Fink (2001) showed that YAT2 is highly induced during phagocytosis,
thereby implicating that carnitine acetyltransferases might be involved in virulence of
the pathogen Candidia albicans.
Although it is clear that carnitine plays an important role in the metabolism of
S. cerevisiae, it is surprising that it was only recently discovered that this organism
does not biosynthesise carnitine (van Roermund et al., 1999; Swiegers et al., 2001;
Swiegers et al., 2002). However, it does efficiently take up carnitine when grown on
non-fermentable carbon sources.
The absence of carnitine biosynthesis in S. cerevisiae has important metabolic
consequences when cells are grown on synthetic media. However, trace amounts of
carnitine are required in order for the carnitine shuttle to function properly. The
components of rich media (peptone and yeast extract) contain sufficient amounts of
carnitine, therefore explaining the lack of phenotype previously observed for these
strains on this media (Kim et al., 1986; Kispal et al., 1988).
It is not clear why S. cerevisiae does not biosynthesise carnitine. It may be that in
conditions where this yeast thrives, high glucose and anaerobiosis, carnitine is not
essential for growth. In industrial conditions, such as during wine and beer
fermentation, carnitine is present in sufficient quantities (Swiegers et al.,
unpublished). However, we showed that Yarrowia lipolytica, Rhodoforula graminis
and Candida cutvete do biosynthesise carnitine. This could be related to efficient
metabolism of fatty acids, requiring carnitine to facilitate the oxidation process.
The genetic introduction of the carnitine biosynthesis pathway in S. cerevisiae
could be of great scientific and commercial benefit. In general, carnitine
biosynthesising yeast would be beneficial for consumers of bread, wine and beer.
The clear benefit of carnitine to human health was discussed in Chapter 2.
Chapters 4 and 5 describe the first molecular work done on carnitine biosynthesis
related to eukaryotic microorganisms. It was interesting to find that the filamentous
fungi Neurospora crassa has an out of the ordinary protein sequence for the two
biosynthesis genes encoding BBH and TMLH, which contained repeat regions that
did not influence the activity of the enzymes. Recently, the complete genome of this
organism was sequenced, making this a well-suited organism to genetically study
carnitine biosynthesis (Gallagan et al., 2003). It will be a challenging task to identify
the other two biosynthesis genes from N. crassa because there is not enough
molecular information available. The use of N. crassa biosynthesis mutants might
overcome these obstacles.
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We also found that the b.cit2 mutant could be suppressed by Ras proteins when
grown on synthetic medium with glycerol as sole carbon source. The role of Ras in
signalling during growth on fermentable carbon sources such as glucose has been
intensively studied (Broach, 1991; Thevelein, 1994). However, much less is known
about the role of Ras in the regulation of metabolism during growth on non-
fermentable carbon sources, except for the well-known growth defect caused by the
Sres? mutant and by the RAS2va/19 allele on non-fermentable carbon sources
(Tatchell et aI., 1985). In fact, before the work described in Chapter 6 commenced,
only one publication was available which linked the suppression of mutants grown on
glycerol and Ras proteins (Mabuchi et al. 2000). In this work it was shown that RAS2
suppresses the mitochondrial atp1-2 mutation of cells grown on glycerol medium. In
our work, the deleted b.cit2 mutant could be completely suppressed by both RAS2
and N. crassa ras-1, indicating the important regulatory role of the Ras protein in
growth of cells on on non-fermentable carbon sources.
We related the phenotypes of the overexpressed Ras directly to the cAMP/PKA
pathway. We also show that Ras overexpression enhances the proliferation of
S. cerevisiae on glycerol. In support of our findings, it has recently been proposed
that Ras and exogenous cAMP increases mitochondrial enzyme content on the non-
fermentable carbon source, lactate (Dejean et al. 2002). We show that RAS2
overexpression increases citrate synthase activity and intracellular citrate levels in
S. cerevisiae. We propose that a general upregulation of respiratory capacity coupled
with the leakage of citrate synthase/citrate from the mitochondria suppresses the
b.cit2 mutant when grown on glycerol medium.
These results indicate that there is still a lot to be learned about the role of Ras in
regards to the regulation of growth on non-fermentable carbon sources. To date, this
area of research has not received much attention. It is clear that Ras is a key element
in regulation of metabolism on non-fermentable carbon sources. In future, it may
become an upstream target for metabolic manipulation for desired industrial
purposes, including controling ethanol levels and biomass yields.
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1. Abstract
Carnitine acetyltransferases (CATs) catalyse the transfer of activated acetyl groups
between the acetylated and free forms of coenzyme A and carnitine. This reaction is
part of the carnitine shuttle, a metabolic pathway that is required for the exchange of
activated acetyl groups between cellular compartments. Indeed, only acetyl-carnitine,
and not acetyl-CoA, can be transported across intracellular membranes. Three CAT
enzymes, encoded by the genes CAT2, YAT1 and YAT2, have been identified in the
model organism Saccharomyces cerevisiae. While genetic evidence suggests that
each CAT plays a unique role in cellular metabolism, our current understanding of
the metabolic role of CATs does not explain why three independent enzymes are
required. To investigate the specific role of each CAT, an accurate method for the
determination of CAT activity is required. Methods employing spectrophotometric
measurements are unreliable, particularly when crude homogenate is used. A
radiolabeled forward exchange assay can be used to eliminate this problem, but
safety concerns make this method undesirable. Here we have developed an HPLC
tandem electrospray mass spectrometric method for the measurement of CAT
activity in crude cellular homogenate. In this method, the conversion of carnitine to
acetylcarnitine is measured quantitatively over a period of time by monitoring the
precursor ion containing the m/z = 85 fragment, which is unique to the acetylcarnitine
molecule. Crude extract from a mutant strain with all three CAT-encoding genes
deleted showed no CAT activity when this method was employed, indicating that
there are only three CATs present in S. cerevisiae.
2. Introduction
Carnitine acetyltransferases (EC 2.3.1.7) are present in eukaryotic organisms and
have been described in yeast, fungi, plants and mammals (Burgess and Thomas,
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1986; Masterson and Wood, 2000; Jernejc and Legisa, 1996; Kozulic et al., 1987;
Stemple et al., 1998; Bieber, 1988). They catalyse the transfer of activated acetyl
groups from acetyl-CoA to L-carnitine or from acetylcarnitine to CoA-SH. This
reaction is required because organellar membranes are impermeable to acetyl-CoA
(Van Roermund et al., 1995), while a carnitine-acetylcarnitine antiport system can
ensure the transfer of the activated acetyl group without loss of energy (Palmieri et
al., 1999; Van Roermund et al., 1999).
In the model organism Saccharomyces cerevisiae, three genes code for carnitine
acetyltransferases, CAT2, YAT1 and YAT2 (Stemple et al., 1998; Bieber, 1988;
Schmalix and Bandlaw, 1993; Kispal et al., 1991; Swiegers et al., 2001). The three
enzymes have unique metabolic functions, since all three are essential in some
genetic backgrounds and no cross-complementation can be observed (Swiegers et
al., 2001; Van Roermund et al., 1995). In order to obtain a better understanding of
the metabolic role of CAT enzymes in yeast, the activity of these enzymes has to be
measured collectively and individually in cells grown in various conditions and an
accurate method to measure CAT activity in crude cellular extracts is required.
Existing methods to measure CAT activity depend on spectrophotometric
measurements of either the formation or disappearance of acetyl-CoA derivatives at
232 nm, or the indirect measurement of the release of CoA-SH with sulfhydryl
reagents. These methods are inaccurate when crude cellular homogenates are used,
due to the high background absorbance (Colowick and Kaplan, 1986). The problem
associated with the spectrophotometric assays has lead researchers to centrifuge
crude cellular homogenate, using the clear, cell-free supernatant for the assay
(Schmalix and Bandlaw, 1993; Kispal et al., 1991; Swiegers et al., 2001). This
practice, however, is not optimal, as some enzyme inevitably will be lost. A possible
alternative is the use of a radioisotope exchange forward assay, but the need for
specialised reagents, working space and equipment, as well as safety concerns
when working with radioactive reagents, makes this method undesirable for routine
assays (Demaugre et al., 1988; McGarry et al., 1983; Stakkestad and Bremer, 1982).
Previously, electrospray mass spectrometry was used by Nolte et al. (1998) to
measure the activity of carnitine palmitoyltransferase I in leucocytes. The method
was shown to be accurate and the specific activity of the enzymes compared well
when other methods of determination were used. Here we present a method based
on tandem mass spectrometry, in which the precursor ions containing the m/z = 85
fragment, which is unique to acetylcarnitine molecules, can be detected. Separation
of the components in the reaction mixture by reverse phase high performance liquid
chromatography (HPLC) was combined with tandem electrospray mass spectrometry
(MSMS). The detection mode employed was multiple reaction monitoring, in which
the first analyser of a triple quadropale mass spectrometer was set to pass the
precursor ion (acetylcarnitine) into the fragmentation cell, where collision-induced
dissociation created the m/z = 85 fragment, which was detected by the second
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analyser. The combination of both HPLC and MS/MS provides a highly selective and
specific method for the detection and quantification of acetylcarnitine in the presence
of high concentrations of L-carnitine. No extraction steps are required in this assay,
contributing to the simplicity and accuracy of the method.
3. Materials and methods
3.1 Yeast strains and plasm ids
All strains used in this study derive from FY23 and are listed together with the
plasm ids in Table 1. For the cloning and disruption of the genes, standard DNA
techniques were used (Sambroek et al., 1989).
Table 1. Strains and plasmids used in this study
Strains:
Strains and plasm ids Genotype Source or reference
FY23
FY23~yat2
I FY23~yat2~cat2Mat1
Plasmids:
YDp-W
Ydp-U
PGEM-T-easy
PGEM- T-easy-CA T2
p~cat2
p~yat1
p~yat1
MATa leu2 trp1 ura3 Winston et al. 1995
MATa trp1 ura3 yat2::LEU2 Swiegers et al. 2001
MATa yat2::LEU2 cat2::URA3 yat1::TRP1 This study
TRP1 Berben et al. 1991
URA3 Berben et al. 1991
Prorneqa
This study
This study~cat2::URA3
~yat1 ::LEU2
Syett : TRP1
Swiegers et al. 2001
This study
3.2 Cloning and disruption of genes
To create a yeast strain without any known CAT-encoding genes, the CA T2 and
YAT1 genes were deleted from strain FY23~yat2 (Swiegers et al., 200 1). A 595 bp
BamHI/Bg/ll fragment internal to the CAT2 gene of the plasmid PGEM-T-easy-CAT2
was replaced by a 1.1 kb URA3 gene from plasmid YDp-U. The resulting construct,
p~cat2::URA3, was used to isolate a 2.9 kb disruption cassette containing the URA3
gene plus CAT2 flanking regions, which was then transformed into FY23~yat2.
Transformants were isolated on selective media and the disruption was verified using
the primers CAT2F1 and CATR1. The ~yat1 disruption construct was created using
the plasmid p~yat1::LEU2 and replacing the LEU2 gene by removing it as a 1.6 kb
BamHI fragment and replacing it with a 0.8 kb TRP1 fragment from plasmid YDp-W.
The resulting disruption construct, p~yat1:: TRP1, was used to isolate a 1.9 kb
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fragment containing the TRP1 gene and YAT1 flanking regions, which was
transformed into strain FY23t!.yat2::LEU2 t!.cat2::URA3. The disruptions were verified
using primers YAT1F1 and YAT1R1.
3.3 Cultivation and homogenisation of yeast
Strain FY23 wild-type was grown in YNO medium [0.67% (w/v) YNS without amino
acids (Oifco) and 2% (w/v) glucose] to an optical density (00600) of 3.0,
corresponding to ca. 1.2 x 108 cells/ml. From this preculture, YNE medium [0.67%
(w/v) YNS without amino acids and 2% (v/v) ethanol] was inoculated to an initial
00600 of 0.15 and the cells were grown to an 00600 of 1.0. A 40 ml sample of this
culture was centrifuged at 5000 rpm for 5 min and the cells were washed with 40 ml
of water and again centrifuged at 5000 rpm for 5 min. After resuspension in 1 ml of
15 mM KCI and 5 mM TRIS buffer (pH 7.4), the cells were transferred into 1.5 ml
microcentrifuge tubes and centrifuged for 3 min at 5000 rpm. The excess water was
removed and the pellet was resuspended in 200)l1 ice-cold 0.05% (w/v) Triton X-100.
Glass beads (0.16 g) were added to the suspension and the cells were vortexed for
10 min at BOC. 100 ul of the crude extract were transferred to new microcentrifuge
tubes and buffered with ice-cold 900 )lI 15 mM KCI and 5 mM TRIS buffer (pH 7.4).
The crude extract was kept on ice and used for the enzyme assay the same day. The
total protein content was measured using the bicinchonic acid (SCA) kit.
3.4 Carnitine acetyltransferase assay
The assay mixture consisted of a buffer containing 13.5 mM KCI and 4.5 mM TRIS
(pH 7.4), complemented with 0.049 mM acetyl-CoA and 2.47 mM L-carnitine. After a
preincubation of 10 min at 30°C, the reaction was initiated by the addition of 10 III of
cell extract with a concentration of 1.3 mg/I total proteins. To measure the formation
of acetylcarnitine, samples were taken at 10 min intervals by removing 100 JlI
aliquots from the sample mixture. These were added to 900 ,ui acetonitrile, thereby
stopping the reaction. The samples were kept on ice and then deproteinised by
centrifugation at 12000 rpm for 5 minutes. The supernatants were transferred to new
tubes and analysed by HPLC/MS/MS.
3.5 Mass spectrometry
Mass spectrometry was performed on a Micromass (Manchester, UK) Quattro triple
quadropole mass spectrometer fitted with an electrospray ionisation source. Solvent
A (acetonitrile/water/formic acid: 30nO/0.05(v/v/v)) was used as carrier solvent and
was supplied to the ionisation source by an LKS/Pharmacia (Sweden) pump. For
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direct injection of the acetyl carnitine standard, the flow rate was 20 Jil/minute and 5
Jil of the standard was injected through a Rheodyne injection valve. The molecular
ion ([M+Hr) of acetylcarnitine was observed using a capillary voltage of 3.5 kV, a
source temperature of 80°C and a cone voltage setting of 20 V. To obtain the
fragment pattern of acetylcarnitine, the molecular ion was dissociated in the
fragmentation cell by collision-induced dissociation at an argon pressure of 2.8 X10-3
mbar, applying a collision energy of 20 eV. The resultant fragments were scanned in
the second analyser.
Quantification of acetylcarnitine in the incubation samples was accomplished by
HPLC/MS/MS. A Phenomenex (Torrance, USA) Luna C8 150X2.00 mm (3Ji) column
was used for separation, with solvent A as mobile phase at a flow rate of 100
Jil/minute delivered by the above mentioned pump. Ten microlitres of sample were
injected by a Waters 747 (UK) autosampler. The eluent from the column was directed
into the electrospray ionisation source of the mass spectrometer. The capillary
voltage, cone voltage, argon pressure and collision energy used were as mentioned
above. Detection was by multiple reaction monitoring, using the molecular ion of
acetylcarnitine as precursor ion and the fragment at m/z = 85 as product ion.
Chromatographic peaks representing acetylcarnitine were integrated and the
concentration in the incubation samples was calculated from a dilution range of
known concentrations of standard acetylcarnitine, prepared in the same buffer as
used for the enzyme assay and diluted to a final concentration of 90/10 (v/v):
acetonitrile/15 mMTris.HCI. The calculations were performed automatically by the
Quantify program of the MassLynx program and expressed as ng/ml.
4. Results
The electrospray mass spectrum of acetylcarnitine is depicted in Figure 1A. The
molecular ion ([M+Hr) at m/z = 204 is observed as the base peak in the spectrum.
Fragmentation of the molecular ion resulted in the fragmentation spectrum shown in
Figure 1B. Using the same conditions, the molecular ion of carnitine was detected at
m/z = 164 and fragmentation produced an ion spectrum in which the most abundant
fragment ion was observed at m/z = 43 (not shown).
For the quantification of acetylcarnitine, the molecular ion at m/z = 204 and the
fragment ion at m/z = 85 were used as precursor- and product ions in the multiple
reaction monitoring mode of detection. Carnitine was detected by using the
precursor- and product ions at m/z = 164 and 43 respectively, in the multiple reaction
monitoring mode. The components of the assay mixture were separated by HPLC
before detection, and Figure 2 indicates that there is no cross-over contamination of
the acetylcarnitine due to the presence of carnitine in the reaction mixture.
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Figure 1. Electrospray mass spectrum of the parent ion from acetylcarnitine (A) at m/z = 204.
The fragmentation resulted in the fragmentation ion at m/z = 84 (B), which was used for
detection.
The concentration of acetylcarnitine in each incubation sample was calculated
from a calibration curve established by using known concentrations of acetylcarnitine
analysed under the same conditions as those used for the assay samples. The
standard curve, with a coefficient of determination of 0.9990, is depicted in Figure 3.
Figure 4 represents the results obtained when CAT activity was measured in a
wild-type yeast strain grown on ethanol. A linear increase in the conversion of acetyl-
CoA to acetylcarnitine is clearly observed. The absence of acetylcarnitine at time
zero is indicated clearly. The zero value was not included in the determination of
activity, however, as some acetylcarnitine may have been transferred from the yeast
crude extract. The specific CAT activity measured in these conditions was 7 pmol of
acetylcarnitine formed per min and ng of protein. The result was highly reproducible
in six independently conducted experiments (Figure 4).
In a second set of experiments, the effect of various protein concentrations on
the formation of acetylcarnitine was measured. Here too, a near linear increase in
product formation for increasing protein concentration over a fixed period of time was
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observed. The reaction was stopped either after 20 min (Figure 5A) or after 40 min
(Figure 58).
As a control, the mutant strain with the three deleted CA T genes showed no
activity, even when grown on other non-fermentable carbon sources, including oleic
acid and acetate (data not shown). These data confirm that S. cerevisiae has only
three CAT-encoding genes. In a second control, a reaction mixture containing
distilled water instead of carnitine also showed no activity.
10 41
A cetylc arni tine
%
10 33
Carniline
%
Figure 2. HPLC chromatogram of the separated components in the reaction mixture. The figure
clearly indicates that there is no crossing over.
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Figure 3. The calibration graph of acetylcarnitine-hydrochloride. The standard curve was used to
determinate the concentration of acetylcarnitine formed during the enzyme assay.
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Figure 4. Time-dependent formation of acetylcarnitine due to the presence of CAT enzymes in
the yeast crude extract. The reaction was performed as described under materials and methods.
The graph presents the average of six repetitions.
A
1.50
~ 1.25"0
].
1.00
4)
..Ei
.~ 0.75
0f 0.50
~
0.25
0.00
0
B
2.00
175~
"0
! 1.50
4) 1.25..Ei
.~ 1.00
0
~ 0.75
0
~ 0.50
0.25
0.00
0
5 10 15 20
Protein [ng]
25 30
5 10 15 20
Protein [ng]
25 30
Figure 5. Protein-dependent formation of acetylcarnitine due to the presence of CAT enzymes in
the yeast crude extract. The reaction was performed with different protein concentrations and
was stopped either after 20 min (A) or after 40 min (B). The graph presents the average of six
repetitions
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5. Discussion
The yeast S. cerevisiae is an important model organism used to study molecular
processes in eukaryotic cells. Due to the ease of genetic manipulation, this organism
has contributed greatly to advancing the understanding of the molecular mechanisms
involved in metabolic processes. In order to have a better understanding of the role
of each of the CAT enzymes in the metabolism of yeast, it is important to study the
activity of these enzymes collectively and individually in a wide range of physiological
conditions. An assay was developed, based on the time-dependent formation of
acetylcarnitine from free carnitine and acetyl-CoA. Acetyl carnitine was measured by
HPLC in combination with tandem mass spectrometry.
Due to the presence of non-volatile salts in the incubation mixture, it was
necessary to separate the acetylcarnitine from the more ionic compounds prior to
detection in the mass spectrometer. Contrary to previously reported methods using
MS/MS for the detection of acetylcarnitine, there is no extraction step of the assay
samples used in this method. The HPLC step is sufficient for the removal of excess
salts present in the assay samples. Simultaneous elution of the analyte and high
concentrations of strong ionic compounds could suppress the ionisation of the analyte
and negatively influence the lower limit of quantification. The inclusion of the
separation step, accomplished by online HPLC on a C8 column, successfully
sequestered acetylcarnitine for optimum sensitivity of detection. To optimise ionisation
and detection, a low concentration of buffer was used and the samples were diluted
by a factor of ten in acetonitrile, prior to separation. The low buffer concentration did
not affect the buffering capacity of the enzyme assay mixture and the enzyme activity
remained unaffected.
A high concentration of carnitine, used as precursor in the enzyme reactions, was
also present in the reaction mixture. As indicated in Figure 2, carnitine and
acetylcarnitine were not completely resolved by the HPLC system employed. The
presence of carnitine, however, did not influence the detection and quantification of
acetylcarnitine, due to the fact that different combinations of precursor and fragment
ions were used in the detection of carnitine and acetylcarnitine. This demonstrates
the inherent specificity of the multiple reaction-monitoring mode of detection and also
provides the possibility of simultaneous quantification of both carnitine and
acetylcarnitine in a single step.
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